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Abstract 
Myxobacteria produce a variety of secondary metabolites displaying important biological 
activities. Recent sequencing of the Myxococcus xanthus DK1622 genome revealed its high 
potential for the production of secondary metabolites and led to the identification of the 
myxovirescin biosynthetic gene cluster. In silico analysis of myxovirescin megasynthetase 
resulted in the proposal that a number of discrete enzymes work together with the 
multimodular PKS to build myxovirescin scaffold, unique for the presence of two different β-
alkyl groups. To test the myxovirescin biosynthetic model, fourteen in-frame deletion mutants 
in the myxovirescin biosynthetic gene cluster were created, and their effects on the production 
of myxovirescin antibiotics evaluated by HPLC-MS analysis of the resulting mutant extracts. 
Novel myxovirescin analogues arising from certain mutant backgrounds were structurally 
elucidated to identify the specific positions of these modifications. In silico analysis of an 
additional 11 kb region encoded upstream from the myxovirescin gene clusters were proposed 
to be involved in the regulation of its production. Genetic disruption of a gene encoding for a 
serine/threonine kinase, and two additional genes encoding for proteins of unknown 
functions, were shown to positively regulate myxovirescin production. 
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Zusammenfassung 
Myxobakterien haben sich in den letzten drei Jahrzehnten als vielseitige Produzenten 
unterschiedlichster Sekundärmetaboliten (SM) mit zum Teil starker biologischer Wirkung 
erwiesen. Unter diesen Bakterien sind diverse Multiproduzenten bekannt, zu denen auch das 
Bakterium Myxococcus xanthus DK1622 zählt. Die erst vor kurzem abgeschlossene 
Sequenzierung des Gesamtgenoms von Myxococcus xanthus DK1622 zeigt das enorme 
Potential für die Produktion verschiedenster SMs. Auf diesem Weg konnte ebenfalls das 
Myxoverescin-Biosynthesegencluster identifiziert werden. Die annotierte Genomsequenz 
lieferte erste Möglichkeiten für eine in silico Analyse der Myxovirescin Megasynthase und 
führte zum Postulat eines möglichen Biosynthesewegs. In diesem bildet eine multimodulare 
PKS das Myxovirescin-Grundgerüst, welches nachträglich durch verschiedene separate 
Enzyme modifiziert wird. Diese Enzyme katalysieren den Einbau zweier ungewöhnlicher  
β-Alkylgruppen. Um die Beteiligung des identifizierten Genclusters an der Myxovirescin-
Biosynthese zu beweisen, wurden vierzehn "in-frame" Deletionsmutanten erzeugt. Die 
Auswirkung der jeweiligen Mutation auf die Produktion des Antibiotikums wurde mittels 
HPLC/MS Analyse der erhaltenen Kulturextrakte untersucht. Um in den neuen Myxovirescin-
Derivaten die spezifische Veränderung innerhalb des Moleküls zu identifizieren, wurde deren 
Struktur aufgeklärt. Stromaufwärts des Biosynthesegenclusters konnte eine ca. 11 kb große 
genomische Region identifiziert werden, in der Gene kodiert sind, die möglicherweise 
regulatorische Auswirkungen auf die Myxovirescin-Produktion haben. Durch 
Geninaktivierungen, sowohl eines Serin/Threonin Kinase kodierenden Gens, als auch zweier 
Gene mit unbekannter Funktion, konnte eindeutig gezeigt werden, dass die jeweiligen 
Enzyme an der Produktionsregulation beteiligt sind.  
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Natural products-importance, applications, and impacts  
The serendipitous discovery of penicillin-producing fungus Penicillium notatum by 
Alexander Fleming, coupled to the later success of Florey and Chain in the development of 
the large scale fermentative process for the production of penicillin, has marked the 
beginnings of the modern era in natural product research.[1] This discovery has triggered the 
golden fever in the discovery of new antibiotics (1940-1960) that were largely based on 
screenings of soil samples for the presence of microorganisms capable to produce biologically 
active compounds. Attempts to cultivate these microorganisms, optimize the production of 
these agents, elucidate their structures, and discover ways of their biosyntheses has made the 
field of natural product research evolve into an interdisciplinary science which combines 
multiple aspects of microbiology, molecular genetics, chemistry, biochemistry and recently 
genomics. 
 In addition to the development of numerous classes of antibiotics in human clinical 
use, such as penicillins (β-lactams), streptomycin (aminoglycosides), erythromycin 
(polyketide macrolactones) and vancomycin (glycopeptides), the major impact of natural 
product research on the history of medicine have had discoveries of immunosuppressive drugs 
cyclosporine and FK-506 (Figure 1). The discovery, followed by the later success in the 
proper administration of these drugs has overcome the major limitation in the field of organ 
transplantation-rejection of the newly acquired organs by the host immune system.[2]  
Effects of the available antibiotic therapies are evident in the greatly decreased death 
rates caused by infectious diseases ranging from 797 cases per 100 000 in 1900 to 36 cases 
per 100 000 in 1980, as reported in the United States.[3] However, increased longevity of 
humans has caused an inevitable increase in the incidence of cancers. Consequently, 
development of new and effective agents for cancer chemotherapy remains high on the 
priority lists of both academic research groups as well as pharmaceutical companies. In 
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addition, the widening threat of HIV epidemics, an alarming spread of tuberculosis around the 
world, and a global threat of antibiotic resistant bacteria in the last two decades remain only 
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Figure 1: Examples of natural products in clinical use: antibiotics penicillin, vancomycin, 
streptomycin, tetracycline and immunosuppressants FK-506 and cyclosporine. 
 
some of the hot issues that call for urgent development of new therapies to treat these 
diseases.[4; 5] Figure 2 illustrates some selected natural products which show promising 
anticancer and anti-HIV activities. 
Today, natural products continue to play a vital role in the discovery and development 
of new drugs. This is evident from the fact that about 50% of all drugs that are currently in the 
clinical use are of natural product origin.[6] A superior advantage of natural products in respect 
to their molecular counterparts obtained by combinatorial chemistry or diversity-oriented 
synthesis approaches generally include their greater structural complexity, higher abundance 
of stereogenic centers, great target specificity and higher water solubility.[7] Such 
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characteristics are the outcome of a long evolutionary process that has conferred selective 
advantages on the producing organisms.  
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Figure 2. Natural products with potential of becoming anticancer and anti-HIV drugs: 
tubulysin A, bryostatin 1 and epothilone. The latter two are currently in phase II and III of 
clinical trials, respectively. Suksdorfin shows anti-HIV activity.  
 
Because of these characteristics natural products are irreplaceable starting materials 
(leads) for the development of drugs with superior characteristics. The drug development 
generally aims at generating libraries of simplified structural analogues of the lead compound, 
e.g. lacking specific regions of the molecule or certain functional groups, in an effort to define 
the true pharmacophore region. A successful example of this approach is the bryostatin 
analogue A, which lacks the scaffolding regions (see Figure 3) but displays higher potency 
than bryostatin itself.[8] Also, further modifications of the lead and its analogues through 
introduction of additional functional groups can be important for improving drug solubility 
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Figure 3. Simpler and more potent: A structurally simplified analogue of bryostatin A shows 
higher potency than the original natural product. "Omitted" functional groups are shown in 
red whereas the green circles indicate the functional groups essential for bryostatin activity.[8] 
 
and reactivity. In addition to the traditional organic synthetic efforts to new structures, some 
of the recent approaches utilize enzyme-directed tailoring as ways of producing new natural 
product variants. For example, in vitro-catalyzed modifications of aglycon libraries by 
glycosyltransferases from natural product biosynthetic pathways have proven as another 
elegant way of generating new potentially active molecules.[9] Another approach to generate 
novel bioactive molecules is through reconstruction of the biosynthetic pathways leading to 
their assembly by using genetic engineering in their natural or in more suitable heterologous 
hosts. The latter two approaches require the use of molecular genetic methods for 
manipulation of the DNA as well as biochemical techniques required for enzyme expression 
and purification.[10]  
 
Natural product producers 
Plants are prolific producers of natural products (NP) and as such have had the longest 
therapeutic applications dating back to the beginnings of the human civilization. Nevertheless, 
mapping of the genes governing NP production in plants is difficult due to their random 
distribution across the genome. In addition, complex organization of eukaryotic DNA makes 
the identification of genes dedicated to natural product biosynthesis extremely time 
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consuming.[11; 12] Contrary to their more complex relatives, bacterial and fungal genes 
dedicated to production of secondary metabolites are generally found clustered in the 
chromosome. The best known producers of natural products within the bacterial kingdom are 
actynomycetes. This bacterial phylum has contributed with the highest number of clinically 
used antibiotics. 
The search for new bioactive secondary metabolite producers also includes marine 
organisms. Coral reefs and deep sea floors are especially densely populated with organisms 
having sedentary life style which maintain their natural niches by chemical means of defense. 
It has been proposed that due to differences between marine and terrestrial habitats, the 
marine natural products may contribute with unique structural diversity.[6] Besides 
cyanobacteria, a wide range of sponges, sea slugs, bryozoans and a variety of other marine 
organisms have been shown as valuable sources of highly cytotoxic compounds.[12] Because 
of this marine organisms are becoming important sources of new compounds for the treatment 
of cancer. However, low levels of their recovery (often 1 mg/ 1-3 kg of tissue) and notorious 
difficulty, often inability to cultivate marine organisms, are one of the major limitations in the 
field of marine natural product research.    
Attempts to identify genes responsible for their biosynthesis by creation of 
metagenomic libraries are starting to provide compelling evidence that the actual producers of 
these compounds are bacteria which have developed symbiotic coexistence with their higher 
eukaryotic hosts. For example, Piel presented evidence that the production of pederin, as well 
as its two structurally related compounds, thiopederin and onnamide, is governed by 
prokaryotic symbionts of their terrestrial and marine hosts, respectively.[13; 14] In addition, an 
increasing number of examples of structural analogues are being isolated from both marine 
and terrestrial bacteria. These insights suggest that the genes responsible for secondary 
metabolism have been acquired very early in the evolution. Indeed, discovery of both marine 
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actinomycetes[15] and marine myxobacteria[16] raise the possibility that this "structural 
uniqueness" may have similar bacterial origins. 
 
Myxobacteria as producers of natural products 
In the past 30 years, myxobacteria have emerged as a new genus of natural product 
producers. The most intense research program in myxobacterial natural products has been 
carried out at the German Research Center for Biotechnology in Braunschweig (Germany), 
resulting in screening of about 7500 myxobacterial strains. These efforts have resulted in the 
structural elucidation of about 100 new compounds and ca. 500 structural derivatives.[17; 18] 
Even though myxobacteria are understudied in comparison with actinomycetes, today they are 
recognized as one of the top producers of natural products in the bacterial kingdom. This has 
been reconfirmed by the recent analysis of Myxococcus xanthus genome, which has revealed 
a stunning 8.6% of the genome dedicated to secondary metabolite production. This percentage 
surmounts the two well- known secondary metabolite producers of Stremptomyces family, S. 
coelicor and S. avertimilis, which dedicate 4.5% and 6.6% of their respective genomes to 
secondary metabolic activities.[19] 
Interest in myxobacterial secondary products continues to grow, at least partially due 
to the enormous success of epothilones, anticancer agents which are currently in the phase III 
of clinical trials. Epothilones show a similar mode of action to that of paclitaxel, another class 
of antitumor compounds isolated from the bark of the pacific yew.[20] However, epothilons are 
also active on paclitaxel-resistant tumours, show better water solubility and can be produced 
from a more sustainable source than trees.[21] Another promising anticancer agent is tubulysin 
A. Tubulysin A shows antiproliferative activity on several cancer cell lines, induces apoptosis 
of cancer, but not of healthy cells, and displays additional valuable antiangiogenic 
properties.[22] 
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Myxobacteria produce a variety of compounds with uncommon mechanisms of action, 
such as soraphen, an inhibitor of fungal acetyl-CoA carboxylase.[23] Disorazol and tubulysin 
cause depolymerization of microtubules and induce mitotic arrest,[24; 25] whereas epothilones 
stabilize them.[26] Rhizopodin and chondramide interfere with the actin system.[27-29] Because 
of such remarkable diversity of compounds that target eukaryotic cells, many myxobacterial 
compounds exhibit high potential of becoming anticancer drugs or drug leads. 
Furthermore, myxobacteria are one of the rare bacterial producers of steroids.[30] 
Steroids are cyclic triterpenes, obtained by cyclization of a linear C30 epoxysqualene polymer 
consisting of six isoprenoid precursors (Figure 4). Whereas production of steroids is common 
in eukaryotes, up to date it has been documented in only two other bacterial species: 
proteobacterium Methylococcus capsulatus[31] and more recently in the planctomycete 
Gemmata obscuriglobus.[32] Whereas both M. capsulatus and G. obscuriglobus produce 
lanosterol, the basic precursor of cholesterol, myxobacteria reveal a wider potential for steroid 
biosynthesis. Among all myxobacteria, the most remarkable is the capacity of Nanocystis sp. 
to synthesize almost all precursors of mammalian-like cholesterol except for the final product. 
Furthermore, Stigmatella aurantiaca Sg a15 is the only known bacterium to produce a 
cycloartenol, a typical product of plants and algaea.[33] In addition to steroid biosynthesis, 
myxobacteria have also devised biosynthetic strategies to incorporate isoprenoid moieties into 
secondary metabolites of polyketide (PK) or polyketide/nonribosomal peptide (PK/NRP) 
origin. Such is the case with leupyrrins (produced by Sorangium cellulosum) which combine 
uncommon isoprenoid and carboxylic acids moieties together with traditional PK and NRP 
building units.[34] Similarly, aurachins (secondary products of S. aurantiaca Sg a15) 
incorporate a farnesyl moiety[35] (Figure 4).  
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Figure 4. Top: Steroids are a class of tetracyclic lipids obtained by slightly different 
cyclizations of epoxisqualene, such as lanosterol and cycloartenol. Dashed lines indicated on 
squalene point out individual isoprenoid moieties. Bottom: Two natural products from 
myxobacteria, leupyrrins and aurachins, integrate isoprenoid-building blocks into their 
respective PKS/NRPS and PKS backbones. 
  
Aside from the presence of an isoprenoid side chain, aurachins are also an example of 
rare bacterial quinoline alkaloids which use anthraniloyl-CoA as the starter unit. Soraphen 
also incorporates a very rare starter moiety, benzoyl-CoA,[36] and uses a methoxymalonyl 
polyketide extender moiety, most likely derived from 1,3-bisphopshoglycerate.[37] Ambruticin 
has a rarely observed methylcyclopropane ring.[38] Moreover, the myxovirescin antibiotics, 
which are the topic of this thesis, contain atypical side chains originating from acetate and 
succinate.[39; 40]  
 Furthermore, some natural products from myxobacteria show striking structural 
resemblance with those isolated from higher marine organisms. For example, chondramide B, 
produced by the genus Chondromyces[41] is a structural cousin of jaspamide, a compound 
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isolated from the marine sponge Jaspis spledens[42; 43] (Table 1). Further, saframycin Mx1 of 
M. xanthus Mx1[44] shares a striking similarity with reinaramycin E isolated from another 
sponge - Reniera sp. - and the potent antitumor metabolite ecteinascidin ET-743 isolated from 
the Caribbean ascidian Ecteinascidia turbinata.[12] For additional examples of structural 
analogues see Table 1. Taking into account the aforementioned limitations in the field of 
marine natural product research, the prospect of the availability of these compounds from the 
more easily accessible terrestrial myxobacterial hosts presents a unique advantage. Therefore, 
by circumventing the need for the construction of metagenomic libraries, a significant short-
cut toward elucidation of their corresponding biosynthetic gene clusters and acceleration of 
their expressions in heterologous hosts can be achieved. An excellent example of this 
approach is the recently published biosynthetic gene cluster governing the biosynthesis of 
chondramide B.[45] 
 
Why do myxobacteria produce secondary metabolites? 
In order to answer this question, a short introduction into myxobacterial physiology is 
required. Myxobacteria are soil, social, δ Proteobacteria that show an extraordinary capacity 
for adaptation towards different environmental conditions.[46] In that respect, myxobacteria 
have developed an extremely complex network of sensory molecules and enzymes which 
functions as a highly sophisticated system dedicated to monitoring of their cellular number 
(quorum sensing), as well as their nutritional status. They move in swarms and prey on other 
microorganisms by releasing a powerful cocktail of proteolytic enzymes. Most myxobacteria 
feed on polypeptides. A notable exception is a cellulose degrading genus Sorangium. When 
faced with starvation, cells initiate an alternative life cycle visible as the directed and 
coordinated swarming movement of hundreds of thousands of cells that culminates in the 
formation of multicellular, three-dimensional structures called fruiting bodies. During this 
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extremely energetically demanding process, 90% of cells are sacrificed (lysed) and only the 
remaining 10% are packaged in fruiting bodies. The completion of the developmental process 
 
Table 1. A list of currently known myxobacterial natural products which share high structural 
resemblance with those isolated from marine organisms. 
    
Myxobacterial 
compound 
Myxobacterial host Structurally similar 
compound 
Marine Invertebrate 
Source 
saframycin[44] Myxococcus xanthus 
Mx1 
reinaramycin E 
ecteinascidin 
(ET 743)[12] 
Reniera sp. (sponge) 
Ecteinascidia 
turbinata (ascidian) 
chondramide[41] Chondromyces  
crocatus 
jaspamide[42; 43] Jaspis sp. (sponge) 
apicularen[47] Chondromyces robustus salicylhalamide[12] Haliclona sp. (sponge) 
rhizopodin[48] Myxococcus stipitatus sphinxolide[12] Neosiphonia superstes 
(sponge) 
 
occurs within the fruiting body and is marked with transformation of vegetative cells into 
dormant and desiccation resistant cells (spores).  
Secondary metabolites are likely to play roles in both vegetative and developmental 
life cycle. During the vegetative cycle, these metabolites may be involved in killing or 
paralyzing other microorganisms by making them easy targets (substrates) for proteases. 
Another function may be in protecting the damaged and semilysed cells during early 
development from becoming preys of other organisms, or alternatively, they may be used as 
toxins to kill the sibling cells and therefore delay development. The latter situation has been 
described for B. subtilis which apparently releases the extracellular killing factor.[49] The high 
potencies of myxobacterial secondary metabolites "speak" in favour of this hypothesis. 
Another evidence for the interdependence between primary and secondary metabolism is the 
identification of positive regulators of both secondary metabolite production and 
development. Regulator ChiR from S. celullosum is essential for both chivosazol production 
and development. Accordingly, disruption of chiR leads to the loss of both phenotypes.[50] 
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Some secondary metabolites, like the yellow-pigmented DKxanthenes, are required for the 
formation of viable spores and therefore play an essential role in development.[51] Addition of 
DKxanthenes to DKxanthene deficient cells partially restores this defect. These insights 
suggest that DKxanthenes may not have defensive, but rather structural or protective roles 
during late development of M. xanthus.   
 
The genome of M. xanthus DK1622 reveals high potential for secondary metabolite 
production  
Genes for secondary metabolism occupy a significant 8.6% of the M. xanthus DK1622 
genome. A total of 18 biosynthetic gene clusters are localized in two chromosomal regions 
between 4.4 and 5.8 Mb and 1.5 and 3.5 Mb of the chromosome.[19] Since M. xanthus 
DK1622 had not been subjected to extensive screenings for secondary metabolite production, 
release of the genome sequence has enabled DNA-based identification of secondary metabolic 
clusters. This approach has led to the identification of four biosynthetic gene clusters, 
homologues of which had previously been discovered in other myxobacterial species. These 
include biosynthetic gene clusters for myxalamides-yellow, lipophilic compounds previously 
isolated from M. xanthus Mx x12 and Cystobacter fuscus,[52-54] myxochromides,[55] another 
family of yellow, lipophilic compounds and the iron-chelators myxochelins.[56] In addition to 
these three classes of secondary metabolites, which have been identified based on similarity 
with their biosynthetic gene clusters from Stigmatella aurantiaca, a putative myxovirescin 
gene cluster has been also detected[57; 58] (Figure 5). Release of the genome sequence, in 
combination with targeted gene inactivation experiments, has facilitated identification of the 
third class of yellow compounds-DKxanthenes.[51] 
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The availability of the genome has also set the stage for the study of global analysis of 
protein profiles in the whole cell mixtures by using powerful liquid chromatography-tandem 
mass spectrometry (LC-MS-MS). This approach has provided real time evidence for the 
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Figure 5. Structures of five known groups of secondary metabolites produced by M. xanthus 
DK1622. 
 
expression of six out of thirteen cryptic secondary metabolic gene clusters that were 
previously suspected to be "silent." [59] These findings open up a new frontier directed toward 
identification of their chemical structures, biological activities and possible physiological 
roles.   
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The genome of M. xanthus DK1622 reveals extraordinary abundance of genes with 
putative functions in sensory transduction and regulation  
Unlike other δ Proteobacteria, M. xanthus seems to have undergone lineage-specific 
duplications of genes encoding sensory transductions and regulations of DNA and protein 
interactions. A stunning 256 genes have been annotated to function as two component 
systems, 97 as serine/threonine protein kinases (STK) and 56 as σ54 enhancer binding proteins 
(EBPs).[19] 
EBPs are activator proteins required for the initiation (activation) of transcription from 
promoters recognized by RNA polymerase associated with the alternative σ54 factor. EBPs 
have modular organization and use their central ATPase domain to initiate transcription upon 
contact with the σ54. In addition to the central ATPase domain,[60] σ54-specific activators 
usually also contain the N-terminal sensory domain involved in signal transduction plus a  
C-terminal DNA-binding domain.[61] As EBPs bind the enhancer boxes located either 
upstream or downstream from the promoter, the interaction of EBPs with the σ54-RNA 
polymerase (σ54-RNAP) complex requires the looping of the DNA. Activation of transcription 
is powered by hydrolysis of ATP, which causes the essential conformational switch in σ54,[60] 
resulting in the formation of an open complex.  
In contrast to other bacteria in which σ54 functions as alternative transcription factors, 
in M. xanthus σ54 (RpoN) is essential.[62] Therefore, the remarkable abundance of EBPs 
present in the genome only highlights the significance of σ54-type regulation in gene 
expression of M. xanthus. Twelve M. xanthus EBPs contain fork head-associated (FHA) 
sensory domains which functions as phosphothreonine and phosphotyrosine binding 
epitopes.[63] An even higher number of EBPs (24) are found located in the close proximity to 
serine threonine/tyrosine protein kinases (STKs).[19] These observations raise the possibility 
that STKs activate gene transcription by coupling their sensory output to the FHA domains. In 
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addition, almost half of the EBPs neighbour histidine protein kinases (HPKs). HPKs 
architectures are also often complex and can include additional sensory modules, such as PAS 
domains, involved in sensing of redox states, or GAF domains, which may be involved in 
sensing and degrading cyclic adenosine or guanosine monophosphates (AMP or GMP).  
 
Myxovirescins-structure elucidation and pharmacological applications 
Myxovirescin A, also known as antibiotic TA, has been previously isolated from three 
different Myxococcus species: Myxococcus xanthus TA and ER15 and Myxococcus virescens 
Mx v48.[64-66] Detailed analysis of its production in M. virescens Mx v48 has revealed a 
family of about 20 myxovirescin analogues, among which myxovirescin A is the most 
abundant product.[40] Myxovirescins are macrolactone antibiotics which inhibit peptidoglycan 
biosynthesis of gram negative bacteria.[67] In combination with their adhesive properties, 
myxovirescin A showed promising results in the treatment of gingivitis in humans.[68-70] 
However, in spite of its good characteristics, myxovirescin A has not been developed for 
commercial production due to the high complexity of its total synthesis and low production 
titers in its natural myxobacterial hosts.  
 
Outline of the dissertation-Biosynthesis and regulation of myxovirescin antibiotics in M. 
xanthus DK1622  
This PhD dissertation focuses on the isolation, structural identification, biosynthesis 
and regulation of production of myxovirescin antibiotics by the developmental model strain 
Myxococcus xanthus DK1622. In the course of this study, the myxovirescin biosynthesis gene 
cluster has been identified on the basis of 99% DNA identity with the segment of Ta-1 
polyketide synthase from a related M. xanthus TA.[58] Based on this information, the 
identification of myxovirescin antibiotics by standard analytical procedures (HPLC-MS) was 
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performed, revealing the production of several myxovirescin antibiotics. Following a larger 
scale fermentation, the two main myxovirescin products were isolated and structurally 
analyzed by nuclear magnetic resonance (NMR).[39] Based on these analyses, the most 
abundant form was assigned as myxovirescin A and its less abundant C-20 deoxy analogue 
myxovirescin C (Figure 6).  
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Figure 6. Top: two main forms of myxovirescin antibiotics produced by M. xanthus DK1622: 
myxovirescin A (1) and myxovirescin C (2). Bottom: Gene organization of the ca. 83 kb 
myxovirescin gene cluster.[39] 
 
The availability of the complete myxovirescin biosynthetic gene cluster in 
combination with the stable isotope labelling data of myxovirescin A provided the first 
opportunity for the reconstruction of myxovirescin biosynthesis. This analysis has revealed 
several intriguing features of the myxovirescin megasynthetase.[39] Some of the most striking 
features included the absence of cis-acting acyltransferase domains within all multimodular 
polyketide synthase modules. Instead, two acyltransferase domains were found encoded by 
one gene, taV. The cluster also encodes more modules then could be theoretically anticipated 
to be required for myxovirescin A biosynthesis. This has led to the proposal that two PKSs, 
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TaI and TaL, may carry out the biosynthesis of the starter 2-hydroxyvaleryl-S-ACP precursor 
(Figure 7). 
Besides discretely encoded acyltransferases, the cluster is rich with additional open 
reading frames (ORFs) encoding for monofunctional proteins (taA-taY). Among them the 
most intriguing is the presence of atypical cassette of genes consisting of two homologues of 
acyl carrier proteins (ACPs), 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) synthases and 
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Figure 7. Precursor biosynthesis. Both TaI and TaL PKSs may catalyze the formation of 
acetoacetyl-S-ACP. In either case, acetoacetyl-S-ACP has to be further methylated at C1 
position, reduced at C2 and hydroxylated at C3 position to form the presumed  
3-hydroxyvaleryl-S-ACP starter intermediate.   
 
enoyl-CoA hydratases (ECH), as well as one monofunctional β-ketoacyl synthase (KS) 
(Figure 8 a). These enzymes have been proposed to carry out the incorporation of C29 
carbon, originating from the C2 acetate label and the ethyl group originating from C2-C3 of 
succinate, two times during formation of myxovirescin polyketide skeleton (Figure 8 b).  
Formation of these side chains was postulated to take place by condensation of acetate and 
propionate units onto the β-keto intermediates 2 and 6, via two HMG-like condensing 
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enzymes TaC and TaF leading to hypothetical intermediates 3 and 7 (Figure 8 c). Following 
condensation, elimination of water and carbon dioxide would have to take place leading to 
methyl and ethyl groups attached to carbons C12 and C16 (intermediates 5 and 9). Further 
modification of the C29 methyl group was postulated to take place via hydroxylation and 
subsequent O-methylation reactions to furnish the methoxymethyl group attached to C29, as 
observed in myxovirescin A (1).   
In the course of the analysis of the DNA region located upstream of the myxovirescin 
biosynthetic gene cluster, two potential regulatory operons have been found (Figure 9 a). 
Some genes were found to encode for σ54 EBP and several other sensory and regulatory 
proteins exhibiting an intriguing modular organization (Figure 9 b). Due to their proximity to 
the myxovirescin biosynthetic genes, these have been postulated to regulate myxovirescin 
production (see also Chapter 5). 
In order to critically evaluate hypotheses pertaining to the formation and regulation of 
the production of the myxovirescin macrolactam antibiotic, we decided to take advantage of 
the relatively fast doubling time of M. xanthus (5-6 hours) and reliable genetic tools available 
for its manipulation.[71; 72] These techniques allow reproducible integrations, as well as 
excisions of plasmid DNA from the chromosome, resulting in gene knockouts or gene 
deletions. In the course of this PhD work, 14 markerless deletion mutants and 3 merodiploid 
mutants have been constructed and their effects on myxovirescin production described.[39; 73] 
Four of these mutants have led to the production of three new myxovirescin analogues. In 
addition to the purification and structural characterization of two myxovirescins from the 
wild-type M. xanthus DK1622, three new myxovirescin analogues have been structurally 
characterized using nuclear magnetic resonance sprectroscopy (NMR) analysis, or a 
combination of high resolution mass spectrometry and tandem mass spectrometry.  
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Figure 8. a) 10.9 kb fragment of the myxovirescin A biosynthetic gene cluster encoding for 
monofunctional enzymes. TaB and TaE are putative ACPs, TaC and TaF homologues of 
HMG-CoA synthases, TaK is a variant β-ketoacyl-ACP synthase (KSS), TaX and TaY are 
homologues of enoyl-CoA hydratases (ECH), and TaH is a putative cytochrome P450.  
b) Structure of myxovirescin A (1) indicating the biosynthetic origin of its building units.[40] 
Boxed carbons originate from glycine, black circles indicate C2 of acetate, triangles indicate 
methyl groups derived from methionine, and connected squares show the ethyl group 
originating from carbons 2 and 3 of succinate. c) A working model of myxovirescin A 
assembly depicts two rounds of modification reactions leading to the formation of C12 β-
methyl and C16 β-ethyl side groups in myxovirescin scaffold. Two ATs encoded by TaV load 
malonyl-CoA (M-CoA) and methylmalonyl-CoA (Mm-CoA), respectively, onto their cognate 
ACPs (TaB and TaE), that become substrates of the decarboxylase TaK. Alternatively, 
propionyl-CoA may be directly loaded on TaE to give propionyl-S-TaE. Condensation of 
intermediate 2 with acetyl-S-TaB and intermediate 6 with propionyl-S-ACP catalyzed by the 
HMGS TaC and TaF, respectively, creates intermediates 3 and 7. Removal of the carboxyl 
groups from intermediates 3 and 7 is a two step process involving dehydration by TaX 
(resulting in intermediates 4 and 8), followed by their sequential decarboxylation to yield 5 
and 9. The carbon labelling pattern is described in b).  
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Figure 9. a) 10.9 kb of the myxovirescin regulatory region located upstream from taA.  
b) MyrB, an enhancer binding protein (EBP), encodes a GAF sensory domain.[74] The AAA 
domain is an ATPase domain and the helix-turn-helix DNA binding motif is indicated as 
HTH. MyvC encodes for a serine threonine kinase (STK), while MyvB shows an interesting 
modular organization consisting of cGMP, GAF and FHA domains. The GAF domain may be 
involved in binding cAMP or cGMP molecules, while the cGMP module may carry out 
cyclization of AMP (GMP) (http://pfam.janelia.org/browse.shtml).The FHA domain functions 
as a universal phosphopeptide-binding module.[63]  
 
Biosynthetic Logic of Polyketide and Nonribosomal Peptides  
 
The biosyntheses of three major classes of these products: polyketides, 
nonribosomally-made peptides and PK/NRPS hybrids has been studied in the considerable 
detail and the common logic of their assembly is relatively well understood. The underlying 
principle of their production is that consecutive condensations of monomer units bound as 
thioesters give rise to an oligomer. PKS assembly lines utilize acyl-CoA thioesters as 
monomer units, whereas NRPS assembly lines select from the pool of proteinogenic and 
nonproteinogenic amino acids as well as aryl acids.[75]  
Many PKSs (also known as type I PKS) and all NRPSs are large polypeptides 
organized into modules, where each module constitutes a compartment endowed with a set of 
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enzymatic domains needed for the incorporation and optional modification of (typically) only 
one extension unit into the oligomer. Accordingly, the processes governing both polyketide 
and non-ribosomally-made peptide biosyntheses conform to a general reaction scheme 
consisting of three basic steps: initiation, elongation and termination. Each initiation module 
usually requires two, each elongation module three and the termination module a minimum of 
four catalytic domains. In PK biosynthesis these include: acyltrasferase (AT), acyl carrier 
protein (ACP) and ketosynthase (KS) domains and in NRP biosynthesis adenylyation (A), 
condensation (C) and peptidyl carrier domains (PCP). A thioesterase (TE) domain is common 
to both pathways. 
 
Initiation of PK and NRP biosynthesis 
The initiation of polyketide biosynthesis commences on the loading module, which 
may entail a KS domain in addition to AT and ACP domains. When present, the KS domain 
is generally characterized by the active site His to Glu substitution (KSQ), and functions as 
dedicated decarboxylase in converting (methyl)malonyl-S-ACP into propionate/acetate-S-
ACP starters of polyketide biosynthesis. However, in many systems which lack the KS 
domain in the loading module (AT-ACP), the acyltransferase selects and loads acetyl-
CoA/propionyl-CoA starter onto the first ACP (Figure 10). The loading module of NRPS 
assembly lines is comprised of an adenylation (A) domain and a PCP domain. A necessary 
requirement for product assembly in both PKS and NRPS assembly lines is posttranslational 
activation of acyl/peptidyl carrier proteins. 
1) Transfer of the acyl/aminoacyl-adenylate moiety onto the 4’ phosphopantetheine 
(Ppant) arm of the acyl carrier (ACP) or peptidyl carrier proteins (PCP)  
In order for a PCP or ACP to accept the acyl/peptidyl extender unit, they have to be 
activated via posttranslational modification. This activation is catalyzed by Ppant transferases 
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and proceeds by covalent attachment of the Ppant arm of coenzyme A onto the conserved 
active site serine of the carrier protein (Figure 10).  
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Figure 10. Postranslational activation of carrier protein via phosphopantetheinyl transferase 
(Ppant-ase) catalyzed reaction.  
 
In PK biosynthesis, the free thiol of the Ppant arm enables thioesterification (loading) 
of the acyl extender unit from the active site serine of the respective AT (acyl-O-Ser-AT) to 
form the acyl-S-ACP.[76] Similarly, during NRP assembly, the free thiol of the Ppant arm 
enables the conversion of the aminoacyladenylate oxoester (aminoacyl-O-AMP) into the 
thioester (aminoacyl-S-PCP) by displacing the AMP. 
 
2)Recognition and binding of the acyl-CoA (PKS) by acyltransferase (AT)/ recognition and 
activation of amino acid via adenylylation (NRPS) 
In PK biosynthesis selection of specific acyl-CoAs: acetyl, malonyl or methylmalonyl-
CoA is carried out by a malonyl (methylmalonyl)-specific acyltransferase (AT). This enzyme 
loads the acyl-CoA onto the active site serine. This results in transient generation of a 
tetrahedral intermediate and ends with the release of CoA and the formation of the acyl-
oxoester (Figure 11 a and b).  
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The first step of NRPS biosynthesis is catalyzed by an adenylylation (A) domain. 
Following the recognition of the cognate amino acid, determined by the specific set of 
residues residing within the A4-A5 substrate binding conserved boxes,[77] adenylation of the 
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Figure 11. a) and b) Initiation mechanisms of polyketide and c) nonribosomally-made peptide 
biosynthesis. a) In PKS, the loading module may encode a KSQ domain which functions as a 
decarboxylase during conversion of malonyl-S-ACP into acetyl-S-ACP. b) Alternatively, the 
AT loads an acetyl (propionyl)-CoA directly onto the first ACP. c) In NRP biosynthesis an 
amino acid first has to be activated as an oxoester adenylate by the A domain before it is 
transferred onto the PCP. This process requires hydrolysis of ATP.  
 
selected amino acid takes place at the expense of ATP (Figure 11 c). Even though the overall 
reaction of amino acid activation is similar to that performed by ribosomal aminoacyl-tRNA-
synthetases, adenylylation domains show lower substrate specificity. 
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Elongation of PK and NRP biosynthesis 
Condensation of the acyl/aminoacyl monomer onto the downstream module 
In PK biosynthesis, ketosynthase catalyzes decarboxylation of the downstream 
(methyl)malonyl-S-ACP and generates a thioester enolate nucleophile. Thioester enolate 
attacks the upstream acyl-S-ACP thioester resulting in the formation of a new C-C bond  
(Figure 12 a). However, in NRP biosynthesis the amine group of the downstream aminoacyl-
S-PCP performs a nucleophilic attack onto the upstream aminoacyl-S-PCP thioesters and 
leads to the formation of a peptide (C-N) bond (Figure 12 b). 
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Figure12. a) Elongation in PKS is catalyzed by KS domain and leads to C-C bond formation. 
b) In NRPS, the condensation is catalyzed by condensation domain (C), which governs 
peptide (C-N) bond formation. The thermodynamic driving force required for condensation 
reactions in both assembly lines comes from the energy-rich thioester-bound substrates.  
 
Reduction of β-ketoacyl intermediates 
In addition to the basic set of catalytic domains required for introduction and linking 
of the extender units, optional domains specialized in processing of the β-ketoacyl 
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intermediates can be present within modules. These include ketoreductase (KR), dehydratase 
(DH) and enoyl reductase (ER) domains, which result in β-hydroxyacyl, α,β-enoyl or fully 
reduced CH2-CH2 bonds (Figure 13). 
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Figure 13. Optional modification of β-ketoacyl intermediates of variable chain length R can 
be achieved through ketoreduction, dehydration and (or) enoyl reduction. These reactions are 
catalyzed by ketoreductase (KR), dehydratase (DH) and enoyl reductase(ER) domains. 
 
Termination of PKS and NRPS biosynthesis 
In both PKS and NRPS assembly lines the fully extended acyl/aminoacyl-S-CP 
thioesters are usually released from the assembly line by the thioesterase (TE) domain. In this 
reaction, oxygen of the conserved serine (Ser-O-) performs a nucleophilic attack on the fully 
extended acyl/aminoacyl-S-ACP thioester by converting it into the corresponding oxoester. 
This intermediate may be hydrolyzed from the assembly line to yield the free acids, or may 
form cyclic lactone structures via nucleophilic capture by one of the side chain hydroxyl 
groups (Figure 14). 
 
 
                                                                  
                                                               Introduction                                                                                            
 
26 
  
AT ACPKS TE
DH KR
AT ACPKS TE
KR
S
O
OH
OH
OH
O
OH
O
O
OH
OH
OH
O
OH
OH
O
O
OH
OH
O
6-DEBS
O
S
 
Figure 14. Release or termination of PKS and NRPS assembled products from the assembly 
line follows the same principle of conversion of thioester into oxoester. This figure illustrates 
the formation of the 6-deoxyerythronolide (DEBS) lactone (lactonization) by nucleophilic 
attack of a side hydroxyl group onto the oxoester. 
 
The most simplistic and best studied system employing the above presented, so called 
type I paradigm of polyketide assembly, is the system which carries out the biosynthesis of 6-
deoxyerythronolide B (DEBS), a precursor of erythromycin [78]. The DEBS assembly line 
consists of seven modules encoded within three 200 kDa big polypeptides. Figure 15 shows 
that each module contributes with one extension unit. Furthermore, the level of β-keto 
processing can be easily correlated with the presence of β-keto reducing domains present 
within each module, therefore allowing the structural prediction of the end product. This 
figure also illustrates an enormous potential of PK biosynthetic systems for the generation of 
structurally diverse compounds by optional recruitment of KR, DH, and ER domains. 
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Figure 15. Example of a typical type I PKS assembly line-biosynthetic scheme for the 
assembly of (DEBS) (Figure is reproduced from).[78] 
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Abstract  
Myxococcus xanthus DK1622 is shown to be a producer of myxovirescin (antibiotic 
TA) antibiotics. The myxovirescin biosynthetic gene cluster spans at least 21 open reading 
frames (ORFs), covering a chromosomal region of approximately 83 kb. In silico analysis of 
myxovirescin ORFs, in conjunction with genetic studies, suggests the involvement of 4 type I 
PKSs (TaI, TaL, TaO and TaP), one major hybrid NRPS/PKS (Ta-1), and a number of 
monofunctional enzymes similar to the ones involved in type II fatty acid biosyntesis (FAB). 
Whereas deletion of either taI or taL causes a dramatic drop in myxovirescin production, 
deletion of both genes (∆taIL) leads to its complete loss. These results suggest that both TaI 
and TaL PKSs may act in conjunction with a methyltransferase, reductases and a 
monooxygenase to produce the 2-hydroxyvaleryl-S-ACP starter, proposed to act as the 
biosynthetic primer in the initial condensation reaction with glycine. Polymerization of the 
remaining 11 acetates required for lactone formation is directed by 12 modules of Ta-1, TaO, 
and TaP megasynthetases. All modules, except for the first module of TaL, lack cognate 
acyltransferase (AT) domains.  Furthermore, deletion of a discrete tandem AT, encoded by 
taV, blocks myxovirescin production, suggesting their "in trans" mode of action. The 
assembly of the myxovirescin scaffold is proposed to switch two times during biosynthesis 
from PKS to HMG-CoA-like biochemistry to embellish the macrocycle with methyl and ethyl 
moieties. Disruption of the S-adenosyl methionine (SAM)-dependent methyltransferase TaQ 
shifts the production toward two novel myxovirescin analogues, designated myxovirescin Qa 
and myxovirescin Qc. NMR analysis of purified myxovirescin Qa reveals the loss of the 
methoxy carbon atom.  This novel analogue lacks bioactivity against Escherichia coli.  
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Introduction 
 
Type I polyketide synthases (PKS), nonribosomal peptide synthetases (NRPS), and 
their hybrids (PKS/NRPS) are multifunctional, multidomain enzymes responsible for the 
production of natural products by incorporation of small building blocks in assembly-line-like 
fashion that is analogous to animal fatty-acid biosynthesis (FAB).[1-2] In all three cases, the 
catalytic domains encoded within each module are responsible for the addition of one 
monomer unit to the growing chain, and its processing by various modification reactions. 
Typically, the fully extended product attached to the last module is dissociated from the 
megasynthetase to yield a free carboxylic acid or lactone structure, which undergoes further 
modifications by additional tailoring enzymes. 
Whereas the unifying theme of PKS, NRPS, and FAB pathways is the catalytic flux of 
thioester-activated intermediates along the megasynthetase, differences in the choice of 
extender units and connecting bonds are reflected in the catalytic domains used to drive 
nonribosomal peptide (NRP), polyketide (PK), or fatty-acid (FA) chain elongation. For 
instance, formation of the peptide bond by NRPSs requires recognition and ATP-driven 
activation of two amino acids by their cognate adenylyation domains (A), coupling of the 
respective adenylated amino acids onto their downstream peptidyl-carrier proteins (PCP), and 
their final condensation by the condensation domain (C).[3] In PKS and FAB pathways, 
selection and loading of extender acyl units are executed by acyltransferases (AT). C-C bond 
formation between the two acyl groups attached to acyl carrier proteins (ACPs) is catalyzed 
by β-ketoacyl-ACP synthase (KS) by decarboxylative Claisen condensation. Unlike saturated 
FA biosynthesis, PKSs display greater variability in the level of β-ketothioester reduction, and 
can combine β-ketoacyl reductase (KR), β-hydroxyacyl dehydratase (DH), and enoyl 
reductase (ER). Additionally, PKSs might also perform methylations of carbon and oxygen[4] 
with S-adenosylmethionine (SAM)-dependent methyltransferases (MT). Carbon-specific 
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methyltransferases couple the methyl group onto the activated α-carbon of the β-ketothioester 
intermediate, either during or post-assembly of the natural product. 
In contrast to the multifunctional type I PKSs and animal FAB megasynthases, FA 
biosynthesis in bacteria and higher plants is governed by monofunctional, iteratively-acting 
enzymes that are encoded as separate ORFs; these are designated type II FAB.[5] FAB in E. 
coli is initiated by KSIII (FabH), which performs the initial condensation of acetyl-CoA with 
malonyl-ACP to yield acetoacetyl-ACP. Two other β-ketoacyl-ACP synthases, KS I (FabF) 
and KAS II (FabB), carry out further elongation steps and show more specificity in their 
choice of substrates.[2, 6-8] 
A closer relationship between the type II FAB and PKS/NRPS-like natural product 
biosynthetic gene clusters came to light with the recent sequencing of pederin, mupirocin, and 
jamaicamide biosynthetic gene clusters.[9-12] In these systems type II FAB enzymes appear to 
act in concert with the type I PKS and NRP megasynthases to create potent natural products. 
Myxovirescins (also known as antibiotic TA) are wide-spectrum antibiotics that are 
active against Gram-negative bacteria, and have to date been exclusively found in the genus 
Myxococcus.[13-16] In addition to their antimicrobial activity, myxovirescins are exceptionally 
adhesive to a variety of surfaces and dental tissues, which makes them good leads for the 
treatment of plaque and gingivitis in humans.[17-19] The sequencing of several ORFs that 
belong to the myxovirescin biosynthetic cluster in the red-pigmented Myxococcus xanthus 
strain ER-15, has been carried out. However, these studies have led to a great underestimation 
of the size of the biosynthetic gene cluster[20] and have failed to pinpoint the function of 
individual genes in myxovirescin biosynthesis, as polar effects of the described mutations 
could not be excluded.[20-24] 
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This is the first report on the identification, isolation, and structure elucidation of 
myxovirescin antibiotics from M. xanthus strain DK1622. Furthermore, based on the genome 
sequence of M. xanthus DK1622, we present the annotation of the complete myxovirescin 
biosynthetic gene cluster, propose its biosynthetic assembly, and by performing a series of in-
frame gene deletions provide the first unambiguous genetic evidence for the involvement of 
certain genes in myxovirescin assembly. Finally, we demonstrate that M. xanthus DK1622 is 
a valuable genetic system for biosynthetic studies and genetic engineering of PKS/NRPS 
pathways, as disruption of the SAM-dependent methyltransferase, TaQ, leads to the 
production of two novel desmethyl analogues of myxovirescin. 
 
Results 
 
M. xanthus DK1622 produces myxovirescin antibiotics 
 
The first hint that M. xanthus DK1622 could be a myxovirescin producer arose when we 
analyzed its genome for the presence of secondary-metabolite biosynthetic genes.[25] The 
genome was analyzed by performing a BLAST search with the previously reported 
PKS/NRPS fragment from ta-1 from M. xanthus ER-15, which has been shown to be 
responsible for myxovirescin biosynthesis. The search revealed the presence of an almost 
identical gene in strain DK1622. Additionally, Ta-1 was identified by MALDI-TOF analysis 
in one of the fractions obtained in the membrane-separation experiments.[26] To find out 
whether M. xanthus DK1622 is indeed a myxovirescin producer, HPLC and MS analyses 
were carried out. These revealed two characteristic peaks with a UV maximum at 239 nm 
(Figure 1 A) and masses diagnostic of myxovirescin antibiotics.[27] Due to the fact that more 
than 30 myxovirescin analogues have been described from the related strain M. virescens Mx 
v48, we set out to perform a detailed chemical analysis of the two substances from strain 
DK1622.  
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Figure 1. HPLC chromatogram traces of A) wild-type M. xanthus DK1622 strain, B) tandem 
acyltransferase mutant ΔtaV (VS1017), and C) methyltransferase mutant taQ (VS1016) 
measured at 239 nm; 1 and 2 elute at 15.2 min and 20.4 min, respectively. M. xanthus 
VS1016 produced two novel metabolites with retention times of 13.9 and 18.5 min. 
 
 
Structural analysis of myxovirescins produced by M. xanthus DK1622 
 
According to high-resolution mass spectroscopy data and NMR analysis (Supporting 
Information), the two substances that showed retention times of 15.2 and 20.4 min (Figure 1 
A) were identified as compounds 1 and 2 (Figure 2 A); NMR measurements were performed 
in CD3OD.  
Analysis of the myxovirescin biosynthetic gene cluster 
 
The myxovirescin biosynthetic gene cluster spans approximately 83 kb (Figure 2 B). It 
is dominated by four ORFs that encode type I PKSs (TaI, TaL, TaO, and TaP) and one major 
PKS/NRPS hybrid, Ta-1. Type I PKSs are flanked from both sides with various individual 
ORFs (taA-taY and taQ-taS), which show similarity to enzymes involved in type II FAS 
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systems (taV, taB-C, taE-F, taK, taX, and taY). The closest homologues of myxovirescin 
ORFs were found in the biosynthetic gene clusters of pederin, mupirocin, and leinamycin 
(Table 1).[10-11, 28]  
 
 
 
 
 
 
 
 
 
 
 
Figure 2. A) Stable isotope labeling of myxovirescin A, adopted from.[16] Myxovirescin C 
(2), the second major product, lacks the oxygen at C20. Boxed carbons originate from 
glycine,  carbons indicate C2 of acetate,  indicate methyl groups derived from methionine, 
and  show the ethyl group that originates from succinate. B) Map of the 82.8 kb 
myxovirescin biosynthetic gene cluster. 
 
Analysis of domains that comprise the myxovirescin megasynthetase 
 
β-Ketoacyl synthases (KS): The myxovirescin biosynthetic gene cluster encodes 16 KS 
domains (Figure 3 A), 13 of which are conserved in the active-site Cys (box 1) and two His 
residues (boxes 2 and 3 in Figure 3 A).[29] Two KSs, TaL_KS1 (the first one found in TaL) 
and KS3, display a His to Gln substitution in the conserved box 2. However, TaK, the only 
discretely encoded β-ketoacyl-ACP synthase, carries a Cys to Ser substitution in the active 
site (Figure 3 A). 
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Table 1. List of myxovirescin ORFs and their protein homologues. 
 
ORF Protein/ 
gene 
Size [Da/bp] Putative 
function/homologue
Origin Similarity/ 
Identity 
Accession 
number of 
     [%] the protein 
homologue 
 
1 TaA/taA 18406/507 transcription 
antiterminator 
Bacteriodes 
thetaiotaomicron 
29/50 AAO77992.1 
2 TaB/taB 9270/252 ACP Bacillus subtilis 
subsp. subtilis strain 
168 
53/77 NP_570904.1 
3 TaC/taC 44851/1239 HMG-CoA synthase 
PksG 
Bacillus subtilis 
subsp. subtilis strain 
168 
66/80 NP_389595.2 
4 TaD/taD 34534/930 unknown    
5 TaE/taE 9170/252 ACP Streptomyces 
atroolivaceus 
41/67 AAN85525.1 
6 TaF/taF 46134/1263 HMG-CoA synthase Streptomyces 
atroolivaceus 
62/75 AAN85526.1 
7 TaG/taG 19599/516 lipoprotein signal 
peptidase II 
Clostridium tetani 
E88 
35/57 NP_782221.1 
8 TaH/taH 53110/1428 cytochrome P450-
dependent enzyme 
Polyangium 
celullosum 
38/56 CAD43453.1 
9 TaV/taV 71444/1974 acyltransferase 
MmpIII 
Pseudomonas 
fluorescens 
43/58 AAM12912.1 
10 TaK 43880/1254 KS I/II PksF Bacillus subtilis 
subsp. subtilis strain 
168 
54/72 NP_389594.1 
11 TaX 29229/789 enoyl-CoA 
hydratase/isomerase
Burkholderia mallei 
ATTC 23344 
56/71 YP_105854.1 
12 TaY 24880/666 enoyl-CoA 
hydratase/isomerase 
PksI 
Bacillus subtilis 
subsp. subtilis strain 
168 
65/79 NP_389597.1 
13 TaI 229067/6267 Pks type I symbiont bacterium 
of Paederus fuscipes 
37/51 AAR19304.1 
14 TaJ 43715/1179 oxygenase OnnC symbiont bacterium 
of Theonella swinhoei
64/79 AAV97871.1 
15 TaL 235874/6549 Pks type I Bacillus subtilis 
subsp. subtilis strain 
168 
47/65 NP_389602.2 
16 Ta-1/ta-1 978123/27 135 OnnI PKS symbiont bacterium 
of Theonella swinhoei
44/60 AAV97877.1 
17 TaN/taN 53325/1458 dioxygenase MmpIII Pseudomonas 
fluorescens 
54/74 AAM12912.1 
18 TaO/taO 547875/15318 Pks type I Bacillus subtilis 
subsp. subtilis strain 
168 
47/65 NP_389602.2 
19 TaP/taP 330422/9114 PksM polyketide 
synthase 
Bacillus subtilis strain 
168 
35/53 NP_389601.2 
20 TaQ/taQ 35468/951 SAM-dependent 
methyltransferase 
Mycobacterium 
tuberculosis 
38/54 NP_217468.1 
21  TaT/taT 37567/1041 unknown, containing 
DTW repeat domain
Bdellovibrio 
Bacteriovorus HD 
100 
33/51 CAE79280 
22 TaS/taS 333/999 radical SAM 
methyltransferase 
Clostridium 
beijerinckii 
31/50 AAS91673 
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Figure 3. Clustal W alignments of the catalytic and conserved domains of: A) β-ketoacyl-
ACP synthases (KS), B) β-ketoacyl-ACP reductases (KR), C) acyltransferases (AT), D) 
methyltransferase (MT), and E) 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) synthases. 
The active-site residues are shown in light gray, active-site substitutions are highlighted in 
dark gray, conserved residues are shown as white letters and are highlighted in dark gray, and 
similar amino acids are presented as white letters on a black background. The numbers 
indicate amino-acid positions within sequences and (X)n indicates the number of amino acids 
that separate the active-site residues. The accession numbers of acyltransferase homologues 
are given in parentheses: PedD from Pederus beetles (AAS47563), PksC and PksE from B. 
subtilis (NP_389591 and CAB13584), MmpIII from Pseudomonas fluorescens (AAM12912), 
LnmG from Streptomyces atroolivaceus (AAN85520), and ORF15 from Streptomyces rochei 
(NP_851437). The accession number of Staphylococcus aureus HMG-CoA synthase is 
AAG02422. 
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Ketoreductase (KR): Three ketoreductases, KR1, KR2, and KR4, display slight 
alterations in the Rosmann fold (GxGxxG), which is required for NADP(H) binding (Figure 3 
B). However, all nine KR domains contain the completely conserved Lys-Ser-Tyr catalytic 
triad that is necessary for ketoreduction.[30] 
Dehydratases (DH): All seven DH domains encoded in the cluster contain a conserved 
His (X)13 Glu signature, in which His and Glu form a catalytic diad that is required for 
enzymatic activity.[29] 
Enoyl reductases (ER): The myxovirescin cluster encodes two ER domains. Both of 
these show high identity with Zn-dependent alcohol dehydrogenases (Conserved domain 
search: COG1064), as well as with enoyl reductases from other systems. Whereas both ERs 
possess the conserved catalytic Tyr and Lys residues,[29] they occupy unusual positions within 
PKS modules (see below). 
Acyl-carrier proteins (ACP): All ACPs encoded in the cluster show the conserved 
catalytic Ser residue. 
Acyltransferases (AT): The myxovirescin cluster has only one atypical AT domain 
encoded within its functional modules (see below). Two more acyltransferases (AT1 and 
AT2; Table 2) are encoded discretely on the same open reading frame designated taV.  Both 
AT1 and AT2 contain a conserved active-site Ser, as well as a His residue that is specific for 
the binding of malonyl-CoA.[31] In a BLAST search, TaV showed the highest similarity to AT 
domains found in pederin, mupirocin, leinamycin, and lankacidin clusters (Figure 3C). All 
these biosynthetic gene clusters lack ATs as integral part of their modules and are referred to 
as "AT-less" or "trans-AT" type I PKSs;[32] instead, they contain separately encoded ATs that 
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Table 2. List of myxovirescin biosynthetic enzymes containing PKS/NRPS domains. 
 
 
Protein Size(Da)  Encoded domains with coordinates in the protein sequence 
 
TaV 71444  AT1 (1-330), AT2 (363-658) 
TaK 43880  KSS 
TaI 229067  GNAT (559-629), ACP (767-808)  
   KS (839-1263), KR (1694-1875),  
ACP (2014-2079) 
TaL 235874 
 
 KS (32-460), KR (1091-1248),  
ACP (1344-1410) 
   KS (1441-1867), ACP (2066-2132) 
Ta-1 978123 
 
NRPS module C (98-538), A (537-1041), PCP (1063-1125) 
  Module 1 KS1 (1154-1582), KR1  
(1932-2109),  
ACP1 (2200-2257) 
  Module 2 KS2 (2300-2737), KR2  
(3357-3543),  
ACP2 (3668-3724) 
  Module 3 KS3 (3759-4181), ACP3 (4391-4443) 
  Module 4 KS4 (4474-4893), KR4 (5547-5730), ACP4 (5823-5880) 
  Module 5 KS5 (5929-6365), ACP5 (6621-6680) 
  Module 6 KS6 (6736-7155), DH6 (7360-7511), KR6 (7819-8002), ACP6  
(8097-8152) 
  Module 7 KS7 (8198-8634), ACP7 (8938-8997) 
TaO 547875 
 
Module 8 ER8 (58-356), KS8 (409-831), DH8 (1041-1179), KR8 (1474-
1662), ACP8 (1759-1812) 
  Module 9 KS9 (1873-2309), DH9 (2500-2666), ACP9 (2830-2886) 
  Module 10 KS10 (2945-3381), DH10 (3564-3736), KR10 (4027-4226), ACP10 
(4327-4384), KS10 (4458-4893) 
TaP 330422 
 
Module 11 MT11 (101-382), ACP11  
(399-446) 
  Module 12 KS12 (502-922), KR12 (1615-1799), MT12 (2008-2280), ACP12 
(2294-2345), ER12 (2294-2345), TE12 (2756-2919) 
 
are thought to act iteratively. Recently, myxobacterial biosynthetic gene clusters responsible 
for the production of disorazol and chivosazol have also been reported to have such gene 
organization.[33-34] Nevertheless, only mupirocin and myxovirescin biosynthetic gene clusters 
contain two AT domains that are encoded as one ORF. 
Methyltransferases (MT): Even though feeding studies with 13C-labeled precursors 
indicate the incorporation of four methyl groups (derived from methionine) into 
myxovirescin[16] (Figure 2 A), only three putative SAM-dependent MT domains are found to 
be encoded in the cluster. Two of these MT domains, MT11 and MT12, are located within 
modules 11 and 12 of TaP (Table 2). The third putative SAM-dependent MT is encoded by 
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taQ, which is immediately downstream of taP. All three MTs contain the conserved SAM-
binding motif, V(I)LEV(I)GXG [35] (Figure 3 D). The only candidate that can carry out the 
fourth methylation is TaS, and the corresponding gene is located at the 3’ end of the cluster, 
about 2.7 kb downstream of taQ (Figure 2 A). 
HMG-CoA synthases/β-ketoacyl-ACP synthase III (FabH): The taC and taF gene 
products show similarity to HMG-CoA synthases and β-ketoacyl-ACP synthases III (FabH). 
The closest homologues of TaC are putative HMG-CoA synthases (PksG) from Bacillus 
subtilis subsp. subtilis strain 168 (66% identity, 80% similarity) and JamH from Lyngbya 
majuscula (64% identity, 77% similarity). TaF shares the highest similarity with the putative 
HMG-CoA synthases LnmM from Streptomyces atroolivaceus (62% identity, 75% 
similarity), and CurD from L. majuscula (47% identity, 65% similarity). Furthermore, both 
TaC and TaF share the conserved Cys-His-Asp catalytic triad with numerous HMG-CoA 
synthases that are involved in the mevalonate pathway, including that from Streptococcus 
aureus (Figure 3 E).[36] 
Genetic analysis of the myxovirescin biosynthetic gene cluster 
To elucidate the function of individual genes in myxovirescin biosynthesis, large 
regions of taV that encode the AT1 and AT2 domains, as well as large regions of taI and taL 
PKSs, were deleted in-frame to ensure the absence of polar effects on downstream ORFs 
(Tables 2 and 3). In addition, the putative methyltransferase, taQ, which is located at the very 
end of the gene cluster (Figure 2 B), was disrupted by plasmid insertion. Wild-type DK1622 
and mutant cells that were fermented with XAD adsorbent resin were extracted with methanol 
(see Experimental Section) and analyzed by HPLC. Unlike wild-type M. xanthus DK1622, 
which produces myxovirescins A and C (Figure 1A), both ΔtaV (VS1017) and taQ (VS1016) 
mutant extracts showed loss of myxovirescin production (Figure 1 B and C). In addition, the  
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                                  Table 3. List of plasmids and strains used in the study. 
 
Plasmid Description of construction 
 
pVS23 639 bp PCR product amplified by using primer pair taV1 and taV2, which contained NotI and SpeI restriction sites, 
respectively, and cloned into pCR2.1-TOPO 
pVS26 662 bp PCR product amplified by using primer pair taV3 and taV4, which contained SpeI and SacI sites, respectively, 
and cloned into pCR2.1-TOPO 
pVS27 1295 bp fragment derived by ligating the 639 bp insert from pVS23 (digested with NotI and SpeI) with the 662 bp 
insert from pVS26 (digested with SpeI and SacI); product was cloned into the NotI and SpeI sites of pSWU41 
pVS50 580 bp PCR product generated by using primer pair taI1 and taI2, which contained XbaI and BamHI sites, 
respectively, and cloned into pCR2.1-TOPO 
pVS51 578 bp PCR product generated by using primer pair taI3 and taI4, which contained BamHI and SpeI sites, 
respectively, and cloned into pCR2.1-TOPO 
pVS52 1152 bp fragment derived by ligating the 580 bp insert from pVS50 (digested with XbaI and BamHI) and the 578 bp 
insert from pVS51 (digested with BamHI and SpeI); product was cloned into the XbaI and SpeI sites of pSWU41 
pVS48 564 bp PCR product generated by using primer pair taL1 and taL2, which contained XbaI and BamHI sites, 
respectively, and cloned into pCR2.1-TOPO 
pVS49 563 bp PCR product generated by using primer pair taL3 and taL4, which contained BamHI and SpeI sites, 
respectively, and cloned into pCR2.1-TOPO 
pVS61 1121 bp fragment derived by ligating the 564 bp insert from pVS48 (digested with XbaI and BamHI) and the 563 bp 
insert from pVS49 (digested with BamHI and SpeI); product was cloned into the XbaI and SpeI sites of pSWU41 
pVS16 450 bp PCR product amplified by using the taQ_knock_frw and taQ_knock_rev primer pair, and cloned in pCR2.1-
TOPO 
pVS75 824 bp PCR product amplified by using taOseq_up and taOseq_down primer pair, and cloned into pCR2.1-TOPO 
  
M. xanthus 
strains 
Genotype description 
DK1622 Wild type 
VS1017 
(ΔtaV) 
Δ1455 bp encoding for AT1 and AT2  
VS1024 
(ΔtaI) 
Δ4044 bp encoding for ACP-KS-KR-ACP domains 
VS1025 
(ΔtaL) 
Δ2382 bp encoding for ACP-KS-ACP domains 
VS1029 
(ΔtaIL) 
Δ4044 bp encoding for ACP-KS-KR-ACP of taI and Δ 2382 bp encoding for ACP-KS-ACP of taL 
VS1016 
(taQ) 
merodiploid mutant created by homologous recombination of pVS16 into the genome of M. xanthus DK1622 
 
 
taQ knockout produced two novel metabolites with retention times of 13.9 and 18.5 min 
(Figure 1 C); these were found to be in the same 5:1 ratio as 1 and 2 in the wild-type cells.  
Investigation of ΔtaI and ΔtaL mutant extracts by HPLC-MS revealed that both M. 
xanthus strains VS1024 and VS1025 display a dramatic drop in antibiotic production 
compared to the wild-type cells (Figure 4 A-C). In order to determine their exact 
concentrations, we developed a quantitative HPLC-MS method that can quantify 1 down to 1 
ng mL-1 (Experimental Section). Using this method, we measured an approximately 100000-
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fold drop in myxovirescin production in both ΔtaI and ΔtaL mutants, in comparison to wild-
type production levels (data not shown). To test whether myxovirescin production persists in 
the absence of both TaI and TaL PKSs, a double ΔtaIL mutant was created (VS1029) and 
analyzed in the same fashion. Deletion of large regions of both genes in strain VS1029 clearly 
led to complete abolishment of myxovirescin production (Figure 4 D).  
                               
 
 
Figure 4. Extracted ion-mass chromatograms (EIC) of myxovirescin A from A) wild-type 
DK1622, B) ΔtaI PKS (VS1024), C) ΔtaL PKS (VS1025), and D) ΔtaIL double PKS mutant 
(VS1029). The high detection ability of the HPLC/MS analysis revealed miniscule levels of 1 
in ΔtaI and ΔtaL mutants (see Experimental Section). Nevertheless, deletion of both PKS-
encoding genes in ΔtaIL mutants led to complete abolishment of myxovirescin production. E) 
MS-MS fragmentation pattern of 1. 
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TaQ is an O-methyltransferase specific for the C29 oxygen 
 
To elucidate the role of taQ methyltransferase, the novel product with the 13.9 min 
retention time (Figure 1 C; exact mass of 610.43248 [M+H]+ and molecular formula 
C34H60NO8) was purified from XAD-adsorbent beads that were cofermented with M. xanthus 
VS1016 culture (8 L), and used for detailed NMR analysis (Table 4).  
MS analysis confirmed the postulated loss of m/z 14 expected for the loss of one 
methyl group. In addition, 1H and 13C NMR spectroscopy data of 3 (Scheme 1A and Table 4) 
were similar to those observed for myxovirescin A,[37] and revealed C20 and C4 ketones (δC =  
Table 4. NMR data of 3 in CDCl3. 
 
Carbon 13C 1H  J (Hz) m Carbon 13C 1H  J (Hz) m 
        
1 18.1 1.36 m 18 21.8 1.69 1.34 
m 
m 
2 34.2 1.82 m 19 42.9 2.40 2.22 
m 
m 
3 73.2 5.24 m 20 212.5 - - 
4 171.6 - - 21 42.4 2.39 m 
5 44.8 3.5 m 22 23.5 1.53 m 
6 69.8 3.96 m 23 26.5 1.24 1.14 (7) 
s 
d 
7 37.4 2.12 1.48 
m 
m 24 36.6 
1.34 
1.06 
m 
m 
8 71.8 3.6 m 25 30.2 1.24 s 
9 80.0 3.3 m 26 41.2 1.63 1.28 
m 
m 
10 29.4 2.09 1.37 
m 
m 27 36.8 2.60 m 
11 31.9 2.5 2.26 
m 
m 28 175.8 - - 
12 146.4 - - 29 108.3 4.79 4.77 
s 
s 
13 80.6 4.21 (9) d  30 * 34.2 1.82 m 
14 129.2 5.50 (15/8) dd 31 12.0 0.84 (7) t 
15 139.7 5.30 (15/11) dd 32 13.7 0.92 (7) t 
16 45.1 1.89 m 33 17.4 1.14  (7) d 
  17 * 34.11 1.41 1.09 
m 
m 34 20.0 0.85 (7) d 
 
                          * indicate interchangeable carbons 
 
 
212.5 and δC = 171.6, respectively), a C28 ester (δC = 175.8), and a secondary amide (δH = 
6.78), together with four secondary alcohols specific to carbons C3, C6, C8, and C9. Overall, 
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the upper part of 3 was found to be in good agreement with that of 1, whereas the lower part 
of the molecule (C5-C15, including C29) indicated structural changes. In addition, the spectra 
of 3 lacked signals for a methoxy group. Moreover, an additional resonance specific for a 
secondary alcohol connected to C13 appeared at δC = 80.6 and δH = 4.21. Another deviation 
between the two compounds was specific to the positions of two double bonds. Whereas 1 
displays a conjugated, disubstituted system specific to C12 and C14 in the macrocycle, 
careful analysis of the chemical shifts of 3 revealed two isolated double bonds; one of them 
comprised an exo-methylene group made of a quaternary carbon C12 (δC = 146.4,) and C29 (t, 
δC = 108.3; δH = 4.79 and 4.77, both broad s). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1. A) Structure of a novel desmethyl analogue of myxovirescin A (3) elucidated by 
NMR spectroscopy. The bonds shown in bold indicate two fragments deduced from 1H,1H 
COSY and HSQC correlations. B) Hydroxylations of two postulated intermediates that result 
from PKS/HMG-CoA reactions. According to the first possibility, hydroxylation at C29 of the 
diene-containing myxovirescin precursor produces intermediate 4, whereas hydroxylation at 
C13 of the exo-methylene-like myxovirescin precursor yields 3. C) Hypothetical conversion 
of 3 into 4 and vice versa, which could take place either by enzymatic or nonenzymatic 
isomerization, might explain the existence of 3 as the main structure revealed by NMR 
 
 
                                                                    Chapter 2                                                           
 
44 
spectroscopy. In wild-type cells, 4 acts as a substrate for TaQ to yield mature myxovirescin A 
(1). 
 
The structure of the C5-C15 fragment, which includes C29, was deduced from 1H,1H 
COSY and HSQC spectra. This allowed the construction of the two fragments shown in bold 
in Scheme 1 A. The first fragment (C12-C16) contains two double bonds separated by a 
secondary-alcohol function at C13. In the 1H,1H COSY, two exo-methylene protons of C29 
showed long-range couplings to the broad doublet of the methine proton of C13, which 
displayed further vicinal correlation to the olefinic proton of C14 at δH = 5.50. The other 
olefinic proton (δH = 5.30) showed the same neighbourhood as in 1 and was therefore 
assigned to C15. The 1H,1H COSY of the second fragment (C5-C11) indicated a complete 
conservation of the connectivity in this part of the molecule.  The confirmation of the  
                                 
 
Figure 5. A) Antibiotic-activity test performed with myxovirescin A (10 µg) and B) its 
desmethyl analogue 3, which were spotted on a filter disc and layered on the lawn of E. coli 
XL-1 blue cells. The lack of inhibition by 3 suggests the indispensability of O-specific 
methylation for the antimicrobial activity of the myxovirescin antibiotic. 
 
structure for 3 was performed by using NMR prediction tools, which calculated similar 
resonance values for the respective carbon and hydrogen atoms. To our surprise, the O-
desmethyl analogue of 1 failed to inhibit E. coli growth in the standard antibiotic assay 
(Figure 5).  
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Proposed biosynthesis of myxovirescin A 
The myxovirescin gene cluster belongs to the "trans-AT" type of natural product 
biosynthetic gene clusters 
All modules of the myxovirescin biosynthetic gene cluster-with the exception of the 
first module of TaI-lack AT domains. Instead, two acyltransferase domains are encoded by 
taV (Table 2). Based on the biochemical evidence that indicates the "trans" activity of 
acyltransferase LnmG of the leinamycin system, which is shown to load malonyl-CoA on 
every ACP of leinamycin megasynthetase,[38] we assumed a similar function for TaV. This 
hypothesis was confirmed by an in-frame deletion of taV, which led to a myxovirescin-
negative phenotype (Figure 1B). 
Starter biosynthesis 
Feeding studies and the overall organization of the myxovirescin gene cluster suggest 
that biosynthesis of the myxovirescin starter unit takes place by fusion of an acetyl-S-ACP 
with malonyl-S-ACP. This is followed by subsequent methylation of the C1 carbon, 
reductions of C2, and hydroxylation of C3 (Scheme 2). The likely candidates for the first 
biosynthetic step are one or both of the first two modular PKSs, TaI and TaL. 
TaI contains a peculiar GNAT domain (see below), followed by ACP-KS-KR-ACP 
domains. The GNAT superfamily of acetyltransferases perform nitrogen-specific 
acetylationreactions on a wide range of substrates, including glycosides, either to achieve 
antibiotic resistance,[39] or to tolerate their own phytotoxins.[40] The GNAT domain of the 
myxovirescin gene cluster shows close similarity to such domains found in the onnamide, 
pederin, and curacin A biosynthetic systems.[9, 41, 42] However, the function of GNAT domains 
in these systems remains obscure. Although the GNAT domain in myxovirescin biosynthesis 
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could catalyze the transfer of the starter moiety to the nitrogen atom of glycine, a more likely 
candidate for this reaction is the C domain of the NRPS module of Ta-1 (see below).                                        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2. Two possible routes to starter biosynthesis. Both TaI and TaL could catalyze the 
first biosynthetic reaction of fusing acetyl-S-ACP with malonyl-S-ACP to yield acetoacetyl-S-
ACP. Acetoacetyl-S-ACP would have to undergo methylation at C1, followed by reductions 
of C2, and final hydroxylation at C3 to yield the C3-hydroxyvaleryl-ACP starter. 
 
Starter biosynthesis could be initiated by loading of CoA-activated acetate and malonate onto 
the two ACPs of TaI by the TaV "trans-ATs," each of which might be responsible for 
transferring one substrate. Next, the TaI KS might catalyze their decarboxylative 
condensation to form an acetoacetyl-S-ACP (Scheme 2). 
The other PKS, TaL, consists of KS-KR-ACP-KS-ACP domains. The first KS domain 
of TaL (TaL-KS1) contains a His to Gln substitution in the conserved box 2 (Figure 3 A), 
which most likely renders it inactive as a condensing enzyme.[29] This mutant KS, referred to 
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in the text as KSH/Q, should be distinguished from KSQ synthase mutants which have 
characteristic active-site Cys to Gln substitutions.[43, 44] The KSH/Q mutation, also observed in 
KS1 of MmpA of the mupirocin biosynthetic gene cluster, was shown to be indispensable for 
mupirocin production, both by deletion of the whole KS domain and by point mutation of the 
active-site Cys to Ala. El-Sayed et al. proposed that KSH/Q might act as a pseudo-loading 
module that either enables the transfer of an intermediate from MmpD to MmpA or loads the 
starter on MmpD.[11] Whereas KSH/Q could help to load the acetyl-CoA onto TaL-ACP1, 
KSH/Q-mediated transfer of intermediates from TaI to TaL is not plausible because it would 
increase the length of the presumed starter unit from 4 to 6 carbons. Finally, TaL-KS2 might 
catalyze decarboxylative condensation of acetyl-S-ACP and malonyl-S-ACP to yield 
acetoacetyl-ACP. 
Irrespective of whether TaI or TaL performs the first biosynthetic step of fusing 
acetyl-S-ACP with malonyl-S-ACP, both PKSs lack adequate biosynthetic domains that are 
needed for the full reduction of the C2 carbon. This suggests an additional interplay of 
"trans"-acting reductive domains in starter assembly. SAM-derived methylation at the C1 
position might be carried out by TaS (Table 1) early during starter biosynthesis, whereas 
oxygenation of C3 could be carried out by the TaJ monooxygenase, the gene for which is 
found to be transcriptionally coupled to taL (Scheme 2). 
To find out which PKS carries out the first biosynthetic step, we have separately 
deleted ACP-KS-KR-ACP coding regions of taI and ACP-KS-ACP coding regions of taL 
(Table 3), and analyzed production of 1 in the resulting mutants. To our surprise, quantitative 
HPLC-MS analysis of both ΔtaI and ΔtaL extracts indicated approximately 100000-fold 
reduction in myxovirescin production compared to the wild-type strain. To further clarify 
whether precursor biosynthesis is dependent on the presence of TaI and TaL PKSs, channeled 
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from the metabolic pool, or simply a product of another PKS encoded in the genome, a double 
ΔtaIL mutant was created (Table 3). The complete loss of myxovirescin production in ΔtaIL 
mutants (Figure 4 D) rules out the second and third possibility and indicates the direct 
involvement of TaI and TaL PKSs in starter biosynthesis. Furthermore, basal levels of 1 in 
ΔtaI and ΔtaL and its absence in ΔtaIL mutants argue that either PKS (TaI or TaL) is 
adequate for starter biosynthesis and myxovirescin production, and eliminates the possibility 
of transfer of an intermediate from TaI to TaL during biosynthesis. Moreover, involvement of 
TaI and TaL in later steps of polyketide assembly seems equally unlikely due to the good 
agreement of the proposed biosynthetic pathway with the enzymatic functions of Ta-1, TaO, 
and TaP (see below). Finally, the dramatic reductions of myxovirescin production in ΔtaI and 
ΔtaL mutants suggests that both TaI and TaL are required for wild-type levels of antibiotic 
production- possibly by adding to the structural stability of the myxovirescin megasynthetase. 
Assembly of myxovirescin A combines HMG-CoA synthase and PKS/NRPS enzymology 
Following biosynthesis of the putative starter moiety, 2-hydroxyvaleryl-S-ACP, the 
NRPS module located at the N terminus of Ta-1 extends this molecule with glycine. The 
adenylylation domain shows a very good agreement with the conserved core region that is 
specific for activation of glycine (DILQLGMIWK)[45] This confirms the results obtained from 
isotope-labeling experiments.[27] Consistent with 1, modules 1 and 2 are expected to follow 
typical PKS assembly-line logic to yield intermediate 5 (Figure 6).  
Module 3 consists of an ACP with the conserved active-site Ser, and a KSH/Q β-
ketosynthase, which is thought to be capable of binding the intermediate to the active-site 
Cys, but which is defective in decarboxylation of the substrate required for elongative 
condensation (see above). Even though module 3 is not likely to be involved in the extension 
of 5, it might be involved in the transfer of the acyl chain to module 4 either through KS3H/Q 
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and ACP3, or directly through ACP3. Mutagenesis studies performed on KS1H/Q of the 
mupirocin system have shown that its active-site Cys is essential for mupirocin production.[11] 
In addition, the above hypothesis is also supported by extensive studies of the PikAIV PKS 
that harbors the last module (module 6) of the pikromycin PKS. This module was thought to 
be skipped when the shorter, 10-deoxymethynolide hexaketide was produced instead of the 
heptaketide narbonolide. However, contrary to expectations, active-site mutagenesis (KS, AT, 
and ACP) of module 6 proved essential, leading to a model that proposed transacylation of the 
product by KS6 and ACP6 without its subsequent elongation.[46] TaK KSS carries out the 
second round of decarboxylation and dehydration reactions, while the second enoyl-CoA 
hydratase/isomerase, TaY, performs the final isomerization to yield intermediate 9. If it is not  
Figure 6. The proposed biosynthesis pathway of myxovirescin A switches two times from 
PKS to HMG-CoA synthase biochemistry. The enzymatic domains are: KS: β-ketosynthase, 
KSH/Q: nonfunctional KS, AT: acyltransferase, KR: ketoreductase, DH: dehydratase, ER: 
enoylreductase, MT: methyltransferase, ACP: acyl-carrier protein, TE: thioesterase, C: 
condensation domain, A: adenylylation domain, PCP: peptidyl-carrier protein, HMG:  
3-hydroxy-3-methylglutaryl synthase, ECH: enoyl-CoA hydratase, KSS: decarboxylase. 
Intermediate 6 attached to ACP5 is shown in abbreviated form to accentuate its resemblance 
to acetoacetyl-CoA. During the first round of HMG-box  reactions, TaC is predicted to add 
acetate onto the β-keto position of 6, while the KSS, TaK, performs sequential 
decarboxylation and dehydration. The modified product undergoes final isomerization by the 
TaX enoyl-CoA hydratase to yield intermediate 7. Intermediate 7 is then subjected to two 
more rounds of PKS extensions directed by modules 6 and 7 to form intermediate 8. In the 
second round of HMG-box reactions, TaF adds propionyl-CoA onto the β-keto position of 8, 
TaK KSS carries out the second round of decarboxylation and dehydration reactions, while the 
second enoyl-CoA hydratase/isomerase TaY performs the final isomerization to yield 
intermediate 9. 
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transferred by module 3, 5 might alternatively be moved directly from ACP2 to KS4 and 
thereby completely bypasses module 3. An example for such a mechanism was recently 
found in the NRPS system that encodes for myxochromide S, in which module 4 was shown 
to be completely skipped during biosynthesis.[47] 
           Following transfer of 5 to KS4, module 4 is proposed to contribute with another 
extension unit while performing β-ketoreduction and dehydration on C10, whereas minimal 
module 5, which consists of only KS and ACP domains, leads to the formation of 
intermediate 6. The isotope labeling scheme, which indicates the addition of a C2 atom of 
acetate at carbon C12 (Figure 2 A), and structural analogy of intermediate 6 with 
acetoacetyl-CoA (Figure 6), suggest that intermediate 6 might be the substrate of a HMG-
CoA synthase-like enzyme. 
           HMG-CoA synthases perform Claisen condensation by mediating the attack of 
acetyl-CoA on the β-keto group of acetoacetyl-CoA.[36] Following addition of acetate at the 
C12 keto carbon of 6, sequential decarboxylation, water elimination (possibly involving 
activation of the hydroxyl group), and isomerization reactions would be required to obtain 
intermediate 7. In our model, TaC HMG-CoA synthase is depicted to add acetate, TaK β-
keto synthase with the Cys to Ser active-site substitution (KSS) would carry out the 
decarboxylation, and the enoyl-CoA hydratase (ECH), TaX, would perform the 
isomerization reactions (Figure 6). The assignment of TaK as decarboxylase was based on 
biochemical studies of Cys to Ser KS point mutants in E. coli. For instance, a Cys to Ser 
mutant of KSI was shown to bind and decarboxylate myristic acid. However, the enzyme’s 
ability to perform condensation was severely compromised.[48] In addition, a Cys to Ser 
mutant of E. coli KSIII exhibited a 425% higher decarboxylation activity than the wild 
type.[49] Decarboxylation enzymes such as KSS might be needed to compensate for the 
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presence of a poor leaving group, such as hydroxyl, which is found in the proposed 
intermediate (Figure 6). In the mevalonate pathway this situation is circumvented by 
activation of the hydroxyl by phosphorylation.[50] However, no gene encoding for a 
hypothetical kinase could be found in the myxovirescin gene cluster. 
           Modules 6 and 7, which encode the same repertoire of catalytic domains as modules 
4 and 5, are expected to yield compound 8. This intermediate, which is attached to the ACP 
located at the C terminus of the Ta-1 megasynthetase, is presumed to act as a nucleophile in 
the second reaction catalyzed by a HMG-CoA synthase; the latter now uses propionyl-CoA 
instead of acetyl-CoA as substrate (see below). Addition of propionyl-CoA onto C16 by 
HMG-CoA synthase (TaF) followed by sequential decarboxylation (TaK), water 
elimination, and isomerization (TaY) are hypothesized to give rise to intermediate 9. 
           Conclusive data confirming the incorporation of propionate rather than acetate at 
carbon C16 came from the analysis of 13C NMR spectra obtained from myxovirescin-
producing   M. virescens strain Mx v48 that were fed with [2,3-13C2]-succinate. This 
experiment indicated incorporation of an intact [2,3-C2]-succinate-derived unit into 1, which 
was likely achieved by conversion of succinyl-CoA into propionyl-CoA.[16] 
           KSS and ECH homologues have been found in all natural product biosynthetic gene 
clusters that harbor HMG-CoA synthases,[11-12, 28, 42, 51] and HMG-CoA synthase-based 
mechanisms for the incorporation of methyl groups have been proposed for mupirocin and 
pederin biosynthesis.[10-11] However, myxovirescin is the first system where a HMG-CoA 
synthase (TaF) is postulated to act upon a substrate other than acetyl-CoA, and to contain 
two HMG-CoA synthases (TaC and TaF) and two enoyl-CoA hydratases (TaX and TaY). 
Nevertheless, only one decarboxylative enzyme KSS (TaK) is present in the cluster and is 
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depicted to act after both HMG-CoA synthases. Similar to models published recently by 
Gerwick s group for curacin and jamaicamide biosynthesis,[12, 42] the two isomerization 
reactions are thought to be carried out by TaX and TaY enoyl-CoA hydratases/isomerases. 
           After the second round of HMG-CoA-like modifications, biosynthesis switches back 
to PKS biochemistry. Intermediate 8, which is attached to ACP7 of Ta-1, is further reduced 
by the ER domain of TaO and transferred to module 8 where another extension with 
malonyl-S-ACP, keto reduction, and dehydration is performed. The ER domain encoded 
prior to module 8 is expected to complete this set of reductive reactions. Module 9 (KS-DH-
ACP) is predicted to extend the polyketide with one more malonyl-S-ACP unit. Although 
DH9 contains the conserved active site, it is unlikely to act without a KR domain. This 
observation is consistent with the intact keto functionality at C20 of myxovirescin A. 
Further, module 10 (KS-DH-KR-ACP) introduces the next malonyl-S-ACP unit followed by 
β-ketoreduction at C22. 
           Module 11 is physically split between TaO and TaP PKSs (Figure 6) and the KS 
domain of TaP is most likely complemented with MT and ACP domains of TaO to create a 
functional module 11. To eliminate the possibility of a frame shift due to errors in 
sequencing, a 0.84 kb region covering the end of taO and beginning of taP was cloned and 
resequenced (Experimental Section). The results confirmed the validity of the sequence. 
Furthermore, this module lacks reductive domains that are expected to saturate C24. 
           Finally, module 12 has the full reductive capacity to saturate the C26 keto group, 
while the MT domain is most likely responsible for methylation of C27. In the last step, the 
linear product attached to ACP12 undergoes cyclization by nucleophilic attack of the C3 
hydroxy oxygen onto the C28 carbonyl to generate the basic myxovirescin lactone fold. 
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Reductive reactions 
           Three out of nine ketoreductase domains contain alterations in the Rosmann fold 
(GxGxxG). KR1 and KR4 contain a conserved Gly to Ala substitution (GxGxxA), which is 
also present in KR1 and KR2 of avermectin.[52] KR2 has a nonconserved Gly to Arg 
substitution, which judging from several KRs with the identical substitution, is also most 
likely to be active.[53, 54] 
          The myxovirescin gene cluster harbors only two out of the five expected ER domains, 
and three double bonds, C10 C11, C16 C17, and C22 C23, as well as the C24 keto 
group, require reduction (Figure 6). It is interesting to notice that the two ERs take unusual 
positions within PKS modules; one ER, for example, precedes KS8. Taking into account 
that, typically, the start of a module is defined with a KS and its end with an ACP or TE 
domain, this ER cannot be functionally assigned to either module 7 (KS-ACP) or module 8 
(KS-DH-KR-ACP), to which it translationally belongs. However, our hypothetical scheme 
suggests a need for enoylreductase within both modules 7 and 8. Accordingly, the first enoyl 
reduction would saturate the C16 C17 double bond of intermediate 9, while the second 
reduction would occur after extension of 9 by module 8 and aid KR8 and DH8 in the full 
reduction of the C18 ketone. Therefore, the ambiguous positioning of the ER domain at the 
interface of modules 7 and 8, along with our proposed assembly scheme, raises the 
possibility that this ER is actively shared by two modules that are encoded on two proteins. 
           Further, analysis of modules 10 and 11 suggests that module 10 “lacks” an ER 
domain that is needed for saturating the C22 C23 double bond. Furthermore, the split  
module 11, in TaO and TaP PKSs, “lacks” a complete reductive loop that is expected to 
saturate the C24 ketone. However, the last module (module 12) contains all three reductive 
domains, with the ER unusually positioned between the ACP and TE domains. We postulate 
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that all the above-mentioned reductive reactions take place on intermediate 12 within 
module 12. This model would explain the physical separation of the ER from the KR and 
DH domains within this module, and would allow the domain to act iteratively and 
independently of the other two reductive domains. Alternatively, intermediates 10 and 11 
would have to skip from their respective modules to module 12 and back, in order to achieve 
the expected reductions before the intermediates are passed to module 12 for the final cycle 
of extension and modification. 
Split modules and shared domains 
           Besides the presence of HMG-CoA synthases, KSS and ECH (HMG-CoA box), and 
irregularly distributed reductive domains, the complexity of myxovirescin programming is 
also evident in the occurrence of modules that appear on two proteins and, therefore, can be 
classified as "split." This situation is encountered in module 11 where the KS domain 
encoded at the C terminus of TaO is likely complemented with MT and ACP domains of 
TaP. Split modules are encountered rather frequently in myxobacterial natural product 
clusters.[33-34, 55] 
           Module 7 can also be considered as split as it consists of KS and ACP domains, 
which are presumably complemented by the HMG box, and finally reduced by the ER 
domain of TaO. In this particular case, the need for a split module is well rationalized with 
the proposed reaction mechanism, which suggests the interference of the HMG-CoA box in 
product assembly, and therefore requires an intact acetoacetyl-S-ACP-like intermediate. 
However, the "irregular" positioning of the ER domain at the interface of modules 7 and 8 
can also be regarded as a "shared" domain.” 
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Auxiliary modifications 
           In addition to the required oxygenation at the C3 position- most likely carried out by 
the TaJ monooxygenase- two more oxidative enzymes, TaH cytochrome P450-dependent 
oxygenase and TaN dioxygenase (Table 1), are expected to perform hydroxylations at C9 
and C29. MT11 and MT12, encoded within the TaP PKS, are expected to methylate carbons 
C25 and C27. 
           By inactivating taQ in M. xanthus DK1622, we were able to demonstrate a shift in 
the production of 1 and 2 toward two novel metabolites (Figure 1 C). Furthermore, NMR 
analysis of the novel compound with m/z 610 [M+H]+ has revealed the loss of the methoxy 
group specific to C29. Therefore, this provides clear evidence that TaQ functions as the O-
methyltransferase (Scheme 1 A). However, contrary to the predicted hydroxyl functionality 
connected to C29, NMR analysis of 3 revealed an exo-methylene specific to this position, 
whereas the hydroxyl group was found to be attached to carbon C13 (Scheme 1 A). 
           Since either an exo-methylene or a diene intermediate might be produced by the 
HMG-CoA-dependent addition of the methyl group (Figure 6), two options that lead to 
myxovirescin A biosynthesis can be envisioned (Scheme 1 B). The first possibility is that 
hydroxylation of the diene-containing intermediate at C29 yields 4, which serves as a 
substrate for TaQ to yield myxovirescin A. The second scenario postulates hydroxylation of 
the exo-methylene intermediate at C13 to yield structure 3, which was defined by NMR 
spectroscopy. Intermediate 3 could be isomerized to 4 and methylated by TaQ (Scheme 1C). 
The second pathway suggests a dual role for TaQ as both isomerase and methyltransferase. 
Therefore, 3 might be a natural precursor of myxovirescin A. Alternatively, 3 can be formed 
by enzymatic or nonenzymatic transformation of 4 in the absence of TaQ methyltransferase.
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Finally, the methylation at C1 could be attributed to TaS-the enzyme that shows homology 
with members of the radical SAM-protein superfamily. This superfamily encompasses a 
wide range of enzymes, some of which function as methyltransferases.[56] The involvement 
of taS in myxovirescin production remains to be proven in further experiments. 
Conclusion 
Myxovirescin megasynthetase shows a number of unusual features such as a dual pathway 
dedicated to starter biosynthesis, multimodular AT-less megasynthetases with "trans"-acting 
acyltransferases, lack of reductive domains, "split" modules, and a thioesterase that is not 
directly preceded by an ACP. In addition, the gene cluster is comprised of a number of 
noncanonical PKS enzymes and domains (GNAT, HMG-CoA synthases, and enoyl-CoA 
hydratases) and a β-ketosynthase that has a Cys to Ser point mutation. All these features 
challenge our previous knowledge pertaining to the organization of PKSs, their colinearity, 
and classification. 
           The myxovirescin biosynthetic gene cluster belongs to the novel family of natural-
product gene clusters that is comprised of pederin, mupirocin, onnamide, curacin A, and 
jamaicamide. All clusters within this family appear to have acquired a novel variation in 
natural-product assembly by combining PKS/NRPS assembly lines with HMG-CoA 
synthase-type biochemistry. Elucidation of the biosynthetic logic that governs 
PKS/NRPS/HMG-CoA-orchestrated assembly of natural products will not only enrich the 
lexicon of natural-product biochemistry with another chapter, but more importantly, pave 
the way to designing novel antitumor and antibiotic analogues by using the HMG-CoA 
toolbox. The myxovirescin system of M. xanthus provides an excellent molecular-genetic 
platform for such studies. 
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Experimental Section 
Growth media: M. xanthus strain DK1622 was grown in casitone yeast extract (CYE) 
medium that consisted of casitone (10%; Difco), yeast extract (5%; Difco), MgSO4  7 H2O 
(0.1%), and 3-morpholinopropanesulfonic acid buffer (MOPS; 10 mM) at pH 7.6. 
Myxovirescin production was assayed in MD-1 medium that consisted of casitone (0.3%), 
CaCl2 2 H2O (0.07%), and MgSO4 7 H2O (0.2%); vitamin B12 (5×10-4 µg L-1) was added 
after cooling. For cloning purposes E. coli strain DH5α was grown in Luria-Bertani (LB) 
medium[57] and supplemented with standard amounts of antibiotic as required. 
Annotation of the myxovirescin biosynthetic gene cluster: The complete sequence of the 
myxovirescin gene cluster was obtained from TIGR (http://www.tigr.org/tdb). Further 
annotation of the catalytic domains was performed by using the PKS-NRPS program kindly 
provided by Jacques Ravel (http://jhunix.hcf.jhu.edu/ ravel/nrps//index2.html). Annotation 
of the nitrogen-specific acetyltransferase (GNAT) and ACP domains of TaI, KR, and TaL 
were carried out by using the Pfam search engine (http://pfam.wustl.edu). MT domains were 
defined by using the natural-product biosynthetic gene database (www.npbiogene.com). 
Construction of in-frame deletion mutants of taV, taI, taL, and taIL: Construction of in-
frame deletion mutants was carried out by amplifying approximately 600 bp regions on each 
side of the desired deletion area with Taq polymerase. Each fragment was subcloned into the 
pCR2.1®-TOPO vector (Invitrogen; see Supporting Information for the list of primers used). 
Following sequencing of the cloned regions, the corresponding amplification products were 
cut out of the pCR2.1-TOPO vector by using the restriction sites indicated (Table 3). The 
fragments were then gel purified and cloned into the pSWU41 vector, which carries a 
neomycin phosphotransferase (nptII) and levansucrase (sacB) gene cassette. The final 
constructs were electroporated into M. xanthus,[58] and kanamycin-resistant, sucrose-
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sensitive clones were checked for proper integration of the plasmid by PCR amplification. 
One transformant which showed the correct genotype was grown in CYE medium for three 
days with daily dilutions. On the third day, 0.2-2.0×108 cells were mixed with CYE-soft 
agar (0.75%; 3 mL) and poured onto CYE-agar plates that contained sucrose (5%), and 
incubated at 30°C for four days. Well-isolated colonies were picked and transferred onto 
CYE-agar containing sucrose (5%), and grown at 30°C for two days before being 
transferred onto CYE-agar containing kanamycin (40 µg mL-1). After two days of growth at 
30°C, colonies that were kanamycin sensitive and sucrose resistant were subjected to 
chromosomal-DNA extraction and their genotypes were confirmed by PCR amplification. In 
one PCR reaction a primer pair was used that recognized sequences outside of the region 
that was initially amplified. This yielded a product that was shorter than the desired deletion. 
As a negative control, the second PCR reaction was performed with a primer that bound 
outside of the amplified region in combination with a primer specific for the deletion area. 
To create a double ΔtaIL mutant, plasmid pVS61 was electroporated into M. xanthus 
VS1024 (ΔtaI). The excision of the plasmid resulted in M. xanthus VS1029. 
Construction of the taQ mutant: To construct a taQ knockout, an internal 450 bp of taQ 
was amplified by using Taq polymerase and the primer pair taQ_knock_for and 
taQ_knock_rev. The former primer contained a base-pair insertion (Supporting Information) 
that created a stop codon. The PCR product was cloned into pCR2.1-TOPO and sequenced. 
The resulting plasmid, pVS16, was then electroporated into M. xanthus DK1622.[58] 
Transformants were grown in CYE medium supplemented with kanamycin, and their 
genomic DNA was analyzed for integration of the plasmid in taQ by using PCR 
amplification. The primers used were taQ_knock_for (specific for taQ) and 21down 
(specific for pCR2.1-TOPO). The taQ knockout mutant was named VS1016. 
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Analysis of the taO-taP intergenic region: To eliminate the possibility of frame-shift 
error(s), 0.824 kb that covered the region near the 3’ end of taO and the 5  region of taP, 
was PCR amplified by using Pfu Turbo polymerase (Strategene) and primers taOseq_up and 
taOseq_down (Supporting Information). Following gel purification of the blunt-ended PCR 
product, A overhangs were added to it by using Taq polymerase, and the modified PCR 
product was cloned into pCR2.1-TOPO to create plasmid pVS75. The sequenced region was 
analyzed for ORFs by using FramePlot 3.0beta software (http://watson.nih.go.jp/ jun/cgi-
bin/frameplot-3.0b.pl). 
Fermentation and extraction conditions: Typically, MD-1 medium (100 mL) that 
contained amberlite XAD-16 (1%; Rohm & Haas, Frankfurt/Main, Germany) was 
inoculated with M. xanthus (1.5×108 cells mL-1). After 3 days at 30°C, the cells and XAD 
beads were centrifuged for 15 min at 10000 g. The combined pellet of cells and XAD beads 
was extracted with methanol (3×50 mL). The total extract was resuspended in methanol (2 
mL) and concentrated into 200 µL. 
Antibiotic assay: In order to test inhibitory activity, E. coli XL-1 blue (0.1 mL) at 0.1 OD600
were mixed with LB-soft agar (3 mL) and plated on a LB-agar plate. Purified antibiotics (10 
µg and 50 µg) were spotted on the filter disk, dried, and placed on the soft agar. The plate 
was incubated at 30°C for 24 h. 
Purification of myxovirescins from M. xanthus DK1622: To purify myxovirescins from 
wild-type M. xanthus DK1622, cells (8 L) were grown in a fermentor (Biostat V, Braun) 
under the conditions described above. At the end of the fermentation, XAD-adsorbent resin 
was removed by filtration through a 0.2 mm sieve (Retsch, Haan, Germany), and antibiotics 
were extracted from the resin by using methanol (3×400 mL). The total methanol extract 
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was then applied to a Sephadex LH-20 column (100 cm×2.5 cm) and eluted with methanol. 
Fractions that tested positive for myxovirescins were concentrated, dissolved in 
dichloromethane: methanol (15:1; 3 mL), applied to a silica-gel column (780×23 mm), and 
eluted by using the same solvent system. Fractions that contained myxovirescins were 
further concentrated, dissolved in methanol, and purified by preparative HPLC by using a 
Nucleosil 100-7 C-18 column (250×21 mm; Macherey & Nagel, Düren, Germany). 
Myxovirescins A and C were purified by sequential preparative HPLC (see above) by using 
different MeOH/H2O mixtures. The final yields of myxovirescins A and C were 3 and 5 mg, 
respectively. 
Purification of myxovirescin Qa from the taQ mutant, VS1016: In order to isolate 
myxovirescin Qa, taQ mutant cells (9 L) were grown in MD-1 medium until the late 
stationary phase was reached. After centrifugation, cells and XAD were extracted with 
methanol (3×400 mL). The total extract was concentrated and separated on a Sephadex LH-
20 column. Fractions that tested positive for myxovirescin Qa (Rf = 0.375) were collected, 
concentrated, and applied to preparative HPLC as described for the purification of 
myxovirescins A and C, and yielded a total of 2 mg of pure compound. 
Myxovirescin A detection and quantification: Detection of myxovirescins by TLC was 
carried out by using a dichloromethane/methanol (15:1) solvent system. Myxovirescins were 
detected as a dark spot under 254 nm ultraviolet light (Rf = 0.26). 
Additional detection by analytical reversed-phase HPLC was carried out by using the 
Dionex P680 pump unit coupled to PDA-100 DAD on a RP 125×2 mm/3 µm Nucleodur C-
18 column (Macherey & Nagel). Solvent A: H2O with formic acid (0.1%); solvent B: 
acetonitrile with formic acid (0.1%); flow rate 0.4 mL min-1, and the following program: 0-2 
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min, 5 % B; 2-17 min to 95 % B; 17-20 min, 95 % B; 20-23 min, 5 % B. Under these 
conditions, myxovirescin A showed a retention time of 15.0 min and a characteristic UVmax 
absorption at 239 nm. 
Liquid chromatography/mass spectrometry (LC/MS) and quantification of 
myxovirescin A by ion-trap MS: LC/MS measurements were performed on an Agilent 
1100 series system equipped with a photodiode-array detector, and coupled to a Bruker HCT 
plus mass spectrometer operated in positive-ionization mode at a scan range from m/z 100 to 
1100. Myxovirescin A showed a characteristic m/z 624.3 [M+H]+. 
In order to quantify myxovirescin A, combined cell and XAD extracts were separated by 
RP-HPLC on a 125×2 mm/3 µm Nucleodur C-18 column by using an Agilent 1100 series 
solvent-delivery system and a flow rate of 0.4 mL min-1. The gradient employed the same 
solvents as used for HPLC-MS and consisted of 0-1 min 70% B, 1-6 min to 95% B. Under 
these conditions myxovirescin A displayed a retention time of 3 min. Quantitative analysis 
was done on a coupled ESI ion-trap MS machine (Bruker HCTplus) operated in the manual 
MS(n) mode. Ions of m/z 624 [M+H]+ were collected and subjected to fragmentation. The 
intensities of the three fragment ions (592, 574, and 556 [M+H]+) were summed up and peak 
integration was carried out by utilizing the Bruker QuantAnalysis v1.5 software package. 
The calibration curve consisted of a series of dilutions of the purified myxovirescin A. 
Samples under investigation were diluted as required to fit the dynamic range of the method 
utilized. 
NMR analysis: NMR analysis was performed in CD3OD by using a Bruker Advance 500 
instrument. 1H NMR spectra were measured at 500 MHz. 13C spectra, 1H,1H COSY, 
gradient spectroscopy HSQC, and HMBC data were obtained at 125 MHz. Distortionless 
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enhancement by polarization transfer (DEPT) spectrum was measured at 135°. 
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Table S1. List of primers used in the study. 
 
Primer name 
 
                 Sequence 5’-> 3’ 
 
taV1 ACAGCGGCCGCACCATCGCGCGGACCTGTGG 
taV2 ATGACTAGTGACAGCGTCCGGCTGGATA 
taV3 TACACTAGTCATGACAACGTGGTGCAG 
taV4 GATGAGCTCGATAGGCTGCTTGCATCAGC 
taI1 GCTCTAGACAGACATTCAGTTCCTTCTGCACCG 
taI2 CGGGATCCCGATGTCGCTCGAAGAGCTCCTG 
taI3 CGGGATCCCTCGGTCTCCGTGGACGCCAC 
taI4 GGACTAGTAGTACCCTCAGGGCCAACTGGTGCT 
taL1 GCTCTAGAGGTCCACAGGCGAGATCGAATGGCA 
taL2 CGGGATCCACGTTGGTGCGCGGGCGCGA 
taL3 CGGGATCCCCGAGCGTCAGCATCGACCG 
taL4 GGACTAGTAGTGGGCGCGGGAAGCACGG 
taQ_ knock frw GCGACCACTAAGGCGGTGGAT 
taQ_knock_rev CGGTGAACTGAGGCGTTTCCT 
taOseq_up GCGAGCGCGTCGTTGAAGAA 
taOseq_down TGCAGGTGTTCCTCACGGGA 
21down CGACGGCCAGTGAATTGTAATA 
taV5 GGAATTCCGTGGATGGCGAACTGCTGCG 
taV6 GGGGTACCCACGCCCGTCTTCAGCCTGG 
taI 6 CGTGTGGAGCATCAAGGAGA 
taI5 GCACTGGAGCGGCTGGAGCG 
taI7 GCTGATGTTCTCCGCGCCCG 
taL6 TCCCTCATCGCCTCCAATGG 
taL7 GTATTGGCTCGCGTCTGGCT 
taL5 CTTGCCGGGTCGAAATCTGG 
 
                      Bold letters indicate restriction sites and underlined base pair insertion 
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Table S2. NMR data for myxovirescins A (left) and C (right) obtained in CD3OD. 
 
 
 
n.a. in the table indicates the carbons which could not be assigned due to the small amount of fatty acid impurity. 
 
 
Carbon 
 
13C 
 
1H J (Hz) 
 
m 
 
13C 
 
1H J (Hz) 
 
m 
 
1 19.5 1.42 m 19.5 1.43 m 
2 35.1 1.77 m 35.2 1.77 m 
3 74.9 4.95 
(8/5) 
dd 74.9 4.93 (8/5) dd 
4 173.3 - - 173.3 - - 
5 46.3 3.31 m 46.4 3.31 m 
6 68.4 3.92 m 68.3 3.92 m 
7 37.3 1.51 m 37.2 1.52 m 
8 72.5 3.73 m 72.5 3.72 m 
9 76.0 3.46 
(10/3) 
dt 76.0 3.47 (10/3) dt 
10 31.7 1.70 
1.50 
m 
m 
31.9 1.71 m 
11 32.4 2.34 
2.15 
m 
m 
32.5 2.32 
2.15 
m 
m 
12 136.9 - - 136.5 - - 
13 130.2 6.07 (11) d 130.4 6.08 (11) d 
14 127.5 6.36 (15/11) dd 127.1 6.32 (15/11) dd 
15 140.1 5.40 (15/9) dd 140.6 5.39 (15/9) dd 
16 46.2 1.93 m 46.5 1.92 m 
17 35.9 1.43 
1.21 
m 
m 
36.3 1.41 
1.22 
m 
m 
18 23.4 1.56 
1.47 
m 
m 
n.a. n.a. n.a. 
19 43.8 2.45 
2.33 
m 
m 
n.a. n.a. n.a. 
20 214.4 - - n.a. n.a. n.a. 
21 43.0 2.42 m n.a. n.a. n.a. 
22 25.0 1.51 m n.a. n.a. n.a. 
23 27.5 1.25 m n.a. n.a. n.a. 
24 37.6 1.33 
1.10 
m 
m 
37.8 1.36 
1.10 
m 
m 
25 31.5 1.49 m 31.6 1.49 m 
26 41.8 1.56 
1.34 
m 
m 
42.0 1.57 
1.36 
m 
m 
27 38.5 2.62 (14/7) dd 38.5 2.62 m 
28 177.9 - - 177.9 - - 
29 71.3 4.10 (12) 
4.06 (12) 
d 
d 
71.2 4.09 (12) 
4.07 (12) 
d 
d 
30 29.5 1.29 
1.43 
m 
m 
n.a. n.a. n.a. 
31 12.18 0.86 (7) t 12.28 0.85 (7.3) t 
32 14.0 0.94 (7) t 14.1 0.95 (7) t 
33 17.7 1.15 (7) d 17.6 1.14 (7) d 
34 20.0 0.86 (7) d 20.1 0.86 (7) d 
OCH3 58.0 3.29 s 58.0 3.29 s 
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           Polyketides (PK), nonribosomal peptides (NRP) and their hybrids (PK/NRP) are 
classes of secondary metabolites whose members exhibit valuable activities with high 
potential for therapeutic applications. The program governing PK/NRP assembly is typically 
encoded within modular megasynthetases on which consecutive condensations of activated 
short-chain carboxylic acids (catalyzed by polyketide synthases; PKS) or amino acids 
(performed by nonribosomal peptide synthetases; NRPS) take place through a thiotemplated 
mechanism.[1] 
           Annotations of several PKS/NRPS gene clusters, including bacillaene, curacin and 
mupirocin,[2-8] indicated that a novel type of Claisen condensation mechanism is used in such 
natural product biosynthesis. Strikingly, all six biosynthetic gene clusters revealed (a) free-
standing homologue(s) of 3-hydroxy-3-methylglutaryl-CoA synthase (HMGS), generally 
surrounded by a set of genes encoding an acyl carrier protein (ACP), a mutant KS with a Cys-
to-Ser active site substitution (KSS) and two homologues of the enoyl-CoA hydratase (ECH) 
family.[4, 7] HMG-CoA synthases are known to couple acetyl-CoA (Ac-CoA) onto the β-keto 
group of acetoacetyl-CoA to yield 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA).[9] It was 
therefore proposed that the above gene products condense Ac-CoA with structurally similar 
β-ketoacyl-S-ACP intermediates of polyketide origin to eventually result in the addition of the 
C2 acetate carbon in their respective structures.[2, 4-6] This hypothetical scheme has been 
recently revised following in vitro reconstitution of the bacillaene enzyme homologues of B. 
subtilis[7, 8] (cf. Scheme 1 C). In comparison with other gene clusters,[4, 7] the myxovirescin 
cluster contains two free-standing ACPs (TaB and TaE) and two HMG synthases (TaC and 
TaF; Scheme 1 A). Curiously, the myxovirescin-labelling scheme indicates two atypical 
pendant groups branching from the basic polyketide backbone, the methylene group derived 
from the C2 portion of acetate attached to carbon C12, and the C2-C3 fragment derived from 
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succinyl-CoA (Succ-CoA) at carbon C16[10] (Scheme 1 B). Accordingly, the proposed 
biosynthetic scheme for myxovirescin assembly envisions two HMGS-like catalyzed 
reactions that would “intersect” the classical PK biochemistry by modifying ACP-bound 
intermediates 2 and 5 (Scheme 1 C). After each round of reactions, polyketide biosynthesis 
would be resumed and carried out by multimodular PKSs. The first one of these reactions is 
postulated to be carried out by the HMG-like synthase TaC by condensation of Ac-S-TaB 
with the C12 β-keto group of substrate 2 to yield 3 (Scheme 1 C). In the second reaction, 
HMG-like synthase TaF should catalyze the condensation of propionyl-S-TaE (Pp-S-TaE) 
with the C16 β-keto group of intermediate 5 to yield 6. In analogy to the KSS PksG of B. 
subtilis,[7] KSS TaK is thought to act twice during the biosynthesis by cleaving carboxyl 
groups from both malonyl-S-TaB (M-S-TaB) and methylmalonyl-S-TaE (Mm-S-TaE) in order 
to supply TaC and TaF, respectively, with their cognate substrates. The Mm-CoA is 
presumably a product of the Mm-CoA mutase-catalyzed conversion of Succ-CoA.[10] 
Similarly, based on in vitro data,[7, 11] two enoyl-CoA hydratases TaX and TaY dehydrate and 
decarboxylate intermediates 3 and 6 to yield 4 and 7, respectively (Scheme 1 C).  
           Even though PksG, the TaC homologue of B. subtilis, has been shown to catalyze the 
formation of HMG-S-ACP in vitro,[7] there has been no in vivo proof for the function of any 
HMGS in PKS/NRPS biosynthesis. Such evidence is especially needed given that, in most 
systems, HMGS homologues are predicted to form much more complex products than HMG-
S-ACP.[7] For instance, TaC and TaF are predicted to act on carbons chains 15 and 19 atoms 
long while tethered to the ACPs of the giant 995-kDa PKS Ta-1, and to utilize atypical 
substrates, such as Pp-S-ACP, in addition to Ac-S-ACP.[6] 
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Scheme 1. A) 10.9-kb fragment of the myxovirescin A biosynthetic gene cluster encoding for 
monofunctional enzymes. TaB and TaE are putative ACPs, TaC and TaF homologues of 
HMG-CoA synthases, TaK is a mutant β-ketoacyl-ACP synthase (KSS), and TaX and TaY are 
homologues of the crotonase family of enoyl-CoA hydratases. B) Structure of myxovirescin 
A (1) indicating the biosynthetic origin of its building units.[10 Boxed carbons originate from 
glycine, black circles indicate C2 of acetate, triangles indicate methyl groups derived from 
methionine, and connected squares show the ethyl group originating from carbons 2 and 3 of 
succinate. C) A working model of myxovirescin A assembly, based on refs.,[6, 7, 11] depicts 
two rounds of modification reactions involving HMGS-like and ECH enzyme homologues 
taking place on the polyketide/nonribosomal peptide intermediates 2, 3, 5 and 6. Two ATs 
encoded by taV load malonyl-CoA (M-CoA) and methylmalonyl-CoA (Mm-CoA) onto their 
cognate ACPs (TaB and TaE), which become substrates of the decarboxylase TaK. Acetyl-S-
TaB and propionyl-S-TaE serve as second substrates for TaC and TaF HMGS-like synthases, 
respectively. The carbon-labelling pattern is described in (B). The C16 C17 double bond of 
intermediate 7 is presumably reduced by TaO PKS. 
           In an effort to provide such in vivo evidence, we have attempted to delete the HMGS 
homologues (taC and taF) and to analyze the engineered strains for the possible modifications 
these mutations would impose on the antibiotic structure. Consistent with the proposed 
working model, we envisioned three possible effects these deletions would have on 
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myxovirescin biosynthesis. 1) The loss of TaC or TaF would not halt the myxovirescin 
biosynthetic machinery but only prevent condensation of the Ac (Pp) unit with the 
PKS/NRPS scaffold, therefore leading to the production of myxovirescin analogues carrying a
ketone in the place of a methoxymethyl or ethyl group at the C12 and C16 positions, 
respectively (cf. Scheme 1 B). In the case of loss of TaC, we assumed that this modification 
would also disrupt the C12-C14 diene system. 2) Antibiotic production would be blocked 
either by jamming of the reaction intermediates on the assembly line, or disruption of the 
megasynthetase complex. 3) Antibiotic production would be circumvented by 
complementation of function supplied by the other HMG-like synthase encoded in the gene 
cluster. Hence, in the case of loss of TaC, TaF would rescue antibiotic assembly by installing 
a Pp unit on both the C12 and C16 β-keto positions of intermediates 2 and 5 to produce 
myxovirescin analogues with two ethyl groups at respective positions. The ethyl group at C12 
might be further modified into a hydroxyethyl or methoxyethyl group. Conversely, in the case 
of loss of TaF, TaC would attach two Ac groups onto intermediates 2 and 5. After additional 
modification reactions on the C12 methyl carbon, a novel analogue of 1 carrying a methyl 
instead of an ethyl group at C16 would be formed. 
           Following construction of two HMGS-like mutant strains, M. xanthus VS1011 (ΔtaC) 
and VS1012 (ΔtaF), the wild-type and mutant extracts were analyzed by HPLC-MS. 
Production of 1 was abolished in both VS1011 and VS1012 (data not shown). Masses of the 
predicted modified products could not be detected with a ΔtaC background. However, a 
unique, novel peak of [M+H]+= 610 with shorter retention time than 1 was apparent in the 
VS1012 extracts. 
           Evidence that the novel metabolite is a myxovirescin analogue was provided by 
tandem MS analysis. In addition, the UVmax absorption at 239 nm of the novel myxovirescin 
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ΔF suggested the same chromophore as in 1. However, in comparison to the production of 1 
by the wild-type strain, production of myxovirescin ΔF in VS1012 was reduced tenfold. 
           The high-resolution mass spectrum (HRMS) of myxovirescin ΔF (m/z 610.4287) 
suggested the molecular formula C34H60NO8+, and thus indicated the loss of one methylene 
group relative to 1. In order to find out at which carbon position this modification occurred, 
myxovirescin ΔF was purified and subjected to NMR analysis (see the Supporting 
Information). Comparative analysis of 1H NMR spectra of myxovirescins A and ΔF indicated 
changes specific to the aliphatic region (Figure 1 A). The spectrum of myxovirescin ΔF 
lacked a triplet at δH = 0.86 ppm assigned to the C31 methyl group of 1. Instead, a new methyl 
group was visible as a doublet at δH = 1.00 ppm (J = 7 Hz). 1H,1H COSY and HMBC 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. A) 1H NMR spectral expansions of the aliphatic regions of myxovirescin A (upper) 
and the novel myxovirescin analogue ΔF (lower). B) The NMR-deduced structure of 
myxovirescin ΔF (8) reveals the presence of a methyl rather than ethyl group at C16. Bold 
lines indicate selected 1H,1H COSY and arrows show important HMBC correlations. 
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analysis showed this new methyl group to be connected to the C16 methine group (δC = 38.3 
ppm, δH = 2.19 ppm); this led to the assignment 8 (Figure 1 B). Therefore, NMR analysis 
provided unambiguous evidence for the presence of a methyl, instead of an ethyl group, at 
C16 of 8.  
           To evaluate whether another HMGS, besides TaC, could be directing production of 8, 
the M. xanthus DK1622 genome was screened for genes encoding HMGS homologues. This 
search revealed only one candidate, MvaS (E value = 10-48), the HMGS of the mevalonate 
pathway.[12] Unlike in some other bacteria, disruption of mvaS in M. xanthus does not cause 
any growth defects, due to the efficient incorporation of leucine, as alternative precursor to 
HMG-CoA, and subsequently isoprenoids by a second pathway.[12-13] Similarly, analysis of 
the ΔtaF and the mvaS::neo, ΔtaF double mutant (strain VS1044) extracts showed equal 
production of 8 (data not shown). 
           Isotope-labelling data for 1 (Scheme 1 B) demonstrate that both C30 and C31 (the 
ethyl group at C16) originate from Mm-CoA. Therefore, the appearance of a methyl group at 
C16 of 8 suggests that, in the absence of TaF, the megasynthetase fails to incorporate Mm-
CoA. The absence of the ethyl moiety in 8 is also supported by the observation that addition 
of vitamin B12 to VS1012 fermentations does not stimulate the production of 8; this is in 
contrast to the observed two- to threefold increase it causes in the production of 1 by the wild-
type strain DK1622 (data not shown). This argues for a role of vitamin B12 in the production 
of Mm-CoA, which takes place through a vitamin B12-dependent Mm-CoA mutase-catalyzed 
conversion of Succ-CoA into Mm-CoA. Indeed, evidence that TaF is directly involved in the 
formation of the ethyl group at C16 is also supported by the complete loss of production of 1 
and appearance of 8 in the ΔtaF background. 
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           Furthermore, the tenfold reduction in the production of 8 in comparison to 1 indicates 
severe impairment of the metabolic flux through the megasynthetase upon removal of TaF, 
with only 2 mg of 8 being produced from 45 L of VS1012 culture (Supporting Information). 
In contrast, elimination of myxovirescin accessory enzymes, such as the methyltransferase 
TaQ,[6] and one of the oxygenating enzymes (V.S. and R.M., unpublished data) results in 
production of the respective desmethyl and deoxy analogues of 1 at 80-100 % of the wild-
type yield. In addition, loss of TaC abolishes myxovirescin production. Taken together, these 
results support the part of our biosynthetic model that depicts TaC and TaF acting directly on 
the “assembly line” rather than after assembly of the antibiotic scaffold.[6] Moreover, these 
insights back the in vitro studies performed with the HMGS homologue PksG of B. subtilis.[7]
           Therefore, having excluded the involvement of the primary metabolic HMGS MvaS in 
the addition of the C30 methyl group of 8, our results argue for a model in which, in the 
absence of TaF, TaC rescues myxovirescin assembly by installing two Ac building blocks, 
one at the C12 and the other one at the C16 β-keto positions of intermediates 2 and 5, 
respectively. This results in a novel antibiotic endowed with two methyl groups, one of which 
is further oxygenated and methylated (8; Figure 1 B). It appears that this rather discrete 
complementation by TaC in the ΔtaF background and the failure of TaF to complement TaC 
in the ΔtaC background highlight the differences between the TaC and TaF HMG-like 
synthases, probably not only in the choice of their cognate substrates, but also in the 
specificity of their docking interactions with the other enzymes comprising the megasynthase 
complex. Alternatively, incorporation of the larger ethyl group early in biosynthesis might 
result in the rejection of the modified intermediate at later biosynthetic steps. 
           In summary, this work provides one of the first in vivo studies (related work on the 
mupirocin system was reported at a recent conference; T. J. Simpson, personal 
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communication) directed toward the elucidation of a novel pathway leading to PKS/NRPS 
natural product assembly, which takes place by a Claisen condensation mechanism previously 
thought to be specific only to HMG-CoA synthases of the primary metabolism. In contrast to 
the S-adenosylmethionine (SAM)-dependent methyltransferases (MT), which use an 
electrophilic substrate (SAM) to methylate the activated C2 carbons of the β-ketoacyl-S-ACP 
intermediate,[9] HMGSs use nucleophilic substrates to methylate the C3 carbon of the same 
type of substrate.[7] Due to enzymatic differences between HMGSs and SAM-dependent MTs, 
introduction of the C30 methyl group onto the C16 carbon by SAM MT appears 
mechanistically unfeasible. HMGSs, in combination with the set of enzymes mentioned 
above, can form methyl or ethyl groups, which may be further processed into 
methylmethoxy,[6] exo-methylene,[14] cyclopropyl[4] or vinyl chloride groups.[5] Knowledge 
gained from these and further studies might benefit future biocombinatorial efforts directed 
towards rational redesigning of known or the discovery of novel molecules with therapeutic 
potential. 
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Table 1. List of primers used in the study. 
 
 
 
 
 
 
 
 
 
 
 
Table 2. List of plasmids and strains used in the study. 
 
 
 
 
 
 
 
 
 
 
 
 
Primer 
 
       Primer Sequence (5’-3’) 
 
Mvi1 CAGGGATCCGCGCTGGAGCTTCATCGTC 
Mvi2 TGCGTCGACGAGTTCTTCAGCGGCGTCATC 
Mvi3 CTCGTCGACGGTGACCAGGAGCTCGATG 
TaFSpeI GACTAGTCAACGTGAAGATGCGCGAGG 
TaF1 TCCACGTAGTTGCCCAACG 
TaF2 CGTGCGACGTGGACGAAAT 
TaF3 GGCTCATCTACTTCGCGTCG 
Mvi5 GTCGGATCCGATTCGCTGCCGAAGTTGTAC 
Mvi6 TGCGTCGACGAGTTCTTCAGCGGCGTGG 
Mvi7 CTCGTCGACAGCCACCAGCAGCTCGATG 
Mvi8 CGGAAGCTTTGGAGGTGAGCGCCGAGC 
taC1 AGGCTCTCGTTCGACTTGCCG  
taC2 GTCGCCGTGGTCGATGGTCCC  
taC3 TATCTGCGGGTGGGGCAGCGC  
Mx619r GGAATTCGCATCCGCCGGCAGCTTCATCAG 
21down CGACGGCCAGTGAATTGTAATA 
Plasmid name 
 
Description 
 
Reference 
 
pVS1 0.6 kb upstream from taF amplified with Mvi1 and Mvi2 primer pair carrying 
BamHI and SalI restriction sites, respectively, cloned in pCR2.1-TOPO vector 
This study 
pVS22 0.6 kb downstream from taF amplified with primers Mvi3 and TaFSpeI 
containing SalI and SpeI sites, respectively, cloned in pCR2.1-TOPO vector 
This study 
pVS3 0.6 kb upstream from taC amplified with primers Mvi5 and Mvi6 carrying 
BamHI and SalI restriction sites respectively, cloned in pCR2.1-TOPO vector 
This study 
pVS4 0.6 kb downstream from taC amplified with primers Mvi5 and Mvi6 carrying 
SalI and HindIII restriction sites respectively, cloned in pCR2.1-TOPO vector 
This study 
pVS7 1.2 kb fragment obtained by ligation of the BamHI/SalI and SalI and SpeI-
containing inserts from pVS1 and pVS22, respectively, ligated in BamHI and 
SpeI sites of pBJ113 vector  
This study 
pVS23a 1.2 kb fragment obtained by ligation of the BamHI/SalI and SalI and HindIII -
containing inserts from pVS3 and pVS4, respectively, ligated in BamHI and 
HindIII sites of pSWU41 vector 
This study 
p619-1 766 bp internal fragment of MXAN_4267 amplified with Mx619f and 
Mx619_r primer pair; 
cloned in pCR2.1-TOPO vector 
[1] 
 
M. xanthus strains 
  
DK1622 Wild type strain [2] 
VS1011 ΔtaC This study 
VS1012 ΔtaF This study 
VS1044 Merodiploid mutant created by homologous recombination of p619-1 in the 
chromosome of M. xanthus VS1012 
This study 
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Table 3: NMR data for 8 obtained in CD3OD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[a] Values taken from HMBC 
[b]  n.d.- not detected 
* [b] not detected due to the overlap with the multiplet signal arising from the CD3OD solvent peak   
 
 
 
 
 
 
 
Carbon  
 
 δ 13C [ppm] 
 
δ 1H [ppm]  
 
multiplicity J[Hz] 
 
1 19.5 1.42 (2H) m 
2 35.1 1.77 (2H) m 
3 74.9 4.95 dd (8/5) 
4 174.0[a] - - 
5 46.4 3.30 m 
6 68.4 3.92 m 
7 37.3 1.50 (2H) m 
8 72.5 3.72 m 
9 75.9 3.44 dd (4/3) 
10 31.7 1.70 
1.49 
m 
m 
11 32.4 2.33 
2.16 
m 
m 
12 137.0 -  
13 130.4 6.05 d (11) 
14 125.8 6.36 dd (15/11) 
15 141.5 5.52 dd (15/9) 
16 38.3 2.19 m 
17 37.6 1.24 
1.27 
m 
m 
18 23.4 1.46 
1.59 
m 
m 
19 43.7 2.46 
2.34 
m 
m 
20 n.d.[b] n.d. n.d. 
21 43.0 2.43 (2H) m 
22 25.0 1.51 (2H) m 
23 27.4 1.27 (2H) m 
24 37.7 1.35 
1.12 
m 
m 
25 31.6 1.48 m 
26 41.9 1.57 
1.34 
m 
m 
27 38.5 2.62 dq (14/7) 
28 179.0[a] - - 
29 71.2 4.07 (2H) s 
30 21.3 1.00 (3H) d (7) 
31 - - - 
32 14.0 0.93 (3H) t (7) 
33 17.7 1.14 (3H) d (7) 
34 20.1 0.86 (3H) d (7) 
35 58.0 3.28[a] * [b] 
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Experimental Section 
 
Mutant construction: Deletions of taC and taF were carried out using the same strategy as 
reported previously,[3] except that the fragments employed for the deletion of taC were cloned 
into the pBJ113 vector. Upon integration of the resulting vector pVS7 in strain DK1622, 
plasmid excision was carried out on galactose (1%).[4]  
 
In order to disrupt the 3-hydroxy-3-methylglutaryl-CoA synthase of the mevalonate pathway 
(mvaS) in the ΔtaF background, plasmid p619-1 (Table 2) was electroporated into VS1012 
cells.[5] A novel, kanamycin resistant mutant M. xanthus VS1044 was confirmed in a PCR 
reaction using the Mx619r and 21down primer pair. 
 
Fermentation of M. xanthus VS1012 and purification of myxovirescin ΔF:To purify 
myxovirescin ΔF, M. xanthus VS1012 cells were inoculated in MD-1 medium lacking 
vitamin B12 at 1.5 x 108 cells x mL-1 and cultivated with Amberlite XAD-16 resin (1%; Fluka) 
for 4 days at 30°C. Fermentations (45 L total) were carried out in batches of 5 L Erlenmeyer 
flasks containing 1.5 L of medium.[3] Following the extraction of the XAD-16 resin with 
methanol, the total extract was purified on a Sephadex LH 20 column. A fraction enriched in 
myxovirescin ΔF was further separated on a silica gel using dichloromethane: methanol 
(25:1) as solvent system. Final purification was carried out by preparative HPLC using a 
combination of gradient and isocratic conditions and different water/methanol mixtures.[3] The 
pure compound (2 mg) was dissolved in CD3OD and subjected to NMR spectroscopy as 
described.[3] 
 
High resolution MS of 8 was performed on Bruker MicrO TOF instrument (Bruker, Bremen, 
Germany). 
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Abstract 
Two acyl carrier proteins (ACPs) TaB and TaE, and two 3-hydroxy-3-methylglutaryl 
synthases (HMGSs) TaC and TaF, have been proposed to constitute two functional ACP-
HMGS pairs (TaB/TaC and TaE/TaF) responsible for incorporation of acetate and propionate 
units into the myxovirescin A scaffold, leading to the formation of β-methyl and β-ethyl 
groups, respectively. Three more proteins, TaX and TaY, which are members of the 
superfamily of enoyl-CoA hydratases (ECH), and a variant ketosynthase (KS) TaK, were 
proposed to be shared between two ACP-HMGS pairs, to give the complete set of enzymes 
required to perform the β-alkylations. The β-methyl branch is presumably further 
hydroxylated (by TaH) and methylated to produce the methylmethoxy group observed in 
myxovirescin A. To substantiate this hypothesis, a series of gene deletion mutants were 
created and the effects of these mutations on myxovirescin production examined.  
  As predicted, ΔtaB and ΔtaE ACP mutants revealed similar phenotypes to their 
associated HMGS mutants ΔtaC and ΔtaF, respectively, providing direct evidence for the role 
of TaE/TaF in the formation of the β-ethyl branch and implying a role of TaB/TaC in the 
formation of the β-methyl group. Production of myxovirescin A was dramatically reduced in a 
ΔtaK mutant and abolished in both ΔtaX and ΔtaY mutant backgrounds. Analysis of a ΔtaH 
mutant confirmed the role of the cytochrome P450 TaH in hydroxylation of the β-methyl 
group. Taken together, these experiments support a model in which discrete ACPs TaB and 
TaE are compatible only with their associated HMGSs TaC and TaF, respectively, and 
function in a substrate specific manner. Both TaB and TaC are essential for myxovirescin 
production and the TaB/TaC pair can rescue antibiotic production in the absence of either TaE 
or TaF. Finally, the reduced level of myxovirescin production in the ΔtaE mutant relative to 
the ΔtaF strain suggests an additional function of the TaE ACP.  
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Introduction 
Polyketides and nonribosomal peptides are structurally diverse classes of secondary 
metabolites assembled from carboxylic-CoA esters and amino acids, respectively.[1] They are 
biosynthesized by specialized protein megacomplexes which are organized into functional 
units called modules, each of which accomplishes a specific round of chain extension. These 
multienzyme systems are known respectively as polyketide synthases (PKS) and 
nonribosomal peptide synthetases (NRPS). Typically, each module minimally incorporates 
three domains: an acyltransferase (AT) which selects specific extension units, a ketosynthase 
(KS) which catalyses carbon-bond formation, and an acyl carrier protein (ACP), to which the 
growing chain is tethered in thioester linkage. Following condensation, the β-ketoacyl-S-ACP 
intermediate may be further reduced by one of the optional domains (keto reductase (KR), 
dehydratase (DH) and enoyl reductase (ER)), before it is transferred from the ACP to the KS 
of the next module for another round of chain extension. Thus, the biosynthesis follows a 
linear assembly program directed by the particular combination of catalytic domains present 
within each module, and the number and order of modules within the PKS. The thioesterase 
(TE) located within the last module terminates the assembly process by facilitating the release 
of the fully extended product by hydrolysis or lactonization.  
 
In addition to the genes encoding type I PKSs, the biosynthetic gene clusters 
responsible for myxovirescin, bacillaene, mupirocin, and several other compounds also 
include a set of discrete genes named "HMG-cassettes".[2-5] Each HMG-cassette comprises a 
set of five genes encoding for a 3-hydroxy-3-methylglutaryl-CoA synthase (HMGS), an ACP, 
a variant KS (in which the active site Cys is mutated to Ser) and two homologous of enoyl-
CoA hydratases (ECH)[5] (Figure 1 a). Furthermore, the PKS responsible for these compounds  
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Figure 1. a) 10.9 kb fragment of the myxovirescin A biosynthetic gene cluster encoding for 
monofunctional enzymes. TaB and TaE are putative ACPs, TaC and TaF homologues of 
HMG-CoA synthases, TaK is a variant β-ketoacyl-ACP synthase (KSS), TaX and TaY are 
homologues of enoyl-CoA hydratases (ECH), and TaH is a putative cytochrome P450.  
b) Structure of myxovirescin A (1) indicating the biosynthetic origin of its building units.[6] 
Boxed carbons originate from glycine, black circles indicate C2 of acetate, triangles indicate 
methyl groups derived from methionine, and connected squares show the ethyl group 
originating from carbons 2 and 3 of succinate. c) A working model of myxovirescin A 
assembly depicts two rounds of modification reactions leading to the formation of C12 β-
methyl and C16 β-ethyl side groups in myxovirescin scaffold. Two ATs encoded by TaV load 
malonyl-CoA (M-CoA) and methylmalonyl-CoA (Mm-CoA), respectively, onto their cognate 
ACPs (TaB and TaE), that become substrates of the decarboxylase TaK. Alternatively, 
propionyl-CoA may be directly loaded on TaE to give propionyl-S-TaE. Condensation of 
intermediate 2 with acetyl-S-TaB and intermediate 6 with propionyl-S-ACP catalyzed by the 
HMGS TaC and TaF, respectively, creates intermediates 3 and 7. Removal of the carboxyl 
groups from intermediates 3 and 7 is a two step process involving dehydration by TaX 
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(resulting in intermediates 4 and 8), followed by their sequential decarboxylation to yield 5 
and 9. The carbon labelling pattern is described in b). d) Following the formation of 
intermediate 9, five more rounds of polyketide extension encoded by TaO and TaP PKSs and 
hydroxylation at C9 take place to yield 10. Hydroxylation of 10 at C29 yields 11 which 
becomes the subsequent target of O-methyltransferase TaQ, giving myxovirescin A (1). 
 
often belong to the so-called "trans AT" family of type I synthases, which lack integral AT 
domains, and hence compensate for these activities with "trans"-acting ATs.  
 
The gene products of the HMG-cassettes have been proposed to constitute a separate 
pathway dedicated to the formation of the β-methyl branches in these secondary metabolites. 
Studies of HMG cassette enzymes from the bacillaene (PksX) pathway in vitro have 
demonstrated their likely roles in the biosynthesis in vivo: the discrete AT charges the ACP 
with the appropriate substrate (typically malonyl-CoA or methylmalonyl-CoA), the variant 
KS catalyzes decarboxylation, while the HMGS acts to couple the resulting acetate or 
propionate unit to the polyketide backbone (Figure 1 c). Finally, the two ECH homologues 
modify the resulting intermediate further by removing water and carboxylic group.   
 
In comparison with similar metabolites which display characteristic β-methyl 
branches, myxovirescin A has a unique β-ethyl branch originating from the C2,C3 of 
succinate, via methylmalonate (Figure 1 b).[6] Formation of both β-branches has been 
speculated to take place via this newly characterized pathway and to require the two pairs of 
free standing ACPs and HMGS activities (TaB/TaC and TaE/TaF), respectively (Figure 1 a). 
The two HMG-CoA-like synthases TaC and TaF have been proposed to carry out 
nucleophilic additions of acetyl-S-TaB and propionyl-S-TaE onto the C12 and C16 β-keto 
positions of the β-ketoacyl-S-ACP polyketide intermediates 2 and 6, respectively.[3; 7] As the 
other three enzymes, the variant KS (TaKS) and the two enoyl-CoA hydratases homologues 
(TaX and TaY), are encoded only once in the gene cluster, they have been proposed to be 
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involved in both rounds of modification reactions (Figure 1 c). Following the formation of the 
C29 methyl carbon connected to C12 and the ethyl group attached to C16, antibiotic 
biosynthesis is suggested to switch back to the classical polyketide biochemistry to generate 
the myxovirescin lactone ring (10). Hydroxylation of the C29 carbon and its subsequent 
methylation would then yield the methylmethoxy group present in myxovirescin A (1) (Figure 
1 d).  
 
In our previous study, we presented genetic evidence that both HMGSs are required 
for biosynthesis of myxovirescin A. Deletion of taC caused the loss of 1, proving that TaC is 
indispensable for myxovirescin production. However, TaF was not absolutely required, as its 
inactivation led to the production of a novel myxovirescin analogue.[7] This new metabolite 
contained a methyl in place of the ethyl group at C16, providing direct evidence for the role of 
TaF in the formation of the ethyl group. Furthermore, production of this novel myxovirescin 
was not dependent on the primary metabolic HMGS mvaS, the only other HMGS homologue 
identified in the M. xanthus DK1622 genome.[7] Hence, the presence of a novel β-methyl 
branch in the new myxovirescin analogue (myxovirescin ΔF) has been rationalized by the 
double action of TaC, which appears to be capable of complementing the function of TaF.[7]  
 
 
To test the remainder of the proposed biosynthetic model, a series of in-frame mutants 
was created and extracts of the resulting strains analyzed by high performance liquid 
chromatography/mass spectrometry (HPLC-MS) for the production of 1, its analogues, or 
possible precursors.   
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Results 
ΔtaB and ΔtaE mutants produce similar phenotypes to those observed for their 
respective HMGSs mutants ΔtaC and ΔtaF 
As suggested by the gene organization in the cluster and low level of sequence 
homology between the two discrete ACPs TaB and TaE (33% identity, 51% similarity), TaB 
and TaE were predicted to interact with their associated HMGS TaC and TaF by forming two 
functional complexes (TaB/TaC and TaE/TaF) (Figure 1 a). Hence, each functional 
ACP/HMGS pair was hypothesized to perform one round of substrate-specific β-alkylation on 
the C12 and C16 β-keto positions of intermediates 2 and 6 (Figure 1, b-c). However, prior to 
associating with their presumed HMGS, each ACP would have to be acylated with a specific 
substrate (TaB with malonate and TaE with methylmalonate), by one of the two ATs present 
in the cluster, and further decarboxylated by a common decarboxylase TaK (Figure 1 c). If the 
two ACPs and HMGS indeed formed two distinct functional pairs, removal of each ACP from 
the megacomplex should have yielded the same phenotype observed for deletions of their 
presumed HMGSs.[7]  
 
 To test these assumptions, both taB and taE were deleted from the DK1622 genome 
to yield M. xanthus strains VS1038 (ΔtaB) and VS1039 (ΔtaE). HPLC-MS analysis of their 
mutant extracts revealed the loss of production of 1 in both strains (data not shown). 
Moreover, the ΔtaE mutant displayed production of the modified myxovirescin analogue that 
was previously isolated from the ΔtaF HMGS mutant background.[7] This myxovirescin 
analogue contains a novel C16 β-methyl branch, and was designated as myxovirescin ΔF (12) 
(Figure 2 a). However, since the levels of 12 in ΔtaE mutant were reproducibly lower then in 
the ΔtaF background, quantitative HPLC-MS analysis was performed to establish its exact 
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concentration. Figure 2 a shows that in comparison with the ΔtaF strain, the production of 12 
in the ΔtaE background was 10-fold lower, indicating an additional role of TaE.  
 
TaB and TaK are required for the formation of β-methyl branches 
 Because the ΔtaF strain specifically produces analogue 12, which contains two 
acetate derived β-methyl groups (one of which is subsequently modified into a β-methylene), 
this background was chosen to confirm that TaB/TaC, along with TaK, act in the pathway 
leading to the formation of 12. Accordingly, both taB and taK were deleted from the ΔtaF and 
the effects of the double mutations on the production of 12 were analyzed. As expected, 
HPLC-MS analysis of the resulting VS1041 (ΔtaBF) and VS1042 (ΔtaKF) double mutant 
extracts indicated the loss of production of 12 (Table 2). 
 
Table 1. Plasmids generated in this study. 
Plasmid  
 
Plasmid description 
 
pVS44 627 bp fragment obtained by amplification with TaX1 and TaX2 primer pair cloned in pTOPO 
pVS45 617 bp fragment obtained by amplification with TaX3 and TaX4 primer pair cloned in pTOPO 
pVS46 578 bp fragment obtained by amplification with TaY1 and TaY2 primer pair cloned in pTOPO 
pVS47 550 bp fragment obtained by amplification with TaY3 and TaY4 primer pair cloned in pTOPO 
pVS59 Inserts from pVS46 and pVS47 cloned in XbaI and SpeI sites of pSWU41  
pVS60 Inserts from pVS44 and pVS45 cloned in XbaI and SpeI sites of pSWU41 
pVS66b 2560 bp fragment amplified with H1/H2 primer pair containing taH plus ca. 600 bp on either 
side of the gene; cloned in pTOPO vector 
pVS68 2560 bp fragment amplified with H1/ H2 primers and cloned in XbaI and SpeI sites of pSWU41 
pVS71 Derivative of pVS68 obtained by amplification with H3/H4 primer pair; the construct lacks 
1422 bp of taH 
pVS72 2276 bp fragment containing  taK plus ca. 600 bp on both sides of the gene amplified with 
K1/K2 primer pair and cloned in pTOPO vector 
pVS73 1484 bp fragment containing taB and ca. 600 bp on both sides of the gene amplified with B2/B3 
primer pair and cloned in pTOPO vector 
pVS77 1425 bp fragment containing taE and ca. 600 bp on both sides of the gene amplified with E2/E3 
primer pair and cloned in pTOPO vector                  
pVS78 Derivative of pVS72 lacking 1179 bp of taK (ΔtaK). Obtained by amplification of pVS72 with 
K3/K4 primer pair.                   
pVS79 Derivative of pVS73 lacking 240 bp of taB (ΔtaB). Obtained by amplification of pVS73 with 
B1/B4 primer pair.                                 
pVS80 Derivative of pVS77 lacking 201 bp of taE (ΔtaE). Obtained by amplification of pVS77 with 
E1/E4 primer pair.                         
pVS81 1097 bp fragment from pVS78 subcloned in BamHI/XbaI sites of pSWU41                   
pVS82 1244 fragment from pVS79 subcloned in BamHI/XbaI sites of pSWU41   
pVS83 1224 bp fragment from pVS80 subcloned in BamHI/XbaI sites of pSWU41                    
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TaK, a variant ketosynthase, is not absolutely required for myxovirescin A production  
taK, like many other discretely encoded KS domains found in the HMGS-containing 
natural product gene clusters, can be distinguished from standard KSs because of its Cys to 
Ser substitution in the active site (KSS). Biochemical analysis of fatty acid KSs from E. coli 
with the identical mutation have shown the enzymes to be severely deficient in catalyzing 
 
Table 2. List of M. xanthus strains used in this study. 
Strain Genotype Myxovirescin 
Analogue 
Reference 
DK1622 M. xanthus wild type A (1) [8] 
VS1019 pVS59 x DK1622 - This study 
VS1020 pVS60 x DK1622 - This study 
VS1028 pVS71 x DK1622 - This study 
VS1032 pVS83 x DK1622 - This study 
VS1033 pVS82 x DK1622 - This study 
VS1034 pVS82 x VS1012 - This study 
VS1035 pVS81 x DK1622 - This study 
VS1036 pVS81 x VS1012 - This study 
VS1023 ΔtaY - This study 
VS1026 ΔtaX - This study 
VS1038 ΔtaB - This study 
VS1039 ΔtaE ΔF (12) This study 
VS1012 ΔtaF 12 [7] 
VS1040 ΔtaK 1 This study 
VS1041 ΔtaBF - This study 
VS1042 ΔtaKF - This study 
VS1030 ΔtaH ΔH (10) This study 
 
condensation, while retaining their decarboxylative functions.[9; 10] Recently, PksF of B. 
subtilis, which shows 54% identity and 71% similarity with TaK, has been shown to 
participate in the pathway dedicated to β-methylation, by catalyzing decarboxylation of 
malonyl-S-ACP to acetyl-S-ACP[5] (compare Figure 1 c). Since there is only a single copy of 
such mutant KSS present in the whole DK1622 genome, and two predicted decarboxylation 
reactions, TaK has been postulated to act twice during biosynthesis to cleave carboxyl groups 
from both malonyl and methylmalonyl-S-ACP substrates (Figure 1 c). Therefore, removing 
taK from the system would be expected to abolish myxovirescin biosynthesis. In order to 
verify the involvement of TaK in myxovirescin biosynthesis, taK was deleted from the 
genome and the effect of this mutation on 1 was analyzed. However, contrary to our 
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expectations, production of 1 was still observed in VS1040 (ΔtaK), although at 120-fold 
reduced levels relative to the wild type (Figure 2 b).  
 
Figure 2. Quantitative HPLC-MS analysis of the VS1012 (ΔtaF) and VS1039 (ΔtaE) a) and 
DK1622 and VS1040 (ΔtaK) b). The error bars represent the standard deviation obtained 
from five independent experiments. 1 and 12 were quantified using Bruker quantification 
software by integrating three major [M+H]+ peaks (578.5, 560.5 and 542.5) of 12 and 592.5, 
574.5 and 556.5 peaks of 1. 
 
TaX and TaY, two members of ECH superfamily, are required for myxovirescin A 
production 
Both TaX and TaY show similarity with members of enoyl-CoA hydratase 
superfamily. In particular, TaX is more similar to PksH of bacillaene and CurE from the 
curacin systems, which both catalyze dehydrations (Figure 3 a), whereas TaY is more closely 
related to the decarboxylases PksI and CurF (Figure 3 b).[5; 11] Based on the sequence 
homologies with these biochemically characterized enzymes, TaX was proposed to dehydrate 
intermediates 3 and 7, respectively, to yield 4 and 8. Further removal of carboxyl groups from 
4 and 8 by TaY should yield intermediates 5 and 9, respectively (Figure 1 c). Unfortunately, 
aside from the observed loss of 1, HPLC-MS analysis of VS1026 (ΔtaX) and VS1023 (ΔtaY) 
mutant extracts did not reveal the production of new analogues of 1 with additional hydroxyl 
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and carboxyl groups attached to carbons C12/C29 and C16/C31, or hydrolytic release of 
possible intermediates 3, 4, 7 or 8 (Figure 1, b-c).  
TaH, a cytochrome P450, hydroxylates the β-methyl group of myxovirescin A  
As indicated in Figure 1 d, following the assembly of the myxovirescin skeleton, 
formation of mature myxovirescin A requires three more modification reactions. We have 
previously shown that the last step in the formation of the methylmethoxy group is catalyzed 
by the SAM-dependent methyltransferase TaQ (Figure 1 b).[3] The two remaining reactions 
are  
 
 
 
 
 
 
 
 
Figure 3. ClustalW alignments of members of TaX and TaY with members of the ECH 
superfamily from bacillaene (PksX) and curacin (Cur) systems. PksH (CAB13587) and CurE 
(AAT70100) have been demonstrated to function as dehydratases, while PksI (CAB13588) 
and CurF (AAT70101) as decarboxylases.[5; 11] The accession numbers are indicated in 
parenthesis. Arrows indicate amino acids which stabilize the thioester carbonyl by hydrogen 
bonding via their peptidic NH groups. 
 
hydroxylations which are expected to target carbons C9 and C29. The three candidates for 
these two reactions are TaH, annotated as a cytochrome P450 hydroxylase (E value = 3 x  
10-51), and two putative oxygenases TaN and TaJ.[3]  
 
To determine the molecular target of TaH, taH was deleted in frame from the DK1622 
chromosome, resulting in strain VS1030. Comparative analysis of mass chromatograms of 
extracts of wild type DK1622 (Figure 4 a, left panel) and VS1030 (Figure 4 a, right panel) 
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(m/z 590–625) revealed an approximately 1 minute delay in the retention time of 
myxovirescins in strain VS1030 relative to the wild type. The UV absorption maxima at 239 
nm showed the same trend (Figure 4 b). In particular, strain VS1030 did not produce 1 
([M+H]+ = 624), but a novel myxovirescin analogue of [M+H]+ = 594. A tandem MS 
fragmentation of [M+H]+ = 594 confirmed that this new compound, named myxovirescin ΔH, 
does not fragment to give a [M+H-32]+ ion, which is characteristic of the fragmentation of 1 
(Figure 4 c, bottom panel). Yet, all the subsequent fragmentations followed a pattern identical 
to the one observed with the reference compound (compare Figure 4 c). Furthermore, the high 
resolution mass spectrum (HRMS) of myxovirescin ΔH [M+H]+ = 594.4358 is in good 
agreement with the molecular formula C34H60O7N+ (calculated m/z [M+H]+ = 594.4364, Δm/z 
= –1.08 ppm, see Supplementary materials), consistent with the loss of a methoxy group 
relative to 1. 
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Figure 4. Analysis of the cytochrome P450 mutant strain VS1030 (ΔtaH). a) Mass ion 
chromatograms in the 590-625 range from the M. xanthus DK1622 (left) and VS1030 (ΔtaH) 
strain (right). b) UV239 nm absorption measured in the DK1622 (left) and VS1030 (right). c) 
Tandem MS fragmentation patterns of myxovirescin A ([M+H]+  = 624) (top) and the novel 
myxovirescin ΔH ([M+H]+  = 594) (bottom). 
 
To confirm whether the largest fragment ion resulting from the fragmentation of 1 is 
indeed a product of the elimination of the C29 methoxy group (neutral loss, Δm/z = 32 units), 
1 was subjected to MS-MS fragmentation and the HRMS of the largest molecular ion ([592]+) 
was determined. The calculated HRMS of 592.4208 was in agreement with the 
experimentally determined mass, and corresponds to the molecular formula C34H58O7N+, 
reflecting the loss of methanol (CH3OH) relative to 1 (Supplementary material). As there is 
only one methoxy group present in 1, myxovirescin ΔH was assigned structure 10 (Figure 1 
d). Interestingly, the production of 10 in VS1030 was equal to the levels of 1 measured in the 
reference strain (Figure 4 b). 
 
Discussion 
Our model for myxovirescin A (1) assembly proposes that the two ACP/HMGS pairs 
are β-branch-specific, whereas TaK, TaX and TaY are shared between the two pathways 
(Figure 1 c). Indeed, in our previous study we have shown that removal of TaC halts 
myxovirescin biosynthesis whereas the loss of TaF leads to the production of a new 
myxovirescin with two methyl groups at the C12 and C16 positions (the methyl group at C12 
being further elaborated into methylmethoxy functionality). In this study we have 
demonstrated that deletions of their proposed accompanying ACPs, TaB and TaE, yield 
similar phenotypes (Table 2 and Figure 2 a). These results provide direct evidence that each 
ACP has a cognate HMGS with which it forms a functional pair (e.g. TaB with TaC and TaE 
with TaF). Thus, the ACPs are not functionally exchangeable during biosynthesis, e.g. TaB 
does not function in combination with TaF and TaE with TaC. Furthermore, these results 
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demonstrate the functional roles of the two enzyme pairs: the TaB/TaC pair directs formation 
of the methyl group, while TaE/TaF directs formation of the ethyl group.  
Another important conclusion arising from this genetic study is that the functions of 
the two ACP/HMGS enzyme pairs are not mutually complementary. Our results suggest that 
TaB/TaC can rescue myxovirescin production in the absence of either TaE or TaF, most likely 
by performing two rounds of acetate delivery (TaB) and acetate condensation (TaC) with 
intermediates 2 and 6 to manufacture myxovirescin ΔF (12). However, the reverse 
complementation cannot occur, as the TaE/TaF enzyme duo cannot substitute for TaB/TaC. 
Therefore, both TaB and TaC are essential for antibiotic assembly. In addition, the ability of 
TaB/TaC to complement TaE/TaF implies a level of flexibility of the TaB/TaC pair in 
docking with module 7 of Ta-1, as well as module 8 in processing the intermediate with the 
shorter side chain. However, the molecular determinants for these protein-protein interactions 
are not known at present time. 
 
Given the expectation that deletions of taB and taE were anticipated to phenotypically 
mimic deletions of their partner HMGSs, it was surprising to measure a 10-fold drop in the 
production of 12 in ΔtaE strain relative to ΔtaF background (Figure 2 a). This result 
demonstrates that the loss of TaE is even more incapacitating to the megasynthetase than the 
loss of the condensing enzyme TaF, and points to an additional and yet unknown function of 
TaE in biosynthesis. The observed functional differences between TaB and TaE are also 
consistent with their low sequence identity. Indeed, given the central role of ACPs in PKS and 
fatty acid biosynthesis, as well as in the pathway leading to β-methyl group formation, it is 
plausible that the divergence of the ACPs was required to insure the correct spatial 
implementation of two different substrates in myxovirescin polyketide scaffold. 
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Unlike the two ACPs, TaK was proposed to act twice during biosynthesis, by 
decarboxylating both malonyl-S-TaB and methylmalonyl-S-TaE intermediates (Figure 1 c). 
Unexpectedly, production of myxovirescin A continued in the ΔtaK background, albeit at a 
120-fold reduced level. However, the production of 12 was completely abolished in ΔtaKF 
background. The genome search for possible homologues of TaK did not identify another 
monofunctional KS exhibiting a similar mutation. Taken together, these results indicate the 
role of TaK in the formation of the β-methyl branch and suggest that either a different enzyme 
decarboxylates methylmalonyl-S-TaE, or that the corresponding "trans AT" loads propionyl-
CoA directly onto TaE ACP. Alternatively, the residual amount of myxovirescin A observed 
in the ΔtaK background could be generated through availability of the low amount of 
spontaneously decarboxylated malonyl-S-ACP and methylmalonyl-S-ACP. 
 
Finally, analysis of the cytochrome P450 mutant has provided the last clue towards 
understanding the biosynthesis of the methylmethoxy group (Figures. 1 d and 4). Formation 
of 10 in the strain VS1030 fully confirms our hypothesis regarding the two-step conversion of 
the methyl into the methylmethoxy group. In contrast to the severe impact of other mutations 
on myxovirescin production (Table 2),[3; 7] production of 10 in ΔtaH was equal to the 
production of 1 in DK1622 (Figure 4 b). Based on this result we conclude that the conversion 
of 10 to 1 takes place following formation of the lactone ring. 
 
An emerging body of evidence combining both in vitro and in vivo observations on 
the bacillaene and myxovirescin systems demonstrates the evolutionary divergence of primary 
and secondary metabolic (SM) HMGSs. These differences include the demonstrated use of 
ACP- instead of CoA-activated substrates.[5] Furthermore, SM HMGSs show wide 
promiscuity toward different substrates. For example, certain HMGS are likely to accept 
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propionyl-S-ACP in addition to acetyl-S-ACP as the first substrates, and perform nucleophilic 
additions on β-ketoacyl-S-ACP intermediates of different chain lengths. For example, PksG is 
catalytically active with acetoacetyl-S-ACP even though its natural substrate is predicted to be 
fifteen carbons long.[5; 12] Similarly, our results suggest that TaF acts on a substrate with C18 
chain length.[7] As the structure of a SM HMGS has not yet been solved, it is to hope that the 
future high-resolution structural information on members of this newly recognized family of 
condensing enzymes will be able to provide deeper insights into their flexibility toward 
heterogeneous substrates.  
 
In contrast to the HMG-like synthases, which have preserved the overall reaction 
mechanism, members of the ECH superfamily are well-known for their mechanistic diversity 
and catalyze various reactions ranging from dehalogenation, (de)hydration, decarboxylation, 
formation/cleavage of carbon-carbon bonds, hydrolysis of thioesters etc.[13] Despite the 
overall differences in their reaction mechanisms, ECH family members share a partial 
reaction mechanism which enables stabilization of enoyl-CoA anion intermediates within an 
oxyanion hole (residues outlined in two boxes, Figure 3). However, consistent with different 
overall reactions they catalyze, the active site residues within the superfamily vary.  
 
Two homologues of this superfamily have been found to be conserved across several 
biosynthetic gene clusters.[2; 5; 14; 15] In vitro characterizations of two pairs of ECHs from the 
bacillaene and curacin systems, and the very recent characterization of TaX and TaY 
(Calderone C. et al., personal communication) have demonstrated their functions as 
dehydratases and decarboxylases, respectively.[5; 11] At this point we cannot differentiate 
whether the observed loss of myxovirescin production in ΔtaX and ΔtaY backgrounds is a 
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result of the rejection of the proposed intermediates 3, 4, 7 or 8 by the assembly line, by the 
requirement of the two enzymes for megasynthetase turnover, or both. 
 
Conclusions  
The mutagenic analysis of eight discrete genes encoded in the myxovirescin gene cluster 
constitutes the first comprehensive in vivo study toward elucidation of the biosynthetic 
pathway leading to the formation and tailoring of β-branches in one secondary metabolite. In 
addition to the elucidation of functional roles of certain genes, our results present evidence for 
the plasticity of myxovirescin megasynthase. However, several aspects of the biosynthesis 
remain to be elucidated, including the nature of protein-protein interactions between β-
modifying enzymes and the PKS multienzyme. Nonetheless, the relative ease of manipulating 
discretely encoded activities in contrast to the giant polyketide synthases, coupled with the 
observed broad substrate specificity of HMGS and ECH homologues, suggests that HMG 
toolboxes and their accessory enzymes may be successfully exploited in future attempts to 
generate new, ‘β-modified’ bioactive compounds.  
 
 
Experimental Section 
Creation of deletion mutants: The general cloning strategy used for the construction of 
vectors intended for creation of in-frame deletions of ΔtaB, ΔtaE, ΔtaH and ΔtaK is 
exemplified here with the deletion of taK. To delete taK, the chromosomal region including 
taK and approximately 600 bp upstream and downsteam from it was amplified using K1 and 
K2 primers (see Supplementary material) and Phusion polymerase (New England Biolabs). 
The resulting 2276 bp PCR product carrying BamHI and XbaI overhangs was gel purified 
(Macherey und Nagel), modified with A overhangs, and cloned in pCR2.1®-TOPO vector 
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yielding plasmid pVS72. Plasmid pVS72 was amplified in the second PCR reaction using 
primers K3 and K4, designed to be in-frame with taK, with Phusion polymerase. Following 
amplification, the PCR reaction was treated with DpnI enzyme to eliminate the template 
DNA. The 5 kb PCR product was gel purified, treated with T4 kinase and T4 ligase, and 
transformed into E. coli DH10B. The new plasmid, pVS76, lacking the taK gene but 
containing the 600 bp upstream and downstream of the gene was submitted for sequencing. 
Finally, the approximately 1200 bp insert was subcloned from pVS76 into BamHI and XbaI 
sites of vector pSWU41 to create plasmid pVS79, which was used for electroporation in M. 
xanthus DK1622. The cloning strategy used to generate plasmids for ΔtaX and ΔtaY 
mutations as well as the creation of in-frame deletion mutants was carried out as described 
in.[3] To create ΔtaEF and ΔtaKF double mutants, plasmids pVS81 and pVS79, respectively, 
were electroporated, and later excised, from the chromosome of VS1012 (ΔtaF background). 
Sequences of all primers are provided in Supplementary materials and the list of generated 
plasmids is given in Table 1.  
 
Growth conditions: Myxovirescin production was assayed in MD-1 medium that consisted 
of casitone (0.3%), CaCl2 2 H2O (0.07%), and MgSO4 7 H2O (0.2%); vitamin B12 (5×10-4 µg 
L-1) was added after cooling and analyzed for myxovirescin production as reported 
previously.[3] 
 
HPLC-MS analysis and quantification of 1 and myxovirescin ΔF: HPLC-MS analysis and 
quantitative HPLC-MS analysis was carried out as described.[3] Myxovirescin ΔF was 
quantified by integrating three major peaks at m/z 576.5, 558.5 and 540.6 peaks.   
 
 
 
                                                                   Chapter 4                                                                
 
103 
High resolution mass spectral analysis (HRMS): Determination of HRMS of myxovirescin 
ΔH and its fragment ions was carried out using ESI-FT/Orbitrap mass spectrometry. 
Measurements were performed using an UPLC-coupled LTQ Orbitrap instrument (Thermo 
Finnigan, Bremen/Germany) in positive ionization mode with a resolution setting of R = 
60000. External calibration in the m/z range 195–2000 was done using "LTQ Calibration 
solution" containing caffeine, MRFA (Met-Arg-Phe-Ala tetrapeptide) and the "Ultramark 
1621" reference mixture. Calculation of the putative molecular formula from the accurate 
mass spectra of target compounds was performed using the XCalibur 2.0 software suite. 
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Table 1. List of primers used in the study. 
 
Primer name 
 
Primer sequence (5’-> 3’) 
 
B1 GGTCCCTGAAGCCTTGCTGCG 
B2 CGGGATCCGTTGGTGTGCCAGTTATTGCCA* 
B3 GCTCTAGACCATCACCTCGTAGCCGTAGT 
B4 GCGAGGCTGTGAGGCGAAGC 
E1 TTCGTCTGTCATCGGCTCACC 
E2 CGGGATCCCATGAAGAGCTGTACGAGCAG 
E3 GCTCTAGATCGTAGCTGTAGTTGCCGAAC 
E4 CTGGTGGCGTTCCTGGCC 
K1 CGGGATCCGCCGTGGAACAGGTCCTTCG 
K2 GCTCTAGAGAGGAACGGCATCACGCAG 
K3 CGAGACAACCAGCTCCTGCAC 
K4 GACCCGATTGATTCATCGTTC 
E5f ATGTTGCGGATGTCGGCG 
E6f TGCATCGCCAGGTAGTCG 
E7r GTCGAAGGCGTACAACTTC 
B5f CCAGCTTCTCCAGCGTGAG 
B6f TTCACCATGCCGCCAAACG 
B7r GCTTGACACGCTGCCTCAT 
K5f TGGACTTCGTGGTGTTGAC 
K6f GCAACAGCTTCTCGCTATC 
K7r GAGACGGGACTGCGGCTGGT 
TaX1 GCTCTAGAAGGCGTGGGGCAAGACTTCCTT 
TaX2 CGGGATCCGCCATCCATCGCTACGTGG 
TaX3 CGGGATCCACAGGTCTGCGCCTCGAAG 
TaX4 GGACTAGTATCTTTGGAGAGGCGTGCGG 
taX5 ACGCAGCAGTTCGCCATCCA 
taX6 CACATAACCGTGTGCGTGGT 
taX7 CGCACTACCTGACGCTGATG 
TaY1 GCTCTAGAATCAGCGGCGTGATGATGGC 
TaY2 CGGGATCCAAACCTCGGCTGTCGCTCGTGA 
TaY3 CGGGATCCCACCTTGCCGAACACGGTGATGA 
TaY4 GGACTAGTATCGTGCTGGCAAAGGCGGA 
taY5 GGACAACACCATCAGCCGCA 
taY6 GCAGTCACCGAAGAGCAGCT 
taY7 GGTGATTTCCGCCATGCAGG 
H1 GGACTAGTCCACCTCCAATTCCGACGAA 
H2 GCTCTAGATAGTTGATGGCTGCAACC 
H3 CAGGAACAACATCATCAACTG 
H4 TTCGCCTACTACGAGATGAAG 
H5 rev GAAAGAGAACCTTCGCTGTCT 
H6 for AGTTCCTGCTGAATCCGTCC 
H7 del GAATCACCTCCAGCATGATC 
 
*Underlined nucleotides indicate restriction sites 
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VS_dH_001 #539 RT: 8.38 AV: 1 NL: 2.37E7
F: FTMS + c ESI Full ms [100.00-2000.00]
530 535 540 545 550 555 560 565 570 575 580 585 590 595 600
m/z
10
20
30
40
50
60
70
80
90
100
R
e
l
a
t
i
v
e
 
A
b
u
n
d
a
n
c
e
594.4358
R=55301
z=1
C 34 H 60 O 7 N 1 = 594.4364
-1.0755 ppm
576.4252
R=56201
z=1
C 34 H 58 O 6 N 1 = 576.4259
-1.0993 ppm
558.4147
R=56601
z=1
C34 H 56 O 5 N 1 = 558.4153
-1.1247 ppm
540.4043
R=58501
z=1
C 34 H 54 O 4 N1 = 540.4047
-0.8129 ppm
Orbitrap measurements for myxovirescin ΔH, in source fragmentation 
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VS_myva_001 #515 RT: 8.01 AV: 1 NL: 1.19E7
F: FTMS + c ESI Full ms [100.00-2000.00]
550 560 570 580 590 600 610 620 630
m/z
10
20
30
40
50
60
70
80
90
100
R
e
l
a
t
i
v
e
 
A
b
u
n
d
a
n
c
e
592.4208
R=55201
z=1
C 34 H 58 O 7 N 1 = 592.4208
0.0965 ppm
574.4103
R=56201
z=1
C 34 H 56 O 6 N 1 = 574.4102
0.1093 ppm
624.4472
R=53401
z=1
C 35 H 62 O 8 N1 = 624.4470
0.3356 ppm
556.3997
R=56301
z=1
C 34 H54 O 5 N 1 = 556.3997
0.0133 ppm
Orbitrap measurements for myxovirescin A, in source fragmentation
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Introduction 
 
Early attempts to optimize myxovirescin production indicated the importance of 
reduced carbon conditions in the production medium. In M. xanthus TA, concentrations of 
peptone larger than 1% caused complete inhibition of antibiotic production, whereas alanine, 
serine and glycine stimulated its formation.[79] Accordingly, the subsequent fermentation 
processes were carried out in 0.5% or 0.3% casitone medium. The importance of the quantity 
and rate of peptone addition, as well as aeration, for myxovirescin production has also been 
documented for a related myxococcus strain, M. virescens.[80] Growth of M. virescens was 
also inhibited by increased intracellular concentrations of ammonium and accumulation of 
aspartic and glutamic acids in the culture supernatants during fermentation. Hence, continuous 
extraction of ammonium boosted myxovirescin production by up to 13-fold.[18] 
Aside from these early physiological studies, there are no published experiments 
addressing the molecular mechanisms of regulation of secondary metabolism in M. xanthus. 
Therefore, we were encouraged to identify a gene locus approximately 11 kb in size located 
upstream from the myxovirescin biosynthetic cluster, which suggested a possible regulatory 
function (Figure 1).  
lacB myrB myrC myvD myvC myvB myvA
1 kb
 
Figure 1. 10.9 kb of myxovirescin regulatory region. Seven genes are organized into two 
putative operons with predicted functions listed in Table 1. The myxovirescin biosynthetic 
gene cluster starts upstream from lacB in the reverse direction.  
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Organization and in silico annotation of the 10.9 kb locus upstream from the 
myxovirescin biosynthetic gene cluster 
 
As outlined in Figure 1, the 10.9 kb region appears to be organized into two operons 
(myr and myv) transcribed in opposite directions. The myr operon consists of three genes. The 
lacB shows similarity (E = 2×10-6) with the B superfamily of Zn-dependent lactamases 
(http://pfam.janelia.org/) (Table 1). In addition to hydrolysis of the beta lactam rings, 
members of this family also catalyze other reactions such as thioesterifications and hydrolysis. 
The second gene, myrB, encodes a σ54-dependent activator protein, also known as enhancer 
binding protein (EBP). MyrB has multimodular structure consisting of a central AAA domain  
specialized in binding and hydrolysis of ATP and C-terminal helix-turn-helix motif for 
binding DNA. The N-terminus of MyrB plays a sensory role and consists of the small-
molecule-binding GAF domain (Figure 2). The EBP class of transcriptional activators bind to 
the enhancer boxes upstream or downstream from the promoter, and initiate transcription via 
σ54 contact-dependent hydrolysis of ATP (Figure 3). This process requires EBP-dependent  
 
Table 1. List of genes comprising two myxovirescin regulatory operons, their proteins and 
identified conserved domains. 
 
ORF/ 
protein 
Size (bp) 
Amino 
acids (aa) 
Closest homologue in the 
PubMed database 
(% identity/similarity) 
Putative function Protein domains identified 
by Pfam search engine 
(amino acid coordinates) 
lacB/ 
LacB 
 
795/265 TaR-3 from S. aurantiaca 
DW4/3-1 (78/86) 
Thioesterase, hydrolase of 
unknown function 
Lactamase B (2-203) 
myrB/ 
MyrB 
 
1590/530 TaR-2 from S. aurantiaca 
DW4/3-1 (81/88)  
σ54-dependent enhancer 
binding protein (EBP) 
GAF (43-180) AAA 
(207429) HTH (483-523)  
myrC/ 
MyrC 
 
2358/786 - Unknown  - 
myvD/ 
MyvD  
 
879/293 S. aurantiaca DW4/3-1 (50/67) Unknown  - 
myvC/ 
MyvC  
(pkn10)  
 
2244/748 Pkn10 of S. aurantiaca DW4/3-1 
(62/73) 
Serine/tyrosine/ 
threonine 
kinase (STK) 
STK (168-412) 
myvB/ 
MyvB   
1734/578 Adenylate cyclase of S. 
aurantiaca DW4/3-1 (78/87 ) 
Signal transduction/ 
transcriptional regulation 
FHA (61-124) GAF (204-
338) AC (377-564) 
 
myvA/ 
MyvA   
912/304 STIAU_4297 of 
 S. aurantiaca DW4/3-1 (59/76) 
Unknown  - 
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GAF AAA HTH
GAF AC
MyrB
FHA
MyvC
MyvB
STK
 
  
Figure 2. The modular organization of MyrB, MyvB and MyvC indicates a complex 
regulatory network involving a variety of domains. GAF domains bind small molecules, 
adenylate cyclases (AC) synthesize cyclic adenylyl monophosphates (cAMP) from ATP. FHA 
domains function as phosphothreonine/phosphotyrosine binding epitopes, and hence may 
transduce a signal to serine/threonine kinase MyvC or vice versa. 
 
bending (looping) of DNA. The conformational switch from the closed to an open RNA-
polymerase-σ54 complex is driven by energy released from ATP hydrolysis.[81] σ54 binds to the 
relatively conserved –12/–24 region upstream from the +1 transcriptional start site. One such 
putative σ54 binding region was identified 242 bp upstream from Ta-1PKS: 
TTGGCTCGCGTCTGGCT, where the letters in bold indicate the conserved nucleotides at  
–12 and –24 positions from the presumed transcriptional start site (Materials and methods).  
MyrB exhibits the same domain organization (GAF-AAA-HTH) as the transcriptional 
activator NifA from Azotobacter vinelandii.[82] NifA is involved in the activation of all but 
one operon carrying out nitrogen fixation. MyrB is also similar to FhlA of E. coli, the 
transcriptional regulator of the formate regulon.[83] However, unlike MyrB and NifA, FhlA 
contains two amino terminal GAF domains. Interestingly, MyrC, MyvA and MyvD do not 
show similarity to any other protein in the database. However, MyvB is composed of three 
conserved protein domains: the adenylate cyclase (AC) domain, which presumably cyclyzes 
ATP into cAMP, the GAF domain, and the FHA domain. FHA domains have been shown to 
interact with phosphothreonine/phosphotyrosine residues.[63] Hence, MyvB may be a part 
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Figure 3. A three-step mechanism for EBP-dependent activation of transcription from  
σ54-specific promoters (Figure reproduced from).[81] 
 
of a signal transduction cascade involving putative serine/threonine kinase MyvC. Curiously, 
myvB and myvC are most likely transcriptionally coupled.  
The presence of the AC domain and two GAF domains suggests a possible role of 
cAMP in the regulation of EBPs. However, analysis of the two GAF domains did not reveal 
the conservation of five residues (NKFDE motif) which were shown to be essential for 
binding of cGMPs to a mammalian phosphodiesterase (PDEs) containing tandem GAF 
domains.[84] These residues were also found to be conserved in cAMP-binding Anabaena 
adenylate cyclase.[85] 
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Results 
To examine the involvement of some of the genes in myxovirescin production, we 
decided to knockout myrC and myvD, as the resulting mutations could not cause polar effects 
on the downstream genes (Figure 1). A third mutant containing a disruption in the gene 
myvD, was obtained from the Prof. Inouye’s laboratory. Upon construction of the two 
merodiploid mutants (Table 1), the three mutants were grown alongside the DK1622 (wild 
type) strain, and the resulting cell extracts were examined for myxovirescin production using 
HPLC (Table 2). Our results indicate that all three mutations exhibit negative effects on 
myxovirescin production: the myrC mutant yields 28 % reduced production relative to the 
DK1622, whereas myvC and myvD mutants produce only 6.5 % and 12.5 % of the wild type 
antibiotic levels.  
 
Table 2. M. xanthus strains, their genotypes and the level of myxovirescin production. 
 
   
M. xanthus strain 
 
Genotype 
 
% of wild type production* 
 
DK1622 Wild type 100 
myrC (VS1013)  pVS64 x DK1622 72 
myvD (VS1014)  pVS66 x DK1622 12.5 
myvC  ppkn10 x DK1622 6.5 
 
*Percentages indicate the average of two independent experiments.  
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Experimental Section 
 
Creation of myrC (VS1013) and myrD (VS1014) mutants: To knock out myrC, a 500 bp 
amplificate was generated using DK1622 genomic DNA and tar_up 5’-
ACTTCAACTAGCTGGGCGAC-3’/ tar_down 5’-CTGGTAGTCGTCGGTGAGGG-3’ 
primer pair. The resulting PCR fragment was cloned in pTOPO vector resulting in construct 
pVS64 (Table 2). To disrupt myrD, a 594 bp amplificate was obtained using 29_up 5’- 
CTCTGTTGAGGTTCGGACTTCTGGC-3’/ 29_down 5’-
ACGCGGGCGAAAAGGACACC-3’ primer pair and cloned in pTOPO to give construct 
pVS66. Nucleotides indicated in bold show changes from the original sequence needed to 
create STOP codons in both genes. Following electroporation of constructs pVS64 and pVS66 
in M. xanthus DK1622, mutant strains VS1013 and VS1014 respectively were verified by 
PCR reaction as reported[39] (Table 2). The myvC (pkn10) mutant was obtained from Inouye’s 
laboratory and was generated by disrupting the central, conserved serine/threonine kinases 
domain. Growth of M. xanthus for myxovirescin production was performed as previously 
reported.[39; 86] 
Identification of putative σ54 binding sites was carried out using manual analysis of 
promoter regions and http://molbiol-tools.ca/mtoolwww-cgi/promscan.cgi web site.  
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Discussion 
 
In silico and genetic analysis of two myxovirescin sensory and regulatory operons 
suggests a complex regulatory scheme involving the σ54-dependent, NifA-like enhancer 
binding protein MyrB, the serine/threonine kinase (STK) MyvC and several other unknown 
proteins. The presence of two GAF domains (one of which is a part of MyrB EBP), known to 
bind small effector molecules, suggests that the regulation of myxovirescin production may be 
subject to allosteric control by as yet unknown effectors. For example, 2-oxoglutarate binds to 
the GAF domain of NifA,[82] and formate to the GAF domain of FhlA.[83] In addition, GAF 
domains of cyanobacteria and eukaryotes bind cAMP and cGMP.[84; 85] Given the observed 
negative effect of high concentrations of ammonia on cell growth, and the upregulation of 
myxovirescin production observed under reduced carbon and nitrogen conditions, it seems 
likely that the key signals of carbon and nitrogen metabolism may be some of the effectors.  
The presence of an adenylate cyclase domain in combination with GAF domains in 
MyvB and MyrB suggests a possible role for cAMP in the regulation of myxovirescin 
production. Interestingly, inspection of the two GAF domains for the presence of the 
conserved signature motif that is involved in binding cyclic cAMP in eukaryotes and 
cyanobacteria,[84; 85] failed to identify classical recognition sites. Unlike in E. coli where the 
role of cAMP as a global regulator has been well established, nothing is known about its role 
in gene expression in M. xanthus.  
Three gene knockouts provide evidence for the role of MyrC, MyvC, and MyvD in 
regulation and (or) sensory transduction circuits leading to myxovirescin production. Two of 
these genes, myrC and myvD do not resemble any other genes in the database. However, 
despite their "uniqueness," we have shown the involvement of both MyrC and MyvD in the 
regulation of antibiotic production. Moreover, the additive effects of myvC and myvD 
knockouts on myxovirescin production suggest that MyvC and MyvD are a part of the same 
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signal transduction cascade. In summary, the concerted action of the proteins with known 
function (such as STK and EBPs) with proteins of unknown function suggests that 
myxovirescin production may be directed by novel regulatory mechanism(s).  
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General remarks on the myxovirescin biosynthetic factory    
In silico analysis of the myxovirescin biosynthetic gene cluster from M. xanthus 
DK1622 indicated several deviations from the classical rules of polyketide assembly, as 
exemplified in the introductory chapter. For example, there appear to be two sets of catalytic 
domains which can function to provide the proposed starter unit 2-hydroxyvaleryl-S-ACP.[39] 
Indeed, we were able to show that myxovirescin production persists upon elimination of 
either the ACP-KS-KR-ACP domains of TaI or ACP-KS-ACP domains of TaL PKS, albeit 
with the greatly reduced titers, demonstrating their functional redundancy. As expected, 
inactivation of both TaI and TaL eliminated myxovirescin production entirely. This set of 
experiments provides genetic evidence that initiation of myxovirescin production may 
commence on either one of the two PKSs. Therefore, the myxovirescin megasynthase is one 
of the rare PKS/NRPS systems known to date which has evolved a dual pathway dedicated to 
starter unit biosynthesis. 
Sequence analysis suggests that the myxovirescin modules lack the three enoyl 
reductase domains required to saturate the C10-C11, C16-C17 and C22-C23 double bonds.[39] 
In addition, one ER is inserted between the ACP and TE domains of the last module, an 
irregular modular organization without precedent to date. Another unusual feature is 
encountered in module 11, which is missing the full reductive loop required to reduce the C24 
carbonyl. Furthermore, module 11 is physically "split" between the PKS TaO, which contains 
the KS domain, and the PKS TaP, which contains a methyltransferase (MT) and ACP 
domains. Whereas such domain separation requires specific protein-protein interactions 
between the C-terminus of TaO and the N-terminus of TaP, this separation might provide 
special access for the required reductive domains.  
Evidently, many aspects of myxovirescin biosynthetic system do not fit the classical 
prototype of a type I system (such as the erythromycin PKS, DEBS). Therefore, the question 
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arises as to how these "irregular," multi-hybrid (PKS/NRPS/HMGS) systems operate? Before 
we can answer this question, a more clear understanding of the structural and mechanistic 
details of the canonical systems is needed. Even though the crystal structure of a canonical 
PKS has not yet been solved, the crystal structure of the KS-AT didomain of module 5 of 
DEBS[87] and the ketoreductase (KR) domain have been reported.[88] In addition, there has 
been significant progress recently in the understanding of the structural aspects of similar, 
multimodular systems responsible for fatty acid biosynthesis. In the past year structures of 
fatty acid synthases from both, mammalls and fungi have been solved.[89; 90] In addition, new 
insights in the workings of both acyl and peptidyl carrier proteins have been reported.[91; 92] 
Among the important observations coming from the animal FAS structure are that the electron 
density corresponding to the acyl carrier protein and thioesterase was missing from the 
electron density map.[89; 90] This finding suggests that the acyl carrier protein and thioesterase 
are highly mobile within the megacomplex. Moreover, calculated distances between different 
catalytic domains ranged between 32–87 Å,[87; 89; 90] signifying that the 20 Å long Ppant arm is 
not sufficient to reach within the active site pockets of other domains, but is rather used to 
"inject" substrates deep into the active site cavities. These insights challenge the previous 
model of a "static" ACP and suggest that ACPs have to undergo significant interdomain 
rearrangements in order to supply all catalytic domains with their needed substrates. In 
addition to the presumed mobility of the acyl carrier proteins in PKS and FAS systems, 
several NMR solution structures of both acyl and peptidyl carrier domains have revealed their 
conformational flexibility.[93-95] Furthermore, a PCP from the tyrocidine synthetase was 
shown to adopt distinct conformational states in order to interact with particular partner 
domains.[95] 
In summary, knowledge obtained from structural studies of fatty acid synthases, KS-
AT didomain and KR domain of a PKS suggest that at least some elements of the structures 
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might be similar, and has lead to a proposal that the modular architectures between fatty acid 
and polyketide synthases will be essentially the same.[87; 88] These new insights are relevant to 
understanding of the myxovirescin multihybrid PKS/NRPS/HMGS synthase.  
 
Conservation of the Pathway Leading to Formation of β-alkyl groups in Secondary 
Metabolites 
The increasing number of secondary metabolic biosynthetic gene clusters in the public 
databases over the last few years has provided evidence that PK/NRP gene clusters can 
include "nonstandard" sets of genes. Annotation of seven such gene clusters has revealed a 
shared set of discrete genes collectively known as a "HMG-cassette", consisting of an ACP, a 
variant KS, a HMG-like synthase and one or two homologues of the enoyl-CoA hydratase 
(ECH) superfamily (Figure 1). HMG-cassettes have been correlated with the presence of C2 
carbon acetate labels, and in some cases, with the carbons derived from methylmalonate 
(myxovirescin, leinamycin) at the so called β-positions in their related natural products 
(Figure 2). This link has led to a proposal regarding the common biochemical roles of their 
respective gene products in the biosynthesis of these β-functionalities. 
HMG boxes are present in the chromosomes of phylogenetically diverse bacterial 
genera such as Bacillus, Streptomyces, Pseudomonas, Cyanobacteria and Myxococci. Recent 
genome sequencing continues to expand the number of genera that incorporate these gene 
sets, demonstrating their presence in Burkholderia mallei,[96] B. pseudomallei,[97] and 
Candidatus Endobugula sertula.[98] Such a wide distribution of this gene group across diverse 
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TaB, E TaK TaC,F TaX TaY TaV1,2myxovirescin (Ta) 
ACP       KSS         HMGS      ECH        ECH        AT
AcpK PksF PksG PksH PksI PksC,E
MacP14 MupG MupH MupJ MupK MmpIIIAT1, 2
JamF JamG JamH JamI JamJ
CurB CurC CurD CurE CurF
PedN PedM PedP PedI PedI PedC,D
bacillaene (PksX)
mupirocin (Mup)
jamaicamide (Jam)
curacin (Cur)
pederin (Ped)
LnmL LnmM LnmF LnmGleinamycin (Lnm)
HMG-box
 
Figure 1. Homologues of the gene products of the "HMG-cassette" have been identified in 
seven gene clusters responsible for secondary metabolite production. Another characteristic 
feature of these clusters is that they belong to the family of "AT-less" systems. 
 
bacterial phyla suggests that the genes were acquired from a common ancestor long ago, and 
retained during the subsequent divergence of the strains.  
Systems which incorporate HMG cassettes often also belong to the family of so-called 
"AT-less" PKSs, in which the AT function is provided "in trans. " However, this is not always 
the case, as the two cyanobacterial systems which incorporate HMG cassettes (jamaicamide 
and curacin) contain AT domains integrated into the modules (Figure 1). This observation 
raises the possibility that the acquisition and transmission of HMG-cassettes and genes 
encoding the "trans ATs" were independent of each other.  
 
 
 
 
 
                                                                  
                                                                   Discussion                                                           
 
123 
Discrete acyltransferases  
In contrast to the paradigm established by the DEBS PKSs, DNA sequencing has 
revealed increasing numbers of type I PKS biosynthetic systems which lack the cis or 
intramodular acyltransferase (AT) domains. In these systems, the integral AT activities 
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Figure 2. Incorporation of the C-2 acetate carbons (indicated with a black circle) and in some 
cases C2-C3 carbons of methylmalonate (outlined with the circle) into this selection of 
secondary metabolites, has been correlated with the presence of HMG-cassettes in their 
respective gene clusters.  
 
are presumably compensated for by "trans ATs. " In addition to the examples of pathways 
incorporating both HMG-cassettes and "trans ATs" (Figure 1), "trans ATs" are present on 
their own in the clusters responsible for biosynthesis of many other natural products, 
including lankacidin,[99] mycosubtilin,[100] chivosazol,[101] disorazol[102] and several others. 
Interestingly, in silico analysis of "trans AT" domains reveals conserved signature sequences 
which correlate with specificity for malonyl-CoA.[103]  
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 Even though "trans ATs" have been detected in many clusters, our knowledge of this 
class of ATs is very limited. Up to date, only two such ATs have been characterized 
biochemically. LnmG, a discrete AT of the leinamycin hybrid PKS-NRPS has been shown in 
vitro to load malonyl-CoA onto five recombinant ACP domains from the system, and to a 
tridomain derived from module 4 (DH-ACP-KR) of LnmJ (Figure 3), but not onto the 
discrete PCP of leinamycin cluster.[104] Similarly, a recent investigation of FenF, the "trans 
AT" of the mycosubtilin system, demonstrated its strong preference for malonyl-CoA, and 
only marginal tolerance towards acetyl- and methylmalonyl-CoA. Moreover, FenF could not 
distinguish between ACPs derived from the mycosubtilin and PksX systems.[100]       
  
Figure 3. Postulated assembly of leinamycin. Loading of malonyl-CoAs onto the six modules 
of LnmI and LnmJ by the "trans AT" LnmG has been demonstrated in vitro (Figure taken 
from).[105] 
Thus, FenF shows a tight specificity in substrate selection, but is more promiscuous towards 
the acyl carrier proteins it charges. Broad tolerance of "trans ATs" towards acyl carrier 
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proteins could be anticipated considering the number of ACPs within these clusters they have 
to serve. 
In myxovirescin gene cluster, the two discrete ATs (AT1 and AT2) are found encoded 
within one open reading frame taV. We hypothesized that AT1 loads malonate extender units 
"in trans" to the AT-less PKS modules of Ta-1, TaO and TaP, as well as onto the discrete 
ACP TaB. AT2 was speculated to load methylmalonyl-CoA/propionyl-CoA onto the discrete 
ACP TaE, thereby supplying the building block specific for the ethyl branch formation. A 
mechanism for loading both malonate and methylmalonate units onto the PKS is also required 
in leinamycin assembly. The leinamycin pathway encodes an "incomplete" HMG-cassette 
consisting of discrete ACP LnmL, a HMGS homologue LnmM, and the ECH LnmF.[104] 
LnmL and LnmM have been proposed to incorporate methylmalonyl-CoA into the dithiolane 
moiety of leinamycin (Figure 3). However, due to the absence of the decarboxylase KSS in 
the leinamycin cluster, the "trans AT" LnmG may directly load propionyl-CoA onto LnmL, 
instead of the proposed methylmalonyl-CoA. This idea remains speculative, as the specificity 
of LnmG for propionate has not yet been assessed. What it suggests, however, is that "trans 
ATs" in these systems may exhibit a certain degree of substrate promiscuity. Thus, one 
possible scenario to explain why the decarboxylase TaK is not required for myxovirescin 
production is by direct loading of the propionyl-CoA onto the TaE ACP by TaV.   
 
Role of discrete ACPs in the pathway dedicated to β-branch formation 
Investigation of the functional roles of HMG-cassette proteins (AcpK and PksFGHI 
enzymes) from the bacillaene (PksX) system in vitro (Figure 4), has demonstrated the 
importance of the discrete ACP AcpK in this pathway. Prior to delivering a substrate to  
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Figure 4. Assignment of functions of six enzymes from the PksX system have demonstrated  
their likely roles in vivo in the formation of β-methyl branches observed in some secondary 
metabolites (Figure reproduced from).[106] 
 
the HMGS PksG, AcpK interacts with the "trans AT" PksC and the KSS decarboxylase PksF. 
Therefore, AcpK participates in multiple protein-protein interactions with other enzymes in 
the pathway.  
The presence of two β-alkyl groups in myxovirescin A is consistent with the presence 
of two pairs of genes coding for ACPs and HMGSs in its associated assembly line (Figures 1 
and 2). Hence, each discrete ACP, TaB and TaE, has been proposed to deliver the specific 
substrate (acetate or propionate) to their associated, HMGS TaC and TaF, respectively. 
Following substrate delivery, each HMGS would then couple one of the substrates onto the 
growing polyketide backbone. Based on this proposal, it was expected that each discrete ACP 
would form a functional pair with only one HMGS, to ensure that the final product has two 
different β-methyl groups.    
Indeed, phenotypic characterization of in frame mutants of taB, taC, taE and taF has 
confirmed this hypothesis,[73; 86] delineating distinct roles for the TaB/TaC and TaE/TaF ACP- 
HMGS pairs. Our results indicate i) the requirement of TaB for the formation of β-methyl 
group and ii) the requirement of TaE in the biosynthesis of β-ethyl group, as well as an 
additional role of this ACP in megasynthetase turnover. Given that the pathway to β-methyl 
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formation is ACP-dependent, it is possible that the divergence of the two ACPs has provided 
the structural basis for the functional separation of the two ACP-HMGS enzyme pairs.   
 
Secondary metabolic HMG-like synthases and the divergence of superfamily of carbon-
carbon condensing enzymes 
 
Until recently, the only known HMGS were those involved in the mevalonate pathway 
of primary metabolism (PM), known to produce 3-methyl-3-methylglutaryl-CoA (HMG-
CoA) by coupling acetyl-CoA with the 4-carbon compound acetoacetyl-CoA. However, the 
discovery of HMGS homologues in secondary metabolic (SM) gene clusters, where they 
appear to install β-alkyl branches in the growing intermediates, implied recognition of 
significantly longer substrates. Specifically, our model for myxovirescin biosynthesis 
predicted that TaC and TaF HMGS should catalyze condensations onto β-ketoacyl-S-ACP 
substrates containing C14 and C18 carbon chains, respectively. In addition, our model also 
required that one HMGS homologue would introduce propionate, a substrate not recognized 
by primary metabolic HMGS. Hence, even though it was shown in vitro that the HMGS PksG 
could catalyze the classical HMG-reaction on ACP-coupled substrates (Figure 4), genetic 
evidence demonstrating the function of HMGS in the biosynthesis of any secondary 
metabolite was still lacking. In particular, it was desirable to demonstrate directly that SM 
HMGS can accept much longer and more complex substrates than acetoacetyl-S-ACP.  
Indeed, we have shown that upon inactivation of TaF HMGS from the myxovirescin 
cluster, the mutant strain (ΔtaF) produced new myxovirescin with a shorter (methyl) side 
group at C16 (Figure 5). Furthermore, production of the same compound was observed upon 
removal of the ACP TaE, confirming our hypothesis that TaF uses a substrate tethered to a 
specific ACP to construct the β-ethyl group. Simultaneously, this experiment provided 
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Figure 5. Production of the new myxovirescin analogue myxovirescin ΔF, which displays a 
methyl (in square) instead of an ethyl side group, was observed with both the ΔtaE and ΔtaF 
mutants. These results confirm our hypothesis that TaF HMGS directs formation of  the β-
ethyl group in an ACP (TaE)-dependent manner.[73; 86]  
 
the first evidence that, as postulated, SM HMGS couple substrates longer than acetate. 
Furthermore, production level of this novel metabolite (myxovirescin ΔF) was not altered 
upon disruption of the primary HMGS mvaS in the ΔtaF background (ΔtaF, mvaS double 
mutant).[73] This experiment showed that despite their overall sequence similarity, no cross-
talk between the primary and secondary HMGS in M. xanthus occurs.  
Taken together, genetic and biochemical characterization of three HMGS-like 
synthases (PksG, TaC and TaF) of secondary metabolism demonstrate three significant 
differences in respect to the HMGS of primary metabolism, in that SM HMGS can: i) operate 
on ACP tethered, instead of CoA activated substrates; ii) accept propionyl-S-ACP, in addition 
to acetyl-S-ACP as nucleophiles; iii) condense their substrates (acetyl-S-ACP or propionyl-S-
ACP) onto β-ketoacyl-S-ACP intermediates of varying chain lengths. Therefore, although the 
overall catalytic mechanism of both PM and SM HMGS appears to be conserved, SM HMGS 
apparently display much greater tolerance towards the type and lengths of their substrates.  
Based on these results, SM HMGS should have an active site tunnel longer than the 16 
Å reported for the S. aureus MvaS,[107] in order to accommodate the long chain substrates. 
However, as there are no crystal structures of any SM HMGS yet available, a simple sequence 
alignment was used to identify any potential differences between primary and secondary 
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HMGSs in terms of their amino acid sequences. This analysis (Figure 6) reveals that 
secondary HMGSs contain two insertions relative to primary metabolic HMGSs. One 
insertion, about 10 amino acids in length, is located about 40 amino acids after the active 
 
 
Figure 6. Amino acid alignment of primary metabolic (PM) and secondary metabolic (SM) 
HMGS indicates two insertions, each approximately 10 amino acids long (indicated with the 
solid bars). Designation of the tertiary structure was done by comparison to the S. aureus 
HMGS, whose crystal structure has been determined (see Figure 7). Arrows indicate 
completely conserved active site residues. Solid bars indicate positions of amino acid 
insertions specific to SM HMGS. Regions shaded in black indicate identical residues; those 
highlighted in light grey indicate conserved residues, while those shown in dark grey are 
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similar. The accession numbers of the PM HMGS are as follows: S. aureus (CAG 41605), M. 
xanthus (YP_632442), S. pneumoniae (YP_816991), and L. monocytogenes (ZP_00232976). 
The accession numbers of the secondary HMGS are: JamH (AAS 98779), CurD (AAT 
70099), MupH (AAM 12922), PksG (CAB 13586), OnnA (AAV97869), and PedP (AAW 
33975). EntHMGS is an HMGS homologue from the etnangien gene cluster (Perlova, O. & 
Müller, R., unpublished results).  
 
site Cys, precisely between β sheets 6 and 7 of the S. aureus HMGS. However, this insertion 
is significantly smaller (4 amino acids) in both the TaF and LnmM HMGSs, the only two 
HMGS proposed to be specific for propionyl-S-ACP instead of acetate. The second insertion 
is located at the extreme C-terminus and is typically 10 amino acids in length, though the 
insertion in PedP is significantly longer.  
Although the functional significance of these insertions remains only hypothetical, it is 
perhaps significant that the locations of these insertions coincide with those observed for other 
members of the condensing enzyme superfamily (Figure 7).[107] For example, the hallmark of 
the thiolase family of condensing enzymes (relative to chalcone synthases, HMGS, and FabH) 
is a characteristic insertion of approximately 100 residues between β-sheets 6 and 7, whereas 
the PM HMGS exhibit a C-terminal insertion of about 67 amino acids, relative to  
other members of the superfamily (Figure 7).[107] Thus, the alignment in Figure 6 indicates 
that the SM HMGS incorporate two insertions relative to PM HMGS. Nonetheless, the 
significance of the observed sequence differences between primary and secondary HMGS will 
need to be evaluated through specific structural and biochemical studies.  
 
 
                                                                  
                                                                   Discussion                                                           
 
131 
 
Figure 7. a) Tertiary structure comparison of four acyl-condensing enzymes. The enzymes 
shown are S. aureus HMG-CoA synthase (HMGS), E. coli FabH, M. sativa chalcone synthase 
(CHS), and S. cerevisiae thiolase (THI) (Protein Data Bank accession numbers 1TVZ, 1D9B 
(35), 1BI5 (32), and 1PXT (9)). b) Structure-based sequence alignment. Conserved Cys, His, 
and Asn residues are shown in red. The core structure is cyan and green; cyan indicates 
helices, and green indicates β-strands (Figure adopted from).[107] 
 
Homologues of Enoyl-CoA Hydratase (Crotonase) Superfamily 
With the exception of the leinamycin pathway, all HMG cassettes contain two 
homologues from the ECH or crotonase superfamily (Figure 1).[106; 108-110] In vitro 
characterization of two pairs of crotonases from the bacillaene and curacin systems have 
demonstrated their functions as dehydratases and decarboxylases.[106; 111] This finding is not 
surprising, as members of the ECH superfamily catalyze diverse reactions including 
dehalogenation, (de)hydration, decarboxylation, formation/cleavage of carbon-carbon bonds, 
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hydrolysis of thioesters, etc.[112] Despite the overall differences in their reaction mechanisms, 
all members of the family can stabilize enoyl-CoA anion intermediates within an oxyanion 
hole (residues outlined in boxes, Figure 8 a-b). Therefore, consistent with the different 
overall reactions that they catalyze, the active site residues within the superfamily vary.  
Very recently, TaX and TaY have been assigned the corresponding functions of 
dehydratase and decarboxylase in vitro and shown to be shared between the two pathways 
leading to the formation of the β-methyl and the β-ethyl branches (Calderone, C. & Walsh C., 
personal communication), confirming our biosynthetic model (Figure 8 c). Therefore, the  
                 
TaX    60  LEGLPHVFCMGADFRAIHDRVDDGRREQGNAEQLYRLWLQLATGPYVTVAHVQGKANAGG 119
PksH 56  LEGLPEVFCFGADFQEIYQEMKRGRKQASSQEPLYDLWMKLQTGPYVTISHVRGKVNAGG 115
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Figure 8. ClustalW alignments of a) PksH and CurF dehydratases with TaX; and b) PksI and 
CurF decarboxylases with TaY. The residues outlined in boxes form oxyanion holes. The 
arrows indicate amino acids which stabilize the thioester carbonyl by hydrogen bonding via 
their peptidic HN groups. c) TaX and TaY are proposed to be shared between the two 
pathways dedicated to incorporation of C2-acetate carbon (black circle) and the C2-C3 
carbons of propionate (connected squares) by catalyzing the two-step reaction needed to 
cleave the carboxyl groups. Very recent characterization of TaX and TaY in vitro has 
confirmed this part of the biosynthetic hypothesis (Calderone C. & Walsh, C., personal 
communication). 
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observed loss of myxovirescin A production upon deletion of either taX or taY may be due to 
the structural disruption of the complex, failure to accept the unmodified intermediates 2, 3, 5, 
or 6 by the next KS, or both reasons. These observations should be taken into consideration 
during future biocombinatorial efforts to re-engineer this pathway. 
 
Plasticity of the myxovirescin HMG toolbox and perspectives toward biocombinatorial 
engineering 
Mutagenesis of the seven genes comprising the two HMG-cassettes in the 
myxovirescin megasynthetase constitutes the first comprehensive in vivo study towards 
understanding the formation of the antibiotic’s two β-branches. In addition, this study 
represents the first attempt towards manipulating the biosynthesis by directed modification of 
the HMG pathway. One of the conclusions derived from this work is that discrete ACPs and 
HMGSs which work in tandem are substrate-specific and not mutually exchangeable. We 
have demonstrated that removal of either TaB or TaC halts myxovirescin production. On the 
other hand, removal of either TaE or TaF is tolerated by the system, causing a switch in the 
programming algorithm and leading to the production of a new myxovirescin analogue. In 
light of our genetic experiments, the observed flexibility of the myxovirescin megasynthase is 
most likely due to the repeated action of TaB-TaK-TaC enzyme trio in introducing two 
acetates at both positions C12 and C16. The observed complementation also strongly supports 
the ability of the TaB/ TaC pair to functionally interact with module 7 of the Ta-1 PKS. 
Despite these important new insights, it is clear that a more thorough understanding of 
protein-protein interactions within myxovirescin megasynthethase is needed. Future studies 
should be directed toward unravelling the nature of docking between the discrete enzymes in 
the pathway (HMGS, their cognate ACPs, the "trans ATs") and the PKS modules. 
Furthermore, detailed biochemical characterization of the substrate selectivity of the "trans 
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ATs" will be needed. Elucidating these features of the biosynthesis in detail should 
significantly enable future development and application of the HMG-toolbox and the "trans 
ATs" in the production of novel biologically active metabolites.  
As an approach in combinatorial biosynthesis, it is significantly easier to manipulate 
enzymes encoded by discrete genes, than those which are part of the multifunctional 
polypeptides. For example, to engineer domain swaps with the PKS proteins, it is necessary to 
define precise domain boundaries and linker regions, an issue which continues to be 
challenging.[87; 89; 90; 113] Also, due to their small size, the corresponding genes can be easily 
cloned either individually, or as sets of genes, using conventional restriction enzyme 
approaches. Furthermore, expression of medium-sized enzymes (50–60 kDa) versus 
megadalton PKSs has a higher probability of yielding properly folded and functionally 
competent enzymes.   
One prospect for introducing β-alkyl groups at different positions in additional natural 
products is through heterologous expression of the HMG-cassettes as part of the existing 
assembly lines which possess at least one minimal module (KS-AT-ACP or KS-ACP). In 
principle, this strategy may be successful, given the demonstrated broad substrate flexibility 
of HMGS and ECH enzymes.  
 
The auxilliary enzymes of myxovirescin biosynthesis  
 
There are four candidates for the three predicted auxiliary reactions leading to 
myxovirescin A. These include a cytochrome P450 hydroxylase TaH, oxygenases TaJ and 
TaN, and a methyltransferase TaQ. In this study we have been able to show that two of these 
enzymes, TaH and TaQ, are responsible for transformation of the C29 β-methyl group into the 
methylmethoxy functionality. By eliminating the cytochrome P450 TaH from the 
myxovirescin megacomplex, we have been able to characterize a new myxovirescin analogue 
with a unique β-methyl group at C12 (Figure 9). Elucidation of this structure supports our 
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biosynthetic model and provides essential genetic and biochemical evidence that the 
incorporation of acetate (and its decarboxylation) take place prior to the addition of the 
methoxy group in myxovirescin A. Furthermore, by analysis of the novel, desmethyl analogue 
of myxovirescin A, myxovirescin QA, we could prove that the SAM-dependent 
methyltransferase completes the modification of this functional group by converting the C29-
hydroxyl into the C29-methoxy functionality. Because removal of TaQ and TaH had little or 
no effect on the yields of the respective desmethyl and desmethylmethoxy analogues of 
myxovirescin A, these enzymes most likely comprise the myxovirescin auxiliary toolbox 
which acts following assembly of the lactam. At this time it is not clear which one of the 
remaining two oxygenases (TaJ and TaN) hydroxylate carbons C3 and C9. 
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Figure 9. Formation of the methylmethoxy group attached at C29 is a two-step process, 
catalyzed by the cytochrome P450 TaH and the SAM-dependent methyltransferase TaQ.[39; 86] 
 
 
Regulation of myxovirescin production 
 
In silico analysis of two myxovirescin sensory and regulatory operons (Figure 10) 
suggests that regulation of its production will be subject to σ54-dependent, NifA-like enhancer 
binding protein MyrB, the serine/threonine kinase (STK) MyvC and several other proteins. 
Three gene knockouts provide evidence for the role of serine/threonine kinase MyrC, and two 
other proteins (MyvC, and MyvD) of unknown function, in the regulation of myxovirescin 
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production. Genetic organization of myvC and myvD, coupled with the additive effects of their 
respective knockouts on myxovirescin production (yielding 6.5 and 12.5% of wild type  
 
lacB myrB myrC myvD myvC myvB myvA
1 kb
 
Figure 10. Knockouts of myrC and myvD, encoding for proteins of unknown function, and 
myvC, encoding for a serine/threonine kinase, produce lower amounts of myxovirescin A 
relative to the wild type strain. 
 
myxovirescin production respectively), suggest that MyvC and MyvD may be part of the 
same signal transduction cascade. 
 Even though we do not yet have a phenotype of a myrB (EBP) knockout, an 
independent line of experiments currently under way in our laboratory gave evidence for the 
role of additional EBPs, encoded elsewhere in the chromosome, in the regulation of 
myxovirescin production (Kegler C. & Müller R., unpublished results). Three additional EBPs 
have been shown to bind to the 750 bp intergenic region located between myxovirescin 
biosynthetic gene cluster and myr operon. Curiously, all three EBP knockout phenotypes were 
characterized with a 70–90% drop in myxovirescin A production, whereas their double 
knockouts lead to an even great reduction of the antibiotic titre. Taken together, these data 
demonstrate that multiple gene products activate and (or) stimulate myxovirescin production, 
revealing their role in the positive regulatory/signal transduction circuitry.  
In addition to the role of the σ54 in the regulation of myxovirescin production, of 
particular interest will be unravelling of the roles of two GAF domains, elucidation of 
function of the adenylate cyclase (AC) domain, as well as the confirmation of protein-protein 
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interactions between FHA domain of MyvB and STK MyvC. Given the observed negative 
effect of high concentrations of ammonia on cell growth, and the upregulation of 
myxovirescin production observed under reduced carbon and nitrogen conditions, it is 
tempting to speculate that the key signals of the carbon and nitrogen metabolism may be some 
of the effectors.  
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In this work Myxococcus  xanthus DK1622 was shown to be a producer of two 
myxovirescin antibiotics: myxovirescin A, the main antibiotic form, and myxovirescin C, its 
C20-deoxy analogue. From the publicly available genome of M. xanthus DK1622, 83 kb of 
the myxovirescin biosynthetic gene cluster were identified. In addition, an approximately 11 
kb region upstream from the gene cluster, has been presumed to be involved in the regulation 
of myxovirescin production. 
Annotation of the myxovirescin gene cluster lead to the biosynthetic model proposing 
in trans loading of malonyl-CoA building blocks onto the "AT-less" multimodular PKSs, as 
well as the possibility of either one of the two PKSs (TaI or TaL) performing the biosynthesis 
of the 2-hydroxyvaleryl-S-ACP starter unit. Biosynthesis of the unusual β-methyl and β-ethyl 
groups was proposed to be executed by seven enzymes comprised of acyl carrier proteins 
(ACPs), 3-hydroxy-3-methylglutaryl-CoA-like synthases (HMGS), variant ketosynthase (KS) 
and homologues of the enoyl-CoA hydratase superfamily. Two acyl carrier proteins (ACPs) 
TaB and TaE, and two 3-hydroxy-3-methylglutaryl synthases (HMGSs) TaC and TaF, were 
proposed to constitute two functional ACP-HMGS pairs (TaB/TaC and TaE/TaF) responsible 
for incorporation of acetate and propionate units into the myxovirescin A scaffold, eventually 
leading to the formation of β-methyl and β-ethyl groups, respectively. Three more proteins, 
TaX and TaY, which are members of the superfamily of enoyl-CoA hydratases (ECH), and a 
variant ketosynthase (KS) TaK, were proposed to be shared between two ACP-HMGS pairs, 
to give the complete set of enzymes required for β-alkylations. The β-methyl branch was 
presumed to be further hydroxylated (by TaH) and methylated (by TaQ) to produce the 
methylmethoxy group observed in myxovirescin A.  
To test the biosynthetic model of myxovirescin biosynthesis, a palette of fourteen in-
frame deletion mutants in the myxovirescin gene cluster were created and their effects on the 
production of myxovirescin antibiotics evaluated by HPLC-MS analysis of the resulting 
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mutant extracts. Novel myxovirescin analogues arising from certain mutant backgrounds were 
subjected to the detailed chemical structure elucidation using the high resolution mass 
spectrometry (HRMS) and the nuclear magnetic resonance (NMR) studies or the combination 
of tandem mass spectrometry (MS-MS) and HRMS analyses. 
Results of our experiments have revealed the indispensability of "trans AT" TaV for 
myxovirescin production. Furthermore, myxovirescin production continued in both ΔtaI and 
ΔtaL mutants, but was abolished in the ΔtaIL double mutant, suggesting that the production of 
the proposed 2-hydroxyvaleryl-S-ACP can commence on either one of the two PKSs. As 
predicted, ΔtaB and ΔtaE ACP mutants revealed similar phenotypes to their associated 
HMGS mutants ΔtaC and ΔtaF, respectively. Based on the structural elucidation of the novel 
myxovirescin analogue produced in both ΔtaF and ΔtaE mutants, direct evidence for the role 
of TaE/TaF in the formation of the β-ethyl branch, and implied roles of TaB/TaC in the 
formation of the β-methyl group, could be deduced. Unexpectedly, production of 
myxovirescin A continued in a ΔtaK mutant but was abolished in ΔtaKF double mutant, 
indicating the need of TaK in the formation of the β-methyl group and questioning its role in 
the formation of the β-ethyl group. However, both TaX and TaY were shown to be required 
for myxovirescin biosynthesis. Analysis of two novel myxovirescin analogues arising from 
ΔtaH and taQ mutant backgrounds have confirmed the role of the cytochrome P450 TaH in 
hydroxylation of the β-methyl group and TaQ methyltransferase in its subsequent 
methylation. Additional disruption of genes positioned upstream from the biosynthetic gene 
cluster has demonstrated that the serine/threonine kinase MyvC, and two other proteins of 
unknown functions, have a positive effect on myxovirescin production. 
 
 
 
 
 
                                                                   Summary 
                                                
140 
In der vorliegenden Arbeit konnte gezeigt werden, dass das Bakterium Myxococcus 
xanthus DK1622 zwei verschiedene Derivate des Antibiotikum Myxovirescin bildet: Sowohl 
Myxovirescin A als Hauptkomponente, als auch Myxovirescin C, einem C20-Deoxy-Analog. 
Anhand der veröffentlichten Genomsequenz von Myxococcus xanthus DK1622 konnte das 
entsprechende Biosynthesegencluster innerhalb eines 83 kb großen Bereiches identifiziert 
werden. Des Weiteren konnten in einem Sequenzausschnitt von ungefähr 11 kb stromaufwärts 
des Genclusters zusätzliche Gene identifiziert werden, deren Genprodukte an der Regulation 
der Naturstoffbildung beteiligt sind.  
Die Annotation des Genclusters und der korrespondierenden Genprodukte führten zur 
Aufstellung eines hypothetischen Biosynthesewegs. In diesem Modell wird die "AT-lose, " 
multimodular Myxovirescin-PKS "in trans" mit den entsprechenden Malonyl-CoA 
Bausteinen beladen. Die Startereinheit 2-Hydroxyvaleryl-S-ACP wird entweder von der PKS 
TaI oder TaL synthetisiert. An der Biosynthese der ungewöhnlichen β-Methyl- und β-
Ethylgruppe sind demnach sieben Enzyme des Genclusters beteiligt. Die beiden ACPs TaB 
und TaE bilden zusammen mit den 3-Hydroxy-3-Methylglutaryl-CoA ähnliche Synthasen 
(HMGS) TaC und TaF funktionsfähige ACP-HMGS Paare (TaB/TaC und TaE/TaF), welche 
für den Einbau von Acetat beziehungsweise Propionat in das wachsende Myxovirescin-
Grundgerüst verantwortlich sind. Im weiteren Verlauf der Biosynthese werden diese beiden 
Einheiten zur β-Methyl- und β-Ethylgruppe modifiziert. Drei weitere Enzyme, TaX und TaY, 
die zur Klasse der Enoyl-CoA Hydratasen (ECH) gehören, als auch die Ketosynthase (KS) 
TaK sind an der β-Alkylierung beteiligt. Die β-Methylgruppe wird anschließend hydroxyliert 
(TaH) und methyliert (TaQ), um schließlich die Methylmethoxygruppe im Myxovirescin A zu 
bilden. 
Um den postulierten Biosyntheseweg zu beweisen wurden vierzehn „in-frame“ 
Deletionsmutanten innerhalb des Genclusters erzeugt und die Auswirkungen auf die 
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Myxovirescin Produktion mittels HPLC/MS Analyse der jeweiligen Kulturextrakte überprüft. 
Auf diesem Weg neu gebildete Myxovirescin-Derivate wurden mittels hochauflösender 
Massenspektrometrie (HRMS) und Kernresonanzspektroskopie (NMR) oder in Kombination 
mit der Tandemmassenspektrometrie (MS/MS) aufgeklärt. 
Die Mutageneseexperimente zeigten eindeutig die Unentbehrlichkeit der trans AT TaV für 
die Biosynthese des Myxovirescins. In den Kulturextrakten der beiden Deletionsmutanten 
ΔtaI und ΔtaL konnte nur eine geringe Menge an Myxovirescin A nachgewiesen werden, 
wohingegen in der Doppelmutante ΔtaIL kein Myxovirescin gebildet wird. Diesem 
Zusammenhang folgend könnte die Startereinheit 2-Hydroxyvaleryl-S-ACP von beiden PKSs 
unabhängig voneinander synthetisiert werden. In den Deletionsmutanten ΔtaB und ΔtaC 
beziehungsweise ΔtaE und ΔtaF konnte ein ähnlicher Myxovirescin-Phänotyp nachgewiesen 
werden. Die Strukturaufklärung der neuen Myxovirescin Derivate aus den Deletionsmutanten 
ΔtaE und ΔtaF zeigt, dass TaE und TaF direkt an der Bildung der β-Ethylgruppe beteiligt 
sind. Weiterhin impliziert sie die Beteiligung des TaB/TaC Paars an der Synthese der β-
Methylgruppe. Entgegen der postulierten Biosynthese konnte in Kulturextrakten der Mutante 
ΔtaK Myxovirescin nachgewiesen werden, das in der Doppelmutante ΔtaKF nicht mehr 
produziert wurde. Diese Ergebnisse deuten darauf hin, dass TaK an der Synthese der β-
Methylgruppe beteiligt ist, aber nicht an der Bildung der β-Ethylgruppe. 
Zusätzliche Inaktivierungsexperimente von stromaufwärts liegenden Genen des 
Biosynthesegenclusters zeigen eindeutig eine Beteiligung an der Regulation der 
Myxoveriscin-Produktion. Dabei handelt es sich um eine Serin/Threonin Kinase (MyvC) und 
zwei weitere Proteine mit unbekannter Funktion.  
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